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O PRIMEIRO DIA - Sérgio Godinho  
  
 
 
 
5 
Acknowledgements 
 
I would like to thank, my supervisor Dr. Paul Caton for his supervision and guidance 
through out my PhD and for having accepted to supervise me after Professor Mary 
Sugden get retired. 
 
I would like to thank, my previous supervisor Professor Mary Sugden for giving me 
opportunity to work with her at the Blizard Institute, Queen Mary University of 
London, for her supervision and guidance during my PhD and for keeping guiding me 
on an informal basis, after getting retired. 
 
I would also like to thank, my supervisors Professor Maria Carlota Saldanha and 
Professor Helena Cortez Pinto for their help and guidance throughout my PhD and for 
allowing me to work at Instituto de Medicina Molecular. 
 
Additionally, I would like to thank, Professor Isabel do Carmo for giving me the 
opportunity to study at Faculdade de Medicina da Universidade de Lisboa and for her 
incredible support for the last 4 years. 
 
I would like to thank everyone who has helped me throughout the past 4 years, in 
particular Dr. Mark Holness, Mr. Sharif Hegazy, Ms. Gertrud Kourtman, Dr. Tania 
Maffucci, Professor Benoit Viollet, Mrs. Irene Smith and Mrs. Susanne Bell. 
 
 
I would also like to thank Bruno, my husband, for leaving his life in Portugal to join 
me in London UK and for his constant support over the last years. 
 
Finally, thank you to Fundação para a Ciência e Tecnologia for funding throughout 
my PhD and thank you Queen Mary University of London for being my host 
university and allow me to work on your laboratories. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
Resumo 
 
A diabetes mellitus tipo 2 (T2DM) é uma doença metabólica de etiologia variada que 
continua a afectar pessoas em todo o mundo. Caracteriza-se essencialmente por  
alterações da ação da insulina e/ou da sua secreção, que resultam numa hiperglicémia 
crónica. O excesso de peso/obesidade e a inactividade física são as principais causas 
da T2DM em indivíduos geneticamente predispostos. A carência proteica durante a 
gravidez (restrição proteica na gravidez; MLP), resulta em recém-nascidos de baixo 
peso (LBW) que, numa fase mais tardia da vida desenvolvem insulinorresistência e 
um fenótipo de diabetes. A SIRT1 e a proteína cinase ativada-AMP (AMPK) 
constituem importantes enzimas responsáveis pela longevidade e pela homeostasia 
energética e, consequentemente, desempenham um papel importante no 
desenvolvimento de doenças metabólicas tais como a T2DM. Através de mecanismos 
de desacetilação, a SIRT1 regula a atividade do receptor nuclear - proliferador de 
peroxissoma α (PPARα) -, controlando assim a expressão de genes envolvidos no 
metabolismo da glucose e dos lípidos. Os factores que regulam o interferão 3 e 4 
(IRF3 e IRF4), por serem repressores chave no processo de adipogénese, também 
merecem especial atenção no que respeita ao desenvolvimento de doenças 
metabólicas. O trabalho aqui proposto tem como objetivo investigar a potencial 
existência de um circuito positivo entre as proteínas AMPK e SIRT1 e tentar 
caracterizar o papel deste circuito, na indução da expressão genética regulada pelo 
PPARα. Ratinhos C57Bl/6 submetidos a jejum ou a uma dieta hiperlipídica (HF) e 
ratos MLP foram usados neste estudo. Os modelos descritos foram usados para 
avaliar o impacto da disponibilidade calórica e proteica no desenvolvimento de 
insulinorresistência e, consequentemente, da T2DM no fígado e tecido adiposo 
(WAT), respectivamente; ratinhos em que o gene AMPK α1/2 foi especificamente 
eliminado no fígado e músculo (AMPK-/-) foram usados para identificar o papel da 
ativação da AMPK e da SIRT1 nas funções ligadas ao PPARα; ratinhos PPARα 
knockout foram usados para investigar a deficiência de PPARα na lipogénese e beta-
oxidação do tecido adiposo visceral; células hepáticas H4IIEC3 cultivadas e tratadas 
com um SIRT1 siRNA, serviram para caracterizar o circuito positivo entre SIRT1 e 
AMPK; mioblastos L6 foram cultivados e tratados com um agonista da AMPK 
(adiponectina) e com insulina; adipócitos 3T3-L1 foram cultivados e tratados com um 
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agonista do PPARα (WY14683) para identificar o papel do PPARα no IRF3 e no 
IRF4. 
 
Através da utilização de tecido hepático AMPK-/- e de células H4IIEC3 silenciadas 
para a SIRT1 verificou-se que, no fígado, a AMPK e SIRT1 regularam-se 
reciprocamente num processo que impede a acumulação de triacilgliceróis. O estudo 
de ratinhos alimentados com uma dieta HF, tratados com mononucleótido de 
nicotinamida (NMN), permitiu estabelecer uma ligação entre o circuito AMPK/SIRT1 
e a fosforilação do substrato do receptor de insulina (IRS-1), sugerindo uma relação 
entre o circuito SIRT1/AMPK e a via da sinalização de insulina. No músculo-
esquelético, a deficiência da AMPK altera os efeitos benéficos da restrição calórica na 
tolerância à glucose, o que prova que este benefício é dependente da AMPK. A 
diminuição da expressão da SIRT1 aliada à deficiência da AMPK, altera a via da 
sinalização de insulina, o que resulta numa diminuição da entrada de glucose para as 
células. No tecido adiposo visceral, a inibição do IRF3 e do IRF4 reduz o processo de 
β-oxidação e aumenta o processo de lipogénese em ratos MLP. Os estudos realizados 
no tecido adiposo levaram à conclusão de que o IRF3 é potencialmente ativado pela 
AMPK, e o IRF4 é ativado pelo PPARα, num processo que envolve adiponectina. 
 
Os resultados obtidos sugerem que o eixo AMPK-SIRT1-PGC-1α-SIRT3 durante o 
jejum/CR é importante na prevenção de distúrbios metabólicos. Regular a atividade 
da AMPK e da sua interação com as sirtuinas na funções ligadas ao PPARα, pode ser 
potencialmente importante para o tratamento de distúrbios como a T2DM e outros 
associados ao envelhecimento. A adiponectina e o NMN são potenciais alvos 
terapêuticos para o tratamento de doenças metabólicas. 
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Abstract 
 
Both genetic and environmental influences determine the risk of developing type 2 
diabetes mellitus (T2DM).  Epidemiological studies indicate that factors influencing 
the prevalence of T2DM include lifestyle (e.g. inactivity and dietary macronutrient 
composition), obesity and age. Interestingly maternal protein restriction (Maternal 
Low Protein; MLP) generates low birth weight (LBW) offspring, who develop insulin 
resistant and diabetic phenotype in later life. Interferon regulatory factors 3 and 4 
(IRF3 and IRF4) are key repressors of adipogenesis. SIRT1, a histone/protein 
deacetylase, and AMP-activated protein kinase (AMPK) are key enzymes responsible 
for longevity and energy homeostasis. Through deacetylation and activation of 
peroxisome proliferator-activated receptor-γ coactivator 1 α (PGC-1α), a 
transcriptional regulator of fatty acid (FA) oxidation, SIRT1 mediates activation of 
peroxisome-proliferator-activated receptor α (PPARα), which is a nuclear receptor 
that controls the expression of genes involved in glucose and lipid homoeostasis. The 
proposed study aims to investigate whether a positive feed back loop exists in 
response to AMPK/SIRT1 activation and try to characterize the role of this pathway 
in the regulatory circuit through which PPARα induces gene expression. C57Bl/6 
mice fasted or fed a high fat diet (HF) and rat MLP-offspring were used to understand 
the importance of nutrient availability in the development of insulin-resistance and 
T2DM in liver and visceral white adipose tissue (WAT) respectively; specific liver 
and muscle AMPK α1/2 double null (AMPK-/-) mice were used to understand the role 
of AMPK on SIRT1 activation and PPARα linked functions; PPARα deficient mice 
were used to investigate the influence of PPARα deficiency on lipogenesis and β 
oxidation in mice visceral WAT; H4IIEC3 liver cell line was cultured and treated 
with a SIRT1 siRNA to better understand the feedback loop between SIRT1 and 
AMPK; L6 myoblasts were cultured and treated with AMPK agonist adiponectin and 
with insulin, and 3T3-L1 adipocytes were cultured and treated with PPARα agonists 
(WY14683) to understand the role of PPARα in IRF3 and IRF4.  
 
Using AMPK-/- liver and SIRT1 knockdown H4IIEC3 cells we found that, in the liver, 
AMPK and SIRT1 regulate each other to prevent lipid accumulation. Studies on HF 
fed mice, treated with nicotinamide mononucleotide (NMN), linked this 
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AMPK/SIRT1 pathway to phosphorylation of the insulin receptor substrate (IRS-1) at 
tyrosine residues, suggesting an involvement of the SIRT1/AMPK axis in the insulin-
signalling pathway. In skeletal muscle AMPK deficiency impairs the beneficial 
effects of CR on glucose tolerance. This is linked to decreased SIRT1 gene 
expression, which could impair insulin signalling pathway, culminating in reduced 
glucose uptake. Using MLP-offspring visceral WAT, we found that suppression of 
interferon regulatory factors 3 and 4 (IRF3 and IRF4, respectively) represses fatty 
oxidation and enhances lipogenesis in MLP-offspring. IRF3 is possibly activated by 
AMPK, where IRF4 is activated by PPARα.  
 
Taken together, our results suggest that AMPK-SIRT1-PGC-1α-SIRT3 axis during 
fasting/CR is important to prevent metabolic disorders. Regulation of AMPK and 
PPARα linked functions together with deacetylation catalyzed by the sirtuins may 
prove to be important for the treatment of T2DM and other disorders associated with 
aging. Adiponectin (which activates AMPK and PPARα) and NMN (which increases 
SIRT1 activity) are potential therapeutic targets for the treatment of metabolic 
disorders.  
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1.1 Insulin 
Insulin is a naturally-occurring peptide hormone synthesized and secreted by 
pancreatic β cells. The release of insulin from secretory granules is dependent on the 
ability of each granule to translocate to the cell surface and fuse with the plasma 
membrane [1]. 
 
1.1.1 Insulin Signalling Cascade 
Glucose is an essential nutrient, supplying fuel for many different organs of the body, 
for which it is the sole source of energy. These include the brain and neurons in 
particular, as well as other organs and tissues, particularly those that lack (e.g. red 
blood cells) or have low oxidative capacity. Since glucose enters cells via facilitated 
diffusion, it is vital that blood glucose levels are maintained within a very narrow 
range, approximately 3.9 – 6.6 mM, depending on prandial state [2]. 
 
Insulin is the major hormone controlling critical energy functions such as glucose and 
lipid metabolism. Insulin activates the insulin receptor tyrosine kinase (IR), which 
phosphorylates and recruits different substrate adaptors such as the insulin receptor 
substrate (IRS) family of proteins (Fig. 1.1) [3]. The IR is a heterotetramer consisting 
of two α subunits and two β subunits that are linked by disulphide bonds. Insulin 
binds to the α subunit of the insulin receptor and activates the tyrosine kinase in the β 
subunit (Fig. 1.1). Once the tyrosine kinase of insulin receptor is activated, it 
promotes autophosphorylation of the β subunit, where phosphorylation of three 
tyrosine residues (Tyr1158, Tyr1162, and Tyr1163) is required for amplification of the 
kinase activity [4]. Receptor activation leads to the phosphorylation of key tyrosine 
residues on IRS proteins, which interact with phosphatidylinositol (PI) 3-kinase (also 
known as PI3K, a lipid kinase). PI3K consists of a p110 catalytic subunit and a p85 
regulatory subunit that possesses two Src homology 2 (SH2) domains that recognise 
the tyrosine-phosphorylated residues in IRS proteins [5] (Fig. 1.1). The activated 
PI3K phosphorylates 3′-phosphoinositides [phosphatidyl-inositol-3,4-bisphosphate 
(PIP2) generating phosphatidyl-inositol-3,4,5-trisphosphate (PIP3) [6], which bind to 
the phosphoinositidedependent kinase 1 (PDK1). Known substrates of the PDKs are 
Akt, also known as protein kinase B (PKB), and also atypical forms of the protein 
kinase C (PKC) [7]. Once active, Akt enters the cytoplasm where it functions to 
regulate a range of cellular metabolic functions in tissues such as the liver, skeletal 
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muscle and white adipose tissue, which serve to regulate glucose and lipid 
homeostasis [8]. 
 
1.1.1.1 Insulin-mediated glycogen regulation 
With respect to glycogen metabolism in liver and skeletal muscle, Akt induces the 
phosphorylation and inactivation of glycogen synthase kinase 3 (GSK3) (Figure 1.1). 
A major substrate of GSK3 is glycogen synthase, an enzyme that catalyses the final 
step in glycogen synthesis. Phosphorylation of glycogen synthase by GSK3 inhibits 
glycogen synthesis; therefore insulin-mediate inactivation of GSK3 by Akt promotes 
glucose storage as glycogen [9].  
 
1.1.1.2 Insulin-mediated regulation hepatic glucose production 
In addition to promoting glucose storage, insulin inhibits the production and release of 
glucose by the liver by blocking gluconeogenesis and glycogenolysis [5]. Insulin 
directly controls the activities of a set of gluconeogenic enzymes by phosphorylation 
and dephosphorylation events leading to regulated expression of hepatic 
gluconeogenesis genes. Forkhead box protein O1 (FOXO1) stimulates expression of 
gluconeogenic genes (e.g. PEPCK and suppresses genes involved in glycolysis and 
lipogenesis, including glucokinase and the transcription factor steroid regulatory 
element-binding protein (SREBP)-1c, respectively [5]. Insulin induces 
phosphorylation of FOXO1, in an Akt-dependent manner, resulting in nuclear 
exclusion of FOXO1 and repression of gluconeogenic gene expression. 
1.1.1.3 Insulin-mediated glucose uptake 
Insulin also promotes glucose uptake in skeletal muscle, adipose tissue and liver, in a 
process mediated by glucose transporters from the GLUT family. GLUT4 is 
distinguished from the other glucose transporters as a high-affinity, insulin-responsive 
glucose transporter protein that is highly expressed in muscle and adipose tissue [10]. 
Insulin activates GLUT4, in a process mediated by Akt signalling, which results in 
GLUT4 translocation to the cell surface to transport glucose into the cell [11].  
 
1.1.1.4 Insulin action in adipose tissue 
Insulin is considered the major anti-lipolytic [12] and prolipogenic regulator [13] in 
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white adipose tissue (WAT). It is well known that insulin stimulates the redistribution 
of GLUT4 from intracellular compartment to plasma membrane in adipocytes [14]. 
As a result, increased postprandial blood glucose was transported into adipose tissue 
through GLUT4. In addition, insulin increases the activity of lipoprotein lipase on 
adipose cell surface, leading to the lipolysis of serum lipoprotein and subsequent 
uptake of free fatty acids (FFA) into adipose tissue. Insulin-induced increase of 
glucose and FFA uptake is important as substrate supply in efficient triglyceride 
synthesis in adipocytes [15].  
 
Data from Akt knockout mouse models offer a clearer answer to the question of 
whether Akt is required for normal glucose homeostasis. While disruption of Akt1 
isoform in mice did not cause any significant perturbations in metabolism, mice with 
a knockout of the Akt2 isoform show insulin resistance, ending up with a phenotype 
closely resembling type 2 diabetes in humans [16, 17]. Consistently, recent studies of 
inherited insulin post-receptor mutations in humans detected a missense mutation in 
the kinase domain Akt2 in a family of severely insulin resistant patients. The mutant 
kinase was unable to phosphorylate downstream targets and to mediate inhibition of 
phosphoenolpyruvate carboxykinase (PEPCK), a gluconeogenic key enzyme [18]. 
Taken together, studies of transgenic mice and rare human genetic syndromes suggest 
that the impairment of insulin activity leading to insulin resistance is linked to insulin 
signalling defects, and specifically, impaired Akt signalling.  
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Figure 1.1 
 
 
 
Figure 1.1: Insulin signaling pathway. SREBP: sterol regulatory element-binding protein; IRS: insulin 
receptor substrate, PI3-K: phosphoinositide 3 kinase (composed of a heterodimer between a p110 
subunit and a p85 subunit); PDK1: phosphoinositide-dependent kinase 1; pAkt: phosphorylated protein 
kinase B (also known as PKB); pGSK3: phosphorylated glycogen synthase kinase 3; mTOR: 
mammalian target of rapamycin. These molecules act in a coordinated manner to regulate glucose, lipid 
and protein metabolism. 
 
In summary, insulin plays a central role in the regulation of blood glucose levels and 
acts in a coordinated fashion to stimulate protein and lipid metabolism by modifying 
the activity of various enzymes and/or transport proteins [3]. Insulin stimulates 
glucose uptake and the anabolic pathways of glycogenesis (synthesis of glycogen), 
lipogenesis [synthesis of long chain fatty acids (LCFA) and their subsequent 
esterification as triacylglycerol (TAG)] and cholesterol synthesis. Concurrently, 
insulin suppresses glycogenolysis (hydrolysis of glycogen) and lipolysis (hydrolysis 
of TAG). Other metabolic effects include suppression of hepatic gluconeogenesis (de 
novo glucose synthesis), hepatic very-low-density-lipoprotein (VLDL) secretion, 
suppression of mitochondrial LCFA oxidation, enhancement of tissue uptake of 
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amino acids, and stimulation of protein synthesis. The overall role of insulin, 
therefore, is to promote anabolism [19].  
 
1.2 Type 2 Diabetes Mellitus 
 
1.2.1 Prevalence of T2DM 
 
Type 2 diabetes mellitus (T2DM) has become a leading health problem throughout 
the world, accounting for almost 90% of all cases of diabetes in adults worldwide 
[20]. Once thought of as a disease of the Western world, the prevalence of T2DM is 
increasing at alarming rates in developing countries [21]. The emerging pandemic is 
driven by the combined effects of population ageing, rising levels of obesity and 
inactivity, and greater longevity among patients with T2DM that is attributable to 
improved management [22].  According to a study by Sardinha et al. in 2012 of a 
representative sample of 9447 individuals, overweight and obesity now affects 66.6% 
of Portuguese males and 57.9% of Portuguese females [23]. Since obesity is 
unequivocally linked to T2DM [24], its prevalence is also expected to increase 
significantly in coming years.  As a result of this epidemic increase in T2DM 
prevalence, a progressive change is predicted in the epidemiological view of various 
pathologies, including coronary artery disease, stroke, diabetic retinopathy and 
neuropathy, and chronic renal failure [24]. Worldwide, it is projected that by 2025 
there will be 380 million people with T2DM and 418 million people with impaired 
glucose tolerance, impacting significantly in economic terms as well as resulting in 
increased morbidity and mortality [20, 22].  
  
1.2.2 Characterization of T2DM 
 
T2DM is defined by a fasting plasma glucose (FPG) equal or higher than 126 mg/dl 
or 7 mmol/l [25]. T2DM, associated with ageing and obesity, is characterized by 
altered lipid and glucose metabolism (fasting or postprandial hyperglycaemia, 
dyslipidemia) as a consequence of combined insulin resistance in skeletal muscle, 
liver and adipose tissue and relative defects of insulin secretion by β cells that may 
arise due to an imbalance between energy intake and expenditure [5]. A degree of 
hyperglycaemia sufficient to cause pathological and functional changes in various 
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target tissues, but without clinical symptoms, may be present for a long period of time 
before T2DM is detected. During this asymptomatic period, it is possible to 
demonstrate an abnormality in carbohydrate metabolism by measurement of plasma 
glucose in the fasting state or after a challenge with an oral glucose load [25]. In the 
natural history of T2DM, pancreatic β cells initially compensate for insulin resistance 
by increasing insulin secretion, but with time, progressive β cell failure leads to 
insulin deficiency, and hyperglycaemia ensues [26]. The chronic hyperglycaemia of 
T2DM is associated with long-term damage, dysfunction, and failure of different 
organs, especially the eyes, kidneys, nerves, heart, and blood vessels [25, 27]. The 
aetiology of the disease remains unclear, but T2DM can now be described as complex 
polygenic disease with a strong genetic component, as indicated by the high 
prevalence in certain ethnic groups and by studies of identical twins [28-31]. 
Nevertheless, the rapid increase in the prevalence of obesity-associated disease 
conditions, (including T2DM) in worldwide populations, suggests the contribution of 
environmental factors. A widely accepted explanation implicates the frequent 
consumption of processed foods with a high-calorie content and the reduction in 
physical exercise due to sedentary lifestyle in modern urban environment, as a major 
cause of obesity and subsequent insulin resistance and T2DM [32, 33].  Indeed, it is 
well known that obesity itself causes some degree of insulin resistance [34]. Lifestyle 
changes, consisting of diet and exercise is often an effective measure to improve 
glucose tolerance in the early stages of T2DM, often complemented with anti-diabetic 
drugs or insulin therapy [35, 36]. 
 
1.2.3 Hepatic glucose and lipid regulation in T2DM 
 
The liver plays a major role in maintenance of glucose homeostasis through control of 
glucose production and uptake. This is achieved through regulation of glucose uptake 
and utilisation through glycolysis and glycogenesis and glucose production via 
glycogenolysis and gluconeogenesis. These processes are particularly important 
considering raised blood glucose levels are a characteristic of T2DM and the 
metabolic syndrome [37]. 
 
In healthy individuals, in the fed state, dietary carbohydrate increases plasma glucose 
levels and promotes insulin secretion from the pancreatic β cells. In the liver, insulin 
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promotes glycogen synthesis and de novo lipogenesis while also inhibiting 
gluconeogenesis and glycogenolisis. In the fasted state, insulin secretion is decreased 
as a result of lower blood glucose concentrations. The drop in insulin (as well as the 
increased action of other hormones, including glucagon) leads to increased hepatic 
gluconeogenesis and glycogenolysis and resultant elevated hepatic glucose 
production. This regulatory system is impaired in T2DM, leading to abnormally 
increased hepatic glucose production, which contributes significantly to 
hyperglycaemia. 
 
Hepatic lipid production diminishes while adipose lipolysis increases. In T2DM, 
ectopic lipid accumulation impairs insulin signalling. With accumulation of 
intramyocellular lipid (IMCL), insulin-mediated skeletal muscle glucose uptake is 
impaired. In the liver, increased lipid accumulation also impairs the ability of insulin 
to regulate gluconeogenesis and activate glycogen synthesis. In contrast, lipogenesis 
remains unaffected and, together with the increase delivery of dietary glucose, leads 
to increased lipogenesis and worsening non-alcoholic fatty liver disease (NAFLD), 
very common in obesity-associated T2DM [37]. 
 
1.2.4 Skeletal muscle glucose regulation in T2DM 
 
Under hyperglycemic, hyperinsulinemic conditions, muscle glycogen synthesis is the 
major pathway for glucose metabolism in both normal and diabetic individuals, and 
defective muscle glucose uptake and glycogen synthesis play a major role in causing 
insulin resistance in patients with T2DM [38]. Defects in the ability of insulin to 
activate enzymes in glycogen synthase, hexokinase II, and enzymes in glucose 
transport have all been implicated in the loss of skeletal-muscle glycogen synthesis in 
type 2 diabetics, making each of the corresponding biochemical events a potential 
target for antidiabetic therapy [38].  
 
Insulin-mediated translocation of GLUT4 to the muscle sarcolemmal membrane is 
impaired in patients with T2DM [39, 40]. Thus, a defect in skeletal-muscle glucose 
transport was implicated as the cause of reduced insulin-mediated glucose metabolism 
in patients with T2DM in two independent studies [39, 40]. Moreover, the results of 
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these studies suggested that ectopic accumulation of lipid within the muscle cell might 
be the cause of insulin resistance. 
 
In healthy fed individuals, in the skeletal muscle, insulin increases glucose transport 
through GLUT4, facilitating glucose entry and glycogen synthesis. On the other hand, 
in fasting conditions, glycogen synthesis stops and glycogenolysis takes place, 
generating glucose-1-phosphate, which is converted to glucose-6-phosphate, which is 
subsequently converted in glucose (plus a phosphate group), by the enzyme glucose -
6-phosphatase. At the same time, gluconeogenesis takes place in the liver. Both 
processes are important to produce enough glucose to feed the muscle under these 
conditions. In T2DM, ectopic lipid accumulation impairs insulin signalling as 
mentioned above. With accumulation of intramyocellular lipid (IMCL), insulin-
mediated skeletal muscle glucose uptake is impaired. Glycogenolysis occours and 
glucose transport as well as glycogen synthase are inhibited [37]. 
 
1.2.5 T2DM in white adipose tissue 
 
In white adipose tissue (WAT), insulin suppresses lipolysis and promotes lipogenesis 
during the fed state. During fasting, adipose TAG lipolysis increases while hepatic 
lipid production diminishes. Impaired insulin action in adipose tissue allows for 
increased lipolysis, which will promote inappropriate direction of lipids to other 
tissues (such as liver) and further exacerbates insulin resistance. Coupled with a 
decline in pancreatic β cells, hyperglycemia develops [37]. 
 
1.2.6 Insulin resistance as a primary factor of T2DM 
 
Although the primary factors causing T2DM are unknown, it is clear that insulin 
resistance, which can be defined as a state of reduced responsiveness to normal 
circulating levels of insulin, plays a major role in its development. Evidence for this 
comes from: a) cross-sectional studies demonstrating the consistent presence of 
insulin resistance in patients with T2DM [41]; b) the presence of insulin resistance in 
non-diabetic offspring of patients with T2DM [42]; c) prospective studies 
demonstrating the usefulness of insulin resistance as a predictive marker of the future 
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development of T2DM [41, 42]; d) prevention of diabetes by insulin-sensitizing 
agents [43, 44]. 
 
1.2.7 Obesity-induced insulin resistance and T2DM 
 
Insulin resistance is defined as a subnormal biologic response to a given concentration 
of insulin. Virtually all patients with T2DM have some degree of insulin resistance 
[45].  
 
Lipid accumulation in skeletal muscle and liver may be a result of increased 
delivery/synthesis of FA to/in these tissues in states in which energy intake exceeds 
adipose tissue storage capacity (as seen in obesity and lipodystrophy), or a 
consequence of either acquired or inherited mitochondrial dysfunction. In 1963, 
Randle et al. [46] suggested that elevated non esterified fatty acids (NEFA) 
concentrations were associated with “several abnormalities of carbohydrate 
metabolism, common to many endocrine and nutritional disorders.” The first of these 
abnormalities described was impaired sensitivity to insulin. Insulin resistance 
associated with longer-term lipid overload is now considered to involve accumulation 
of lipids in insulin-responsive tissues other than adipose tissue, so- called ectopic fat 
deposition [47]. The detrimental effects on insulin sensitivity and other cellular 
processes are known as lipotoxicity [48]. It should be noted that is not only pure 
plasma NEFA elevation that is responsible for insulin resistance—plasma TAG 
concentrations are also increased [38].  
 
In skeletal muscle, insulin resistance manifests primarily as a reduction in insulin-
stimulated glycogen synthesis, which is in turn a consequence of reduced glucose 
transport into the myocyte. The coordinated intracellular response to insulin requires a 
complex signaling pathway. In muscle, insulin binds to its receptor, activating the 
receptor tyrosine kinase activity, with subsequent phosphorylation and activation of 
insulin-receptor substrate 1 (IRS1). When phosphorylated, IRS1 activates PI3K. This 
enzyme, through signaling intermediates, activates Akt2, which phosphorylates and 
inactivates AS160, a protein that prevents translocation of GLUT4 through its 
interaction with Rab proteins. Thus, insulin promotes the docking and fusion of 
GLUT4-containing vesicles to the plasma membrane [49] (Fig. 1.2). 
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Figure 1.2 
 
 
 
Figure 1.2: Muscle insulin-resistance. DAG: diacylglycerol; GLUT4: glucose transporter: 4 G6P, 
glucose 6-phosphate: GSK3: glycogen synthase kinase- 3; IRS: insulin receptor substrate; IKK-β: IkB 
kinase-β; JNK-1: Jun kinase-1; LCCoA: long-chain acylcoenzyme A; nPKCs: novel protein kinase Cs; 
PI 3-kinase: phosphoinositol 3-kinase; PIP2: phosphatidylinositol 4,5-bisphosphate; PIP3: 
phosphatidylinositol (3,4,5)-trisphosphate; PTB: phosphotyrosine binding domain; PH: pleckstrin 
homology domain; SH2: src homology domain, UDP-glucose: uridindiphosphat-glucose. Adapted 
from Savage, Petersen and Shulman 2007. 
 
Peterson and his collaborators discovered that an impaired mitochondrial function 
with a lower rate of conversion of diacyl-glycerol (DAG) to triglycerides (TGs) (due 
to a genetic predisposition) would lead to intracellular DAG accumulation, which 
impairs insulin-signalling pathways [50]. 
 
In the liver, insulin resistance is associated with a reduced ability of insulin signalling 
to inhibit glucose production, whereas somewhat paradoxically insulin-stimulated 
lipogenesis seems to be enhanced [51]. Increases in intracellular DAG, due to 
increased lipogenesis and/or decreased mitochondrial FA oxidation, activate PKC-ε 
(protein kinase C-ε), which binds to and inactivates the insulin receptor kinase 
resulting in reduced insulin-stimulated IRS-1 and IRS-2 tyrosine phosphorylation. 
This in turn results in reduced insulin activation of PI3K and Akt2. Reduced Akt2 
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activation results in lower GSK3 phosphorylation and lower FOXO phosphorylation, 
which in turn results in lower insulin-stimulated liver glycogen synthesis and 
decreased suppression of hepatic gluconeogenesis, respectively [51] (Fig. 1.3).  
 
Figure 1.3 
 
 
 
 
Figure 1.3: Liver insulin-resistance. DAG, diacylglycerol; FOXO, forkhead box protein O; GLUT2, 
glucose transporter2; G6P, glucose 6-phosphate; GSK3, glycogen synthase kinase- 3; IRS, insulin 
receptor substrate; IKK-β, IkB kinase-β; JNK-1, Jun kinase-1; LCCoA, long-chain acylcoenzyme A; 
nPKCs, novel protein kinase Cs; PEPCK, phosphoenolpyruvate carboxykinase; PIP2: 
phosphatidylinositol 4,5-bisphosphate; PIP3: phosphatidylinositol (3,4,5)-trisphosphate PI 3-kinase, 
phosphoinositol 3-kinase; PTB, phosphotyrosine binding domain; PH, pleckstrin homology domain; 
SH2, src homology domain. Adapted from Savage, Petersen and Shulman 2007. 
 
The tyrosine phosphorylation of IRS1 and associated activation of PI3K are impaired 
in rodent models of insulin resistance in liver, muscle tissue and adipose tissue [3, 52-
54]. Similarly, IRS1-associated PI3K activity is greatly reduced in muscles of 
individuals being given a five-hour intra-lipid infusions (1.5ml/min), indicating that 
the lipid-induced reduction in insulin-stimulated glucose transport was attributable to 
a defect in insulin signaling [55].  
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As well as reinforcing the importance of life-style interventions in the management of 
T2DM, dietary restriction to limit the stress on energy stores, and exercise to increase 
mitochondrial number and function, these ideas about the molecular pathogenesis of 
insulin resistance have provided several new therapeutic targets for the treatment and 
possible prevention of T2DM [51].  Savage, Petersen and Shulman [51] suggest that 
insulin resistance in skeletal muscle is the earliest event in the pathogenesis of T2DM 
in most patients. Muscle insulin resistance is, in turn, associated with peripheral and 
portal vein hyperinsulinemia, which promotes hepatic steatosis, at least in part by 
inducing SREBP-1c-mediated de novo lipogenesis and inhibiting fatty acid oxidation. 
Research conducted by Wolfram et al. [56] suggests that hyperinsulinemia induces 
nuclear exclusion and inhibition of forkhead box protein A2 (FOXA2), a regulator of 
fatty acid oxidation. In time, this leads to lipid accumulation in the liver, hepatic 
insulin resistance, and ultimately T2DM. Adipocyte dysfunction due to either obesity 
or lipodystrophy is associated with excessive and untimely delivery of fatty acids to 
the liver and skeletal muscle and probably contributes to insulin resistance in both 
organs, by altering the balance between fatty acid uptake/synthesis and disposal 
leading to increases in intracellular lipid content [38] (Fig. 1.4). 
 
Figure 1.4 
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Figure 1.4: Obesity induced insulin resistance (A) Insulin-sensitive muscle. (B) Insulin-resistant 
muscle. (C) Insulin-sensitive liver. (D) Insulin-resistant liver. IRS=insulin-receptor substrate. 
IR=insulin receptor. PI3K=1-phosphatidylinositol 3-kinase. GLUT4=glucose transporter 4. 
DAG=diacylglycerol. PKC=protein kinase C. Ser=serine. Thr=threonine. FOX01=forkhead box O1. 
FOXA2=forkhead box A2. G6P=glucose-6-phosphate. GS=glycogen synthase. GSK=glycogen 
synthase kinase. Green circle with plus sign represents activation. Red circle with minus sign 
represents inactivation. Solid line with arrowhead represents increase or accumulation of substrate. 
Dotted line indicates inhibition of pathway. Adapted from Samuel et al. 2010.  
 
1.2.8 Treatment of T2DM 
 
Non-pharmacological approaches including diet modification, weight control, regular 
exercise and patient education are used as first-line therapy for the management of 
T2DM and remain important for optimization of metabolic control. When lifestyle 
modification fails to achieve or sustain adequate glycemic control, insulin or oral anti-
diabetic agents are typically used to manage the disease [36]. 
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1.2.8.1 Oral agents 
 
Treatment options with oral agents are quite diverse, including metformin (insulin 
sensitising, primarily via inhibition of hepatic glucose production), thiazolidinediones 
(TZDs) (insulin sensitising PPARγ ligands/activators), α-glucosidase inhibitors 
(inhibition of gut glucose absorption) and sulphonylureas (β cell insulin 
secretagogues) [36]. Several new drugs with glucose-lowering efficacy offering 
certain advantages have recently become available, such as injectable glucagon-like 
peptide-1 (GLP-1) agonists and oral dipeptidyl peptidase-IV (DPP-IV) inhibitors. 
These drugs exacerbate the effects of the incretin pathway, leading to elevated 
glucose-stimulated insulin secretion, reduced gastric emptying and direct action on 
the hypothalamus to suppress appetite and ultimately, normalised fasting and 
postprandial glycaemia [57]. 
  
Metformin is typically prescribed as the first-line therapy following life-style changes, 
followed by co-prescription of other therapies if adequate glycaemic control is not 
maintained. The choice of therapy usually depends on a number of factors, including 
age of patient and presence of contraindications [58].  
 
1.3 AMPK  
 
1.3.1 AMPK as a pharmacological target 
 
Several studies have reported that AMP-activated protein kinase (AMPK), a 
phylogenetically conserved serine/threonine protein kinase, is one of the probable 
targets of major anti-diabetic drugs in particular metformin, and of insulin sensitizing 
adipokines (e.g., adiponectin), which are in turn target of TZD’s [58-60]. Evidence 
accumulated over the past few years indicates that AMPK acts as an integrator of 
regulatory signals monitoring systemic and cellular energy status, thus providing 
powerful validation of the concept of targeting the AMPK pathway for the treatment 
of T2DM [36]. 
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1.3.2 Functions of AMPK 
 
ATP hydrolysis provides the energy required for cellular functions. Thus, cells require 
strategies to ensure that adequate regeneration of ATP (from ADP and Pi) is 
maintained. ATP regeneration must be matched to cellular ATP demand, which varies 
with cellular functions, such as muscle cell contraction, hepatic synthesis of glucose, 
adipocyte-dependent synthesis of TAG, cellular synthesis of proteins or pancreatic β 
cell insulin secretion. In addition, many metabolic stressors including glucose 
deprivation, poisoning and hypoxia, lower ATP availability and therefore require 
adjustments to conserve ATP expenditure, in order to allow the cell survive. AMPK 
responds to a requirement to increase cellular ATP production and/or conserve 
available ATP. AMPK is activated by a decline in intracellular ATP concentrations, 
which, through the adenylate kinase reaction, concomitantly elevates intracellular 
ADP and AMP concentrations. As a consequence, AMPK activation occurs in 
response to a rise in AMP associated with metabolic stresses that interfere with ATP 
production (e.g., hypoxia or glucose deprivation) or accelerated ATP consumption 
(e.g., muscle contraction), so as to preserve or maintain tissue function [19]. More 
recently, not only AMP but also ADP, has been shown to activate mammalian and 
yeast AMPK and thus, a rise in intracellular ADP may equally be important for 
AMPK activation [61].  
 
AMPK achieves its capacity to control cellular energy balance by switching on ATP 
generating catabolic pathways and switching off ATP consuming anabolic pathways. 
Thus, for activating catabolism and production of ATP, AMPK increases the 
following processes; long-chain fatty acid (LCFA) uptake into skeletal muscle and its 
mitochondrial oxidation; glucose uptake and glucose and glycogen breakdown. 
Conversely, in order to preserve cellular ATP, AMPK supresses anabolic pathways, 
such as glycogen, lipid and protein synthesis and gluconeogenesis [19].  
 
The acute metabolic actions of AMPK are particularly important in insulin-responsive 
tissues, such as liver, cardiac and skeletal muscle, adipose tissue and the pancreatic β 
cell. Through phosphorylation of key downstream targets, AMPK can regulate 
essential metabolic fluxes, such as glycemic control, insulin action, insulin secretion 
and metabolic substrate selection. In poorly controlled T2DM, AMPK plays an 
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essential role in opposing hyperglycemia, through its glucose-lowering effect, follow 
activation by metformin. It is also important in preventing lipid-induced insulin 
resistance, because of its capacity to inhibit adipocyte lipolysis and to promote LCFA 
uptake, suppressing circulating lipid levels. Furthermore, by stimulating 
mitochondrial LCFA oxidation, AMPK can attenuate ectopic lipid accumulation in 
skeletal muscle and liver [19, 62]. Taken together the physiological functions of 
AMPK and the suspected role of AMPK in metabolic disorders, activation of AMPK 
pathway appears as a promising tool to prevent and/or to treat metabolic disorders, in 
particular, obesity, insulin-resistance and T2DM. 
 
1.3.3 AMPK structure, activation & post-translational modification 
 
AMPK is a heterotrimer of three subunits: α, β and γ subunits, appearing in several 
isoforms with different action properties [19, 62, 63] (Fig.1.5). The α-subunit (α1 and 
α2 in mammals) contains the catalytic site whereas regulatory β- (β1 and β2) and γ- (γ1, 
γ2 and γ3) subunits are important to maintain the stability of the heterotrimeric 
complex. The β subunit contains a central region that allows AMPK complex to bind 
glycogen. The γ subunit contains four tandem repeats known as cystathionine β-
synthase (CBS) motifs and each one of them bind one molecule of an adenine 
nucleotide in a mutually exclusive manner (Fig. 1.5). Charge occupations depend on 
the relative intracellular concentrations of AMP, ADP and ATP, which means, depend 
on the ‘energy state’ of the cell (Fig. 1.5) [19, 62, 63]. ADP, like AMP, stimulates 
AMPKα (Thr172) phosphorylation but, unlike AMP, ADP does not directly activate 
phosphorylated AMPK [61].  
 
 
 
 
 
 
 
 
 
 
35 
Figure 1.5  
 
Figure 1.5: Mechanisms regulating AMP-activated protein kinase activity. AMPK is composed of three 
subunits (α, β and γ) shown within the oval area delimited by the dashed membrane. Arrow-
headeddashed lines indicate mechanisms of regulation. AICAR: 5-aminoimidazone-4-carboxmide-1- β-
D-ribofuranoside; AMPK: AMP-activated protein kinase; CAMKKβ: Ca2+-calmoduline dependent 
protein kinase kinase β; MO25: Mouse protein 25; P: Phosphate, PP2C: Protein phosphate 2 C; SIRT1: 
Sirtuin 2 orthologue; STRAD: Ste 20-related adaptor protein; ZMP: AICAR monophosphatase. 
 
1.3.4 Upstream regulators of AMPK 
 
AMPK upstream kinases include liver kinase B1 (LKB1), which also activates 
additional kinases of the AMPK family [64], and the Ca2+-calmodulin-dependent 
protein kinase kinase β (CaMKKβ) [61, 63] (Fig. 1.5). LKB1, originally identified as 
a tumor suppressor, exists as a complex with two accessory subunits, STRAD and 
MO25. Studies have suggested that constitutive activity of the LKB1 complex is 
required to promote activation by the AMP-dependent pathway [65]. However, recent 
studies indicate that cytosolic localization and activity of LKB1 can be governed by 
LKB1 acetylation status in the liver (Fig. 1.5) [66]. The phosphorylation status of 
AMPKα (Thr172) is also determined by the rate of phosphor-AMPKα (Thr172) 
dephosphorylation, catalyzed by AMPK phosphatases (Fig 1.5). Dephosphorylation is 
slower when either AMP or ADP is bound to the γ subunit, such that net AMPKα 
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(Thr172) is increased and AMPK activity is sustained. AMPK phosphatases include 
members of the protein phosphatase 2C (PP2C or PPM1) family [19] (fig. 1.5).  
 
1.3.5 AMPK activation and improved lipid-induced insulin resistance in 
T2DM 
 
As described in section 1.1, in insulin-responsive tissues, insulin signalling is initiated 
following the binding of insulin to the cell surface insulin receptor, a member of the 
receptor protein tyrosine kinase superfamily. Insulin binds to the leucine-rich C-
terminal domains in two extracellular α chains. This results in conformational change 
that brings the two transmembrane/intracellular β chains (which each contain a PTK 
domain) into closer association, stimulating auto- and trans- phosphorylation of 
tyrosine residues on the β chains. In turn, this initiates an intracellular signalling 
cascade, which phosphorylates tyrosine residues on downstream target proteins, 
including the insulin receptor substrate (IRS) proteins. Most insulin responses are 
initiated through IRS1 and IRS2; both of them are expressed in the main insulin target 
tissues (skeletal muscle, heart, adipocyte and liver) as well as in the pancreatic β cell. 
Defects in phosphorylation of tyrosine residues on the insulin receptor β chains and 
on the IRS proteins represent a central feature of the impaired insulin-stimulated 
uptake of glucose into striated muscle seen in lipid-induced insulin-resistance. 
Impaired insulin signalling related to reduced IRS tyrosine phosphorylation is 
associated with excessive intracellular lipid accumulation [38].  Activation of AMPK 
promotes acute oxidation of LCFA, an opposite action to that of insulin. Increased 
LCFA oxidation (induced by AMPK activation) can suppress glucose breakdown 
through substrate competition (the glucose/FA cycle) and, therefore, can lower 
ectopic lipid accumulation, improving insulin signaling. LCFA oxidation directly 
inhibits glucose transport and phosphorylation and high rates of LCFA exert an acute 
and sustained inhibitory effect in glucose oxidation [19].  
 
1.3.6 AMPK activation combats obesity by suppression of adipogenesis 
and adipocyte glucose uptake 
 
Obesity can arise either from the recruitment of adipocyte progenitor cells 
(preadipocytes) that differentiate into additional mature adipocytes or from excessive 
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TAG accumulation in mature adipocytes resulting in adipocyte hypertrophy.  
Although insulin and AMPK have opposite effects on adipogenesis and adipocyte 
glucose uptake, effects of AMPK activation to suppress adipogenesis and adipocyte 
glucose uptake are beneficial in metabolic diseases (such as T2DM) associated with 
obesity since they attenuate expansion of the adipose tissue mass and the development 
of obesity. Increases in AMPK activity caused by administering AICAR in vivo are 
associated with anti-obesity and insulin-sensitising effects [67]. Importantly, AICAR-
induced AMPK activation evokes a reduction in fat mass without any evidence of 
ectopic lipid deposition, even though it does not increase ATP demand [68]. 
 
The PPAR subtypes (α, β/δ and γ) are transcription factors of the nuclear hormone 
receptor superfamily.  PPARs are activated by lipid-derived ligands and thereby act as 
sensors of “lipid status”, translating nutritional signals into metabolic responses.  
PPAR activation is potentially important for the correction of dyslipidemia and the 
associated hyperglycemia in T2DM: PPARγ activation augments white-adipocyte 
glucose uptake and lipid storage, whereas activation of PPARs α and β/δ promote 
lipid clearance via oxidation in liver and striated muscle.  PPARγ activation is 
necessary and sufficient for differentiation of pre-adipocytes into adipocytes 
(increasing the storage capacity for TAG), and is essential for the survival of the 
differentiated adipocyte [69]. The AMPK activator AICAR inhibits adipogenesis in 
3T3-L1 or F442A preadipocytes [70, 71], and suppresses PPARγ mRNA expression 
in cultured adipocytes [72]. 
 
1.3.7 AMPK opposes insulin’s anabolic actions mediated via mTORC1 
 
The mammalian target of rapamycin (mTOR) is a Ser-/Thr- protein kinase that 
operates as a catalytic subunit in two multimeric signalling complexes, mTORC1and 
mTORC2 [73-75].  mTORC1 activation promotes anabolism, including protein and 
lipid/sterol synthesis  [76], ketogenesis [77] and inhibition of autophagy [78]. The 
mTORC2 complex has emerged as a strong candidate kinase for hydrophobic domain 
phosphorylation of the insulin-signalling kinase Akt [79].  In mTORC2, mTOR is 
complexed with mLST8 (also known as GβL, G protein β-like), mSin and RICTOR 
(Rapamycin-Insensitive Companion of mTOR, a positive regulator of mTORC2). 
Tissue-specific knock-out of RICTOR in adipose tissue decreases insulin-stimulated 
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glucose uptake and GLUT4 translocation [80]. 
 
A widely-accepted pathway of mTORC1 activation involves activation of PI3K and 
Akt. Akt on mTOR has now been identified as mTOR(Ser1261), and phosphorylation 
of this site may initially regulate mTOR activity in mTORC1 [81]. In contrast to 
phosphorylation of Ser2448, Ser2481 and Ser1261, phosphorylation of mTOR (Ser2446) by 
AMPK inhibits mTOR protein kinase activity, and this phosphorylation is increased 
by nutrient deprivation but suppressed by insulin [82]. 
 
Thus, to summarise, whereas insulin stimulates mTORC1 activity, AMPK inhibits it, 
thereby opposing insulin’s anabolic actions mediated via mTORC1. Nonetheless, 
AMPK activation can oppose the development of insulin resistance in skeletal muscle 
induced by nutrient excess (exposure to high glucose or high glucose plus branched 
chain amino acids), which has been proposed to be secondary to mTOR 
hyperactivation [83]. These authors suggested that down-regulation of AMPK activity 
in skeletal muscle in response to nutrient excess precedes mTOR activation and, 
moreover, that AMPK activation by AICAR diminishes mTOR signalling and insulin 
resistance in concert.  
 
The livers of insulin-resistant, diabetic mice manifest selective insulin resistance, 
suggesting a bifurcation in the insulin-signaling pathway: Insulin loses its ability to 
block glucose production (i.e., it fails to suppress PEPCK and other genes of 
gluconeogenesis), yet it retains its ability to stimulate fatty acid synthesis (i.e., 
continued enhancement of genes of lipogenesis). Enhanced lipogenesis is 
accompanied by an insulin-stimulated increase in the mRNA encoding SREBP-1c 
[84]. Li et al. have shown that exposure of rat hepatocytes to insulin produced a 
sugnificnt increase in SREBP-1c mRNA and a significant decrease in PEPCK mRNA. 
Insulin-mediated changes in both mRNAs are blocked by inhibitors of PI3K and Akt, 
indicating that these kinases are required for both pathways. In contrast, 
subnanomolar concentrations of rapamycin, an inhibitor of the mTORC1 kinase, 
blocked insulin induction of SREBP-1c, but had no effect on insulin suppression of 
PEPCK. A similar selective effect of rapamycin was observed in livers of rats and 
mice that experienced an insulin surge in response to a fasting-refeeding protocol. 
These results establish mTORC1 as an essential component in the insulin-regulated 
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pathway for hepatic lipogenesis but not gluconeogenesis, and may help to resolve the 
paradox of selective insulin resistance in livers of diabetic rodents. 
 
1.4 PPARα 
 
Peroxisome proliferator activated receptor-alpha (PPARα), along with PPAR and 
PPAR, is a member of the nuclear hormone receptor superfamily. At binding of their 
ligand, PPARs form heterodimers with 9-cis retinoid X receptors (RXRs) and bind to 
DNA response elements in target gene promoter regions. Forming a heterodimer with 
RXRα, PPARα binds to a DNA response element, namely the nuclear receptor 
response element (NRRE). At binding of the NRRE within the promoter of PPAR 
target genes, gene transcription is activated. Induction of PPARα gene targets requires 
the interaction of PPARα with PGC-1, often in complex with other enzymes and co-
activators. Formation of these complexes is required for full transcriptional induction 
of PPARα targets in a variety of tissues. [85-87]. The main physiological function of 
PPARα appears to involve control of critical genes in lipid and lipoprotein 
metabolism. Thus, PPAR regulates lipid uptake and oxidation, in contrast with that 
of PPARγ, which promotes uptake but subsequent storage of lipid as TAG in adipose 
tissue [85, 88]. PPARα expression is relatively high in hepatocytes, enterocytes, 
vascular and immune cell types such as monocytes/macrophages, endothelial cells, 
smooth muscle cells, skeletal muscle, lymphocytes, non-neuronal cells like microglia 
and astroglia [89]. PPARα target genes include carnitine palmitoyltransferase I (CPT 
I), mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase (the rate limiting enzyme 
of ketogenesis), peroxisomal acyl-CoA oxidase (peroxisomal β-oxidation), and 
microsomal cytochrome P450 (CYP) FA ω-hydroxylases. Thus, PPARα plays a 
critical role in maintenance of lipid homeostasis (oxidation and production) [86]. In 
the fasting state, PPARα is activated by adipose-derived FAs, thereby enhancing the 
generation of ketone bodies through FA oxidation in liver and peripheral blood 
mononuclear cells [90]. Despite suppression of insulin levels and increases in FA 
supply, PPARα-deficient mice exhibit an impaired ability to adequately up-regulate 
hepatic FA oxidation in response to fasting [91]. PPARα deficiency leads to 
accumulation of hepatic TAG and elicits dysregulation of hepatic lipid and 
carbohydrate metabolism in mice [92]. Insulin resistance induced by excess of non-
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esterified FA and circulating TAG can be corrected by the administration of PPARα 
activators by actions to promote removal of intracellular lipid through tissue FA 
oxidation [93]. In light of these findings, PPARα is potentially a powerful molecular 
target for the treatment of obesity and metabolic disorders. 
 
In WAT, the role of PPARα is not yet established because of the low expression of 
the nuclear receptor in that tissue [85]. PPARγ is highly expressed and active in 
WAT, suggesting that in this tissue adipocyte differentiation and TG storage are 
dominant and lipid catabolism occurs in a very low rate [85]. One study showed that 
PPARα activation in WAT prevents inflammation, and dual activation of PPARα and 
-γ enhances the action of adiponectin by increasing both adiponectin and adiponectin 
receptors (AdipoRs), which can result in the amelioration of obesity-induced insulin 
resistance [94]. 
 
1.5 PGC-1α 
 
In addition to ligand-mediated activation, PPARs also are co-activated by 
transcriptional co-activators and co-repressors. Transcriptional co-activators interact 
indirectly with the PPARs and other nuclear receptors to establish a platform for 
recruitment of other proteins important to chromatin remodeling and recruitment of 
the RNA polymerase II complex. One of the most well studied PPARα co-activators 
is PGC-1 [95] The PGC-1 co-activators [PGC-1α, PGC-1β, and PGC-related co-
activator (PRC)] have been well described as important regulators of mitochondrial 
metabolism [95]. These co-activators have an impact on cellular biologic responses, 
enabling the cell to meet changing energy demands associated with various 
physiologic stimuli. These responses include augmenting mitochondrial biogenesis, 
respiratory rates, and uptake and metabolism of substrate. The first member of the 
PGC-1 family to be identified was PGC-1α. It was discovered as a result of its 
interactions with the nuclear receptor, PPAR-γ, in brown adipose tissue, a 
mitochondria-rich tissue specialized for thermogenesis. Expression of PGC-1α, also is 
increased in association with physiologic and pathologic stimuli such as exercise and 
starvation [95].  
 
PGC-1α is highly expressed in tissues that rely on aerobic metabolism for ATP 
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production (e. g. skeletal muscle) and relatively low expressed in the liver [95]. 
However, hepatic PGC-1α gene expression is robustly induced in response to fasting 
(Yoon et al. 2001). PGC-1α activates expression of PPARα target genes involved in 
hepatic FA oxidation [96]. Rates of FA oxidation are also diminished in hepatocytes 
isolated from PGC-1α–deficient mice [97]. The reduction in FA oxidative capacity 
likely contributes to the fasting-induced hepatic steatotic phenotype observed in one 
of the mutant lines. Surprisingly, the expression of PPARα target genes involved in β-
oxidation is not reduced in generalized PGC-1α–/– mice [97]. However, hepatocytes 
isolated from PGC-1α–deficient mice exhibit diminished mitochondrial respiration 
rates[97], providing one mechanistic explanation for the reduced capacity for hepatic 
fatty acid oxidation. During periods of fasting, the liver catabolises fatty acids to 
produce 3-carbon substrates for use in gluconeogenesis, the most important source of 
de novo glucose production in higher organisms. PGC-1α gene expression is activated 
in liver by fasting and glucocorticoids, and it is now recognized that it regulates 
hepatic gluconeogenesis [95]. 
 
1.6 Calorie Restriction 
 
Calorie restriction (CR; also called dietary, food, or energy restriction), a reduction of 
intake of a nutritious diet (at least, 30% reduction), is often reported as the most 
robust non-genetic mechanism to extend healthspan and lifespan of yeast, worms, 
flies, and rodents [98, 99]. Studies in the lower-order organisms have sparked interest 
in the possibility that CR or a CR mimetic can have similar effects on health and 
lifespan in larger, more complex, and longer-lived species and, potentially, in humans. 
To explore this possibility, studies of the effects of CR on aging in nonhuman 
primates (NHP) formally began nearly 25 years ago. In 2009, a study [100] which 
began in 1989 at the Wisconsin National Primate Research Center (WNPRC) in 
Madison, concluded that CR did extend life in rhesus monkeys. The investigators 
found that only 13% of the dieting group died from age-related causes, compared with 
37% of the control group. The investigation started when the animals were aged 7-14 
(adults) and the maximal lifespan of these animals in captivity is nearly 40 years. 
Nevertheless, another 25-year study in rhesus monkeys, fed 30% less than control 
animals, more recently published in Nature [98], represents a setback for the notion 
that a simple, diet-triggered switch can slow ageing. Instead, the findings, suggest that 
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genetics and dietary composition matter more for longevity than a simple calorie 
count. Meanwhile, there is a dearth of evidence that caloric restriction slows ageing in 
humans. Observational studies have found that people of average weight tend to live 
longest [101]. To date, CR has not been conclusively proved to slow ageing and 
related diseases in human and non-human primates but, however, fasting and CR have 
been shown to result in increased insulin sensitivity and lower blood glucose as well 
as reduced body weight and fat in rhesus monkeys.  
 
It is has been proposed that the response to CR may have evolved as an adaptive trait 
to postpone reproduction during food scarcity to times of greater food availability. 
This may have led animals to take advantage of the fact that storage of fat was a sign 
of food availability and in turn that leanness was a sign of food scarcity. Thus when 
food was plentiful, the most advantageous strategy was to reproduce. On the other 
hand when food was scarce the opposite strategy would be most advantageous. In 
modern times, particularly in the Western society, calorie-rich foods are freely 
available but food behavior and metabolic processes did not evolve for an 
environment permitting continual over consumption [102]. 
 
1.6.1 Sirtuins 
 
There is growing evidence that the metabolic network is an integral regulator of 
cellular physiology. Dynamic changes in metabolite concentrations, metabolic flux, or 
network topology act as reporters of biological or environmental signals, and are 
required for the cell to trigger an appropriate biological reaction. Changes in the 
metabolic network are recognized by specific sensory macromolecules and translated 
into a transcriptional or translational response. The protein family of sirtuins, 
discovered more than 30 years ago as regulators of silent chromatin, potentially 
fulfills the role of a metabolic sensor during aging and conditions of caloric restriction 
[103]. 
 
The SIR (silent information regulator) mutants and genes were first discovered in 
1979 in saccharomyces cerevisiae [104].  In mammals, the sirtuin family of proteins 
is a seven-member group (SIRT1–7) of highly conserved, NAD-dependent protein 
deacetylases that function in the regulation of various biological processes. Each 
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member of the family is characterised by a conserved 275 amino acid catalytic core 
domain and a unique N-terminal and/or C-terminal domain of variable length [105]. 
The mammalian sirtuins occupy different sub-cellular compartments. SIRT1, SIRT6 
and SIRT7 are nuclear based. SIRT2 (and under certain conditions, SIRT1) is present 
in the cytoplasm, whilst SIRTs3 - SIRT5 are found in the mitochondria. The activity 
within the cell of each sirtuin also differs. SIRT1 and SIRT5 are histone deacetylases, 
but SIRT5 can also exert demalonylase and desuccinylase activity [106]. SIRT 4 and 
SIRT6 have ADP-ribosyl transferase activity [105]. However several studies have 
shown that SIRT6 has also deacetylase activity [107]. SIRT2 and SIRT3 demonstrate 
both deacetylase and ADP-ribosyl transferase activity. SIRT7 enhances rDNA 
transcription in the nucleous [108]. 
 
1.6.1.1 Regulation of sirtuins in calorie restriction 
 
CR decreases the activity of pro-aging pathways such as insulin and growth hormone 
signaling and oxidative stress. On the other hand, CR stimulates the activity of 
cellular stress-resistance pathways including DNA repair and autophagy promoting 
cell survival in response to environmental stress [109]. It has been shown that in 
yeast, CR reduces cellular NADH concentrations, thereby increasing the 
NAD+/NADH ratio and promoting SIR2 activity [110]. In a number of lower model 
organisms, sirtuins are required for the lifespan extension provided by CR [109]. 
Studies have shown that in mice, SIRT1 protein levels are elevated during CR in the 
brain, WAT, muscles, liver, and kidney [111, 112].  
 
CR induces the expression of SIRT3, particularly in brown adipose tissue (BAT) 
[113]. However, during CR in mice, cellular NAD+ levels and the NAD+/NADH ratio 
fluctuate significantly depending on tissue type, suggesting that sirtuins have tissue-
specific responses to CR. Nevertheless, it appears that SIRT1 regulates energy 
metabolism and physical responses to CR, while SIRT3 is able to mediate CR-
associated reduction of oxidative damage, preventing age-associated hearing loss 
[109]. These evidences clarify the importance of sirtuins in CR-mediated prevention 
of age-associated functional decline, suggesting that sirtuins may be important 
therapeutic targets for a number of age-related diseases.  
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In summary, over-expression of sirtuins has been reported to increase lifespan in 
model organisms [114, 115]. CR is known to increase lifespam in yeast, worms, flies, 
and rodents [98, 99], and studies suggested that CR increases lifespan by activating 
sirtuins in yeast, C. elegans and Drosophila  [115-117]. However, several aspects of 
the role of sirtuins in ageing have proved controversial. Subsequent studies have 
suggested that sirtuins do not mediate CR effects on ageing, at least in budding yeast 
and C. elegans [118, 119]. Burnett et al. have found that CR increased fly lifespan 
independently of SIR2 [120]. These recent findings do not rule out a role for sirtuins 
in determination of metazoan lifespan, but they do cast doubt on the robustness of the 
previously reported effects on lifespan inmodel organisms. 
 
1.6.1.2 SIRT1 
 
Mammalian SIRT1 shares the closest similarity to SIR2, a protein that was first shown 
to play an essential role in the control of yeast replicative life span. In mammals, 
SIRT1 appears to play an important role in controlling glucose metabolism, insulin 
action, fat storage, and nutrient sensing [102, 121]. 
 
Although there is no consistent evidence that SIRT1 content and/or activity declines 
with ageing, activating this pathway might still be beneficial in preventing some 
manifestations of aging. Resveratrol is a plant-derived polyphenol that may activate 
SIRT1 [122] and is reported to exert antioxidant, anti-inflammatory, and anti-
tumorigenic properties. It has been suggested that through activation of SIRT1, 
resveratrol may function as a CR mimetic. Resveratrol treatment has been shown to 
increase life span in several organisms, including, most notably, high-fat–fed mice, 
which had improved insulin sensitivity, mitochondrial function, and survival [123]. 
More recently, treatment of obese mice with SRT1720, a synthetic activator of 
SIRT1, resulted in similar improvements in survival as were observed in resveratrol-
treated mice [124]. These studies make a case that both natural and synthetic SIRT1 
activators can improve health and survival, though the belief that these effects are 
SIRT1-dependent remains controversial, particularly with respect to the actions of 
resveratrol. In addition, the concept that CR uniformly increases SIRT1 has also been 
challenged, as one study reported that CR decreased SIRT1 activity in liver [125] and 
another study has reported that CR has no effect on SIRT1 protein expression in 
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skeletal muscle and adipose tissue, while increases SIRT3 expression in the same 
tissues [126]. This suggests that targeting SIRT1 to delay age related diseases (such as 
T2DM) might be more complex than had been originally anticipated. 
 
1.6.1.3 SIRT1 in hepatic glucose and lipid metabolism 
  
SIRT1 is an important regulator of hepatic glucose and lipid metabolism. Contrasting 
effects of SIRT1 are reported with respect to hepatic gluconeogenesis. For instance, 
SIRT1 has been shown to repress gluconeogenic gene expression through inhibition 
of HNF4α [127] and, during short-term fasting (6 to 8 hours), SIRT1 inhibits cAMP 
response element binding protein (CREB)-regulated transcriptional coactivator 2 
(CRTC2; also known as TORC2), a key mediator of early phase gluconeogenesis 
[128]. In contrast, prolonged fasting (24 to 48 hours) increases SIRT1-mediated 
deacetylation (and activation) of PGC-1α leading to elevated gluconeogenesis [128, 
129]. Furthermore, several studies support the notion that elevated SIRT1-mediated 
gluconeogenesis plays a key role in mediated abnormal elevation of hepatic glucose 
production in T2DM [130-132].  
 
SIRT1-has also been reported to play a critical role in regulation of hepatic FA 
oxidation and regulation of lipid homeostasis [109]. Hepatic deletion of SIRT1 leads 
to impaired PPARα signaling, while overexpression of SIRT1 activates PPARα, 
increasing expression of PPARα gene targets, and increased fatty acid oxidation. 
SIRT1 induces PPARα signaling through deacetylation of PGC-1α [133]. 
Interestingly, SIRT1 does not affect the formation of the PPARα–PGC-1α complex, 
since in SIRT1 knockdown hepatocytes PGC-1α is still recruited to the PPAR 
response element (PPRE) of FA oxidation genes. However, PGC-1α remains 
acetylated when SIRT1 is not present so it is unable to induce transcription of PPARα 
gene targets.  
 
SIRT1 also regulates hepatic cholesterol and bile acid homeostasis through direct 
modulation of the liver X receptor (LXR), farnesoid X receptor (FXR), and SREBP 
family of transcription factors [109]. Li and collaborators have previously shown that 
SIRT1 can directly deacetylate LXRs, resulting in increased LXR turnover and target 
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gene expression [134]. Systemic deletion of SIRT1 in mice results in decreased serum 
HDL levels [125, 134].  
 
Consistent with the notion of an important role for SIRT1 in regulating hepatic fatty 
acid oxidation, a deletion of hepatic SIRT1 by floxing exons 5 and 6 leads to the 
development of liver steatosis even under normal chow diet [135], whilst hepatic 
overexpression of SIRT1 mediated by adenovirus attenuates hepatic steatosis and ER 
stress, and restores glucose homeostasis in mice [136], confirming the essential role of 
SIRT1 in maintaining hepatic metabolic homeostasis. 
 
GCN5 counters the effect of SIRT1 by acetylating PGC-1α, inhibiting its 
transcriptional activity [137-139]. Hence, the balance between relative levels and 
activity of SIRT1 and GCN5 could provide regulatory convergence point for 
induction of PPARα gene targets and potentially other SIRT1 targets. 
 
In summary, these findings imply that hepatic SIRT1 plays a critical role in metabolic 
regulation, and activation of SIRT1 in the liver may prove beneficial in treating 
obesity-associated diseases, such as T2DM. However, contrasting effects of SIRT1 
are reported with respect to hepatic gluconeogenesis. Further studies need to be done 
in order to understand the role of SIRT1 in the development of T2DM, concerning the 
gluconeogenic pathway. 
 
1.6.1.4 SIRT1 regulates skeletal muscle glucose and lipid metabolism 
 
In skeletal muscle, SIRT1 regulates glucose and lipid metabolism in part through 
deacetylation of PGC-1α. PGC-1α is responsible for switching mitochondrial 
metabolism from glucose to fatty acid oxidation under conditions of starvation [138]. 
In muscle (and also in liver), GCN5 acetylates PGC-1α with a repressive effect on its 
activity [137], whereas SIRT1, induced by fasting, deacetylates PGC-1α in vitro [138, 
140].  
 
Additionally, SIRT1 improves insulin sensitivity in skeletal muscle. A study from 
Schenk et al. has shown an improvement in insulin sensitivity, secondary to increased 
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insulin-stimulated PI3K activity, in mice submitted to 20 days of CR although, in 
mice lacking SIRT1 (through deletion of the exon 4 that encodes for the deacetylase 
activity of SIRT1 gene), this improvement in insulin sensitivity was completely 
abrogated [141]. In this study Schenk has found that SIRT1 is required for the 
deacetylation and inactivation of the transcription factor Stat3 during CR, which 
resulted in decreased gene and protein expression of the p55α/p50α subunits of PI3K, 
thereby promoting more efficient PI3K signaling during insulin stimulation.  
 
1.6.1.5 SIRT1 in white adipose tissue 
 
White adipose tissue (WAT) is the major fat storage organ in the body. SIRT1 is up 
regulated in WAT in response to food withdrawal, where has been shown to repress 
PPARγ, by docking with its cofactors NCoR (nuclear receptor co-repressor) and 
SMRT (silencing mediator of retinoid and thyroid hormone receptors) [111]. 
Moreover, in differentiated adipose cells, up regulation of SIRT1 leads to decreased 
fat storage and increased lipolysis [87]. 
 
WAT also functions as an endocrine organ, secreting a number of bioactive peptides, 
known as adipokines, such as leptin and adiponectin, which control energy balance, 
glucose regulation, and FA catabolism. In addition, adipose tissue macrophages 
(ATMs) are prone to secrete high levels of inflammatory mediators, such as tumor 
necrosis factor alpha (TNFα), interleukin-6 (IL-6), and inducible nitric oxide synthase 
(iNOS), resulting in a heightened inflammatory status particularly under obesity 
conditions [142].  In obesity, insulin resistance has been linked to leptin resistance 
and decreased plasma adiponectin [143, 144]. SIRT1 increases adiponectin 
transcription in adipocytes through deacetylation and activation of FOXO1, which 
enhances the interaction between FOXO1 and C/EBPalpha, resulting in increased 
adiponectin production [145]. Effects of SIRT1 in leptin levels are not well 
established yet.  
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1.6.1.6 SIRT1 and AMPK: A regulatory feedback loop? 
 
1.6.1.6.1 AMPK regulation by SIRT1 
 
Downregulation of AMPK in response to high glucose, with a parallel decrease in 
SIRT1 activity was observed in cultured HepG2 cells [146, 147]. In both studies there 
was an increase in the release of lactate, suggesting a decrease in the NAD+/NADH 
ratio, which could have contributed to the decrease in SIRT1 activity. Lan et al 
demonstrated that overexpression of SIRT1 in human embryonic kidney-293T cells 
diminished lysine acetylation of LKB1 and caused its movement from the nucleus to 
the cytoplasm, where LKB1 became active and activated AMPK. In contrast, 
transfection with short hairpin (sh)RNAi for SIRT1 had opposite effects on these 
parameters and also decreased the phosphorylation of another LKB1 target, the 
AMPK-related kinase MARK1 [66]. Hou et al found later that the ability of 
resveratrol to activate AMPK in vitro (HepG2 cultured cells) and in vivo (mouse 
liver) required the presence of both: LKB1 and SIRT1 [148]. These findings together 
with the demonstration that SIRT1 and AMPK share common activators, actions and 
target molecules [149], led us to believe that AMPK activity is regulated by SIRT1 in 
an LKB1-dependent manner.  
 
1.6.1.6.2 SIRT1 regulation by AMPK 
 
Fulco et al observed that glucose restriction impaired the differentiation of skeletal 
muscle myoblasts, an effect preceded by a much earlier decrease in cellular ATP and 
an increase in the activity of AMPK. They also found that incubation with 5-
aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR), a more direct AMPK 
activator, produced a similar sequence of events. In both situations, the inhibition of 
myoblast differentiation was accompanied by an increased transcription of the NAD+ 
biosynthetic enzyme NAMPT, which in turn increased the NAD+/NADH ratio. 
Conversely, both myoblasts derived from SIRT1+/− mice and cells transduced with 
shRNAi for SIRT1 were resistant to the effect of AMPK activation on muscle 
differentiation, strongly suggesting that it was SIRT1 mediated [150]. In a subsequent 
study, Canto and Auwerx [151] demonstrated that AMPK activation by AICAR 
increased PGC-1α-mediated gene expression in a SIRT1-dependent manner in C2C12 
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myocytes and mouse embryonic fibroblasts. They have also shown that various 
AMPK activators (AICAR, metformin and the mitochondrial uncoupler 
dinitrophenol), but not direct SIRT1 activators, increased NAD+ levels and the 
NAD+/NADH ratio and that this resulted in SIRT1 activation, as evidenced by the 
deacetylation and activation of PGC-1α. The two groups differ in that Fulco et al. 
[150] proposed that the key linkage between increased AMPK and SIRT1 activities 
was the upregulation of NAMPT, whereas Canto et al. [151] found that AMPK could 
alter the NAD+/NADH ratio and activate SIRT1 apparently independently of 
NAMPT. Iwabu et al. have provided evidence that adiponectin induces extracellular 
Ca(2+) influx by adiponectin receptor 1 (AdipoR1), which was necessary for 
subsequent activation of CaMKKβ (AMPK upstream kinase), AMPK and SIRT1, 
increased expression and decreased acetylation of PGC-1α, and increased 
mitochondria in myocytes [152]. Moreover, muscle-specific disruption of AdipoR1 
suppresses the adiponectin-mediated increase in intracellular Ca(2+) concentration, 
and decreased the activation of CaMKKβ, AMPK and SIRT1 by adiponectin. 
Suppression of AdipoR1 also resulted in decreased PGC-1α expression and 
deacetylation, decreased mitochondrial content and enzymes, decreased oxidative 
type I myofibres, and decreased oxidative stress-detoxifying enzymes in skeletal 
muscle, which are associated with insulin resistance [152]. These studies, together 
with the studies that show that AMPK is regulated by SIRT1, suggest a possible 
feedback loop between both proteins, which might be an interesting target for the 
treatment of T2DM. 
 
1.6.1.7 SIRT3 
 
SIRT3, the most well characterised mitochondrial sirtuin, is highly expressed in 
metabolically active tissues such as brown adipose, muscle, liver, kidney, heart, and 
brain [109]. SIRT3 deficient mice exhibited striking mitochondrial protein 
hyperacetylation [153]. These hyperacetylated proteins include subunits of oxidative 
phosphorylation complexes and metabolic enzymes such as: a) acetyl-CoA synthetase 
2 (AceCS2), an enzyme that catalyzes the production of acetyl-CoA from acetate; b) 
glutamate dehydrogenase (GDH), which interconverts glutamate and α-ketoglutarate 
(KG) and is a pivotal enzyme in regulating amino acid entry into the TCA cycle; c) 
long-chain acyl CoA dehydrogenase (LCAD), a central enzyme in the fatty acid β-
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oxidation pathway; and d) 3-hydroxy-3-methylglutaryl CoA synthase 2 (HMG-
CoAS2), the rate-limiting step in β-hydroxybutyrate synthesis, as well as oxidative 
stress reducing enzymes, in particular, isocitrate dehydrogenase 2 (ICDH2), 
superoxide dismutase 2 (SOD2), and MnSOD [109, 154]. ICDH2 catalyzes the 
irreversible oxidative decarboxylation of isocitrate to KG and CO2 [154]. The 
increased production of KG mediated by NADP-dependent isocitrate dehydrogenase 
(NADP-ICDH) and its decreased utilization via the TCA cycle confer a unique 
strategy to modulate the cellular redox environment. KG is a key participant in the 
detoxification of reactive oxygen species (ROS) in live organisms [155]. The capacity 
of SIRT3 to deacetylate and activate ICDH2 is then important to protect cells from 
ROS production and age-related oxidative damage [154]. SIRT3 also protects in vitro 
fertilized mouse pre-implantation embryos against oxidative stress [156]. 
Furthermore, two studies showed that SIRT3 deficient mice failed to suppress 
oxidative stress in response to CR, where in cultured cells overexpression of SIRT3 
and/or ICDH2 increases NADPH levels and protects from oxidative stress-induced 
cell death [157, 158]. These observations demonstrate that SIRT3 can delay the onset 
of a number of oxidative stress-associated pathologies in multiple tissues and suggest 
that SIRT3 may be a novel target for these age-associated diseases as well as aging 
itself. 
 
A number of recent studies have reported that hyperacetylation of mitochondrial 
proteins in SIRT3 deficient mice results in a variety of metabolic abnormalities 
including reduced ATP production, decreased rates of fatty acid oxidation, and fatty 
liver [159-162]. However, since SIRT3 null mice display minimal phenotypes under 
normal feeding conditions, particularly when they are young [153], much work still 
needs to be done to determine whether the effects of SIRT3 deletion on these 
processes are physiologically relevant, and whether they are direct consequences of 
particular hyperacetylated mitochondrial proteins. Furthermore, it remains to be 
answered whether SIRT3 is required for CR-mediated extension of lifespan or it is 
only a part of CR- elicited anti-aging circuits [153]. 
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1.7 The interacting metabolic roles of AMPK, the lipo-oxidative PPARs and 
SIRTs 
 
Whereas PPARγ activation augments white-adipocyte glucose uptake and lipid 
storage in the fed state, activation of the lipo-oxidative PPARs α and β/δ promote 
lipid clearance via oxidation in liver and striated muscle and assume an important role 
in lipid management during periods of carbohydrate scarcity (e.g., fasting). By 
promoting metabolic adaptations that enhance the oxidation of lipid, which might 
otherwise be stored (adipose tissue) or accumulated ectopically (liver, skeletal 
muscle), PPARα and PPARδ/β shift energy production away from carbohydrate 
oxidation and are insulin sensitising and, in this regard, have metabolic actions that 
complement the more acute actions of AMPK.  
 
There is an associated loss of co-repressors and recruitment of coactivators (e.g. 
PPARγ co-activator-1α, PGC-1α). PGC-1α induces mitochondrial biogenesis and 
triggers mitochondrial proliferation. In oxidative muscle and liver, PGC-1α 
cooperates with PPARα to increase the expression of genes encoding mitochondrial 
FA oxidation enzymes, thereby increasing the capacity for FA oxidation and 
intracellular lipid clearance [163]. AMPK activation by AICAR increases expression 
of PPARα target genes and PGC-1α in cultured muscle cells and mouse skeletal 
muscle, whereas inhibition of PPARα and PGC- α by siRNAs prevents AICAR-
stimulated increases in LCFA oxidation [164]. 
 
PGC-1α and -β are also substrates for the sirtuin class of NAD+- dependent protein 
deacetylases. In general, AMPK and SIRT1 have similar metabolic effects: they 
mutually regulate one other and share common metabolic targets [149]. As noted 
previously, SIRT1 (and possibly SIRT3) deacetylate and activate the AMPK kinase 
LKB1. Both SIRT1 and SIRT3, similarly to AMPK and the lipo-oxidative PPARs, 
promote LCFA oxidation.  SIRT1 protein expression increases in response to 
prolonged caloric restriction.  This is associated with increased mitochondrial 
biogenesis mediated by activated PGC-1α [112], which is post-translationally 
deacetylated and activated by SIRT1 [129, 140].  AMPK could be a key sensor and 
effector in mediating the beneficial effect of caloric restriction on health and lifespan, 
as discussed in detail elsewhere [165].  Deficient AMPK activity compromises 
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SIRT1-dependent responses of skeletal muscle to both fasting and exercise, resulting 
in impaired PGC-1α deacetylation, which in turn suppresses induction of 
mitochondrial biogenesis and mitochondrial gene expression [166].   
 
In liver, SIRT3 regulates the acetylation status of several metabolic enzymes in the 
mitochondrial matrix, including LCAD.  LCAD is deacetylated and activated in wild-
type mice on fasting, promoting β-oxidation [167].  Like PPARα-/- mice, SIRT3-/- 
mice appear phenotypically normal in the fed state (although they show marked 
hyperacetylation of several mitochondrial proteins) but, during fasting, their livers 
exhibit lower rates of LCFA oxidation, together with higher levels of FA-oxidation 
intermediates and TAG accumulation [168]. Increased SIRT3 preserves ATP 
biosynthetic capacity and protects myocytes from oxidative stress-mediated cell death 
[159].  Conversely, SIRT3 deficiency decreases O2 consumption and causes the 
development of oxidative stress, leading to impaired insulin signaling via increased 
Ser-phosphorylation and decreased Tyr-phosphorylation of IRS-1. This effect is 
mimicked by knockdown of SIRT3 in cultured myoblasts, which exhibit reduced 
mitochondrial oxidation, increased ROS, and increased Ser- phosphorylation in 
combination with decreased Tyr-phosphorylation of IRS-1 [169].  Steady-state ATP 
levels are reduced in SIRT3−/− mouse embryonic fibroblasts, which may result from a 
defect in deacetylation of electron transport chain components [159].  AMPK 
regulates the expression of oestrogen-related receptor α (ERRα), which binds to the 
SIRT3 promoter [170].  
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1.8 Aim of the thesis 
 
AMPK and SIRT1 both regulate each other and share many common target 
molecules. Furthermore, both AMPK and SIRT1 can interact with and regulate PGC-
1α and PPARα and this is an essential requirement for full transcriptional induction of 
PPARα gene targets as well as interaction with other nuclear receptors. Given this, my 
research sought to establish and characterise the links between SIRT1 and AMPK and 
induction of PPARα gene targets in modulating insulin-responsive tissues, with the 
view of establishing the potential for use of dual SIRT1 and AMPK activators as an 
effective treatment in T2DM.  
 
Specific aims: 
1. To delineate further the potential regulatory importance of deacetylation of 
PGC-1α by the NAD+ regulated protein deacetylase SIRT1 and its regulation 
by AMPK in modulating the function of PPARα gene expression in the liver, 
in response to alteration in nutritional status; 
 
2. To understand the impact of nutrient availability (starvation, high fat, and 
maternity low protein diet) in lipogenesis in insulin sensitive tissues; 
 
3. To investigate whether a feedback loop exists to regulate AMPK and SIRT1 
activation in liver and muscle, in vivo and in vitro, whereby AMPK activates 
SIRT1 through NAMPT or -oxidation and, in turn, SIRT1 causes further 
activation of AMPK;  
 
4. To investigate whether AMPK deficiency modulates SIRT1 activity and to 
understand the role of AMPK-SIRT1 pathway in the context of insulin 
response, in skeletal muscle and liver in vivo and in vitro; 
 
5. To examine the role of IRF3 and IRF4 in the maternal low-protein model of 
fetal programming, to better understand the mechanisms responsible for onset 
of obesity following exposure to an adverse intra-uterine environment. 
 
54 
I have used disease models (muscle and liver specific AMPK α1/2-/- mice, PPARα 
knockout mice) as well as specific diet administration (CR, high fat, high fructose and 
maternity low protein diet) to achieve the objectives. 
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Chapter: 
2. Materials and Methods 
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2.1 Materials 
 
 Reagents of analytical grade and deionized water (obtained from Triple Red 
Laboratory Technology Ltd., Buckinghamshire, UK) were used. 
 
Nuclease-free water, RNase-free 50 ml and 15 ml falcon tubes, 1.5 ml microfuge 
tubes, 0.2 ml qPCR tubes and the scrambled sequence siRNA (negative control) were 
purchased by Ambion (Cambridgeshire, UK). Full range rainbow recombinant 
protein molecular weight marker (range 10,000 – 250,000), hybond ECL 
nitrocellulose membranes and hyperfilm ECL were obtained from Amersham, GE 
Healthcare (Uppsala, Sweden). Acrylamide (40%), Ammonium Persulfate (APS), 
DC Protein Assay and Western Blotting system were purchased from Bio-rad 
laboratories (Hertfordshire, UK). Triglyceride assay kit was purchased from Cayman 
Chemicals (Ann Arbor, US). Antibodies were purchased from Cell Signaling 
Biomanufacturing and Life Science Research (New England Biolabs, Hertforshire, 
UK). Optimem Medium® was purchased from Gibco, Life Technologies Ltd (Paisley, 
Strathclyde, UK). Polyclonal goat-anti-rabbit secondary antibody, Lipofectamine® 
RNAiMAX (transfection reagent) was purchased from Invitrogen, Life Technologies 
Ltd (Paisley, Strathclyde, UK). Insulin ELISA kit was purchased from Mercodia 
(Uppsala, Sweden). Catch and Release v2.0 immunoprecipitation reversible kit, 
monoclonal mouse anti-SIRT1 and monoclonal rabbit anti-SIRT6 antibodies were 
obtained from Millipore (Millipore UK Limited, Watford, UK). Proteinase K®, 
RNase – Free DNase® set, RNeasy® mini, midi and maxi RNA extraction kits for total 
RNA isolation and were obtained from Qiagen Sample and Assay technologies (West 
Sussex, UK). Polyclonal goat anti-PGC1-α, polyclonal mouse anti-IRS-1 antibodies 
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Ammonium 
persulfate (NH4S2O8), Antibiotics (100 U/ml penincillin and 0.1g/l streptomycin), 
bovine serum albumin (BSA) lyophilized powder, bromophenol blue, 2-deoxy-D-
glucoseethanol, dimethyl sulphoxide (DMSO), Dulbelcco’s Modified Eagle Medium 
(DMEM), Dulbecco’s phosphate – buffered saline (DPBS), ethylene 
diaminetetraacetic acid (EDTA), Foetal Calf Serum (FCS), glycerol, Hank’s Balanced 
Salt Solution (HBSS) + Ca2+ and Mg2+, hydrochloride acid (HCL), insulin solution 
from bovine pancreas 10 mg/ml in 25 mM HEPES pH 8.2, l-glutamine 200 mM (100x 
stock), 2-β-mercaptonethanol, magnesium sulphate (MgSO4.7H2O), methanol, 
58 
N,N,N,N tetramethylethylenediamine (TEMED), penicillin 5000 U/ml – streptomycin 
5 mg/ml (50x stock), phosphate-buffered saline (PBS) tablets, polyclonal rabbit anti-
mouse secondary antibody, potassium chloride (KCL), protease inhibitor cocktail, 
radio-immunoprecipitation assay (RIPA) buffer, sodium carbonate (Na2CO3), sodium 
chloride (NaCl), sodium dodecyl sulphate (SDS),  tris(hydroxymethyl)aminomethane 
[NH2C(CH2OH)3 ] (TRIS-base), tris(hydroxymethyl)aminomethanehydrochloride 
(C4H11NO3 · HCl ) (TRIS-HCL), Trypsin/EDTA solution and Tween
® 20 viscous 
liquid were purchased from SIGMA – Aldrich (Guillingham, UK). Pipettes, tips, 
serological pipettes, 96 well plates (for protein essay and qPCR) and disposable 
gloves were purchased from Starlab (Blakelands, UK). Glucose assay kit was 
purchased from Thermo Electron (Melbourbe, Australia). Absolute qPCR Mix, One 
target plus siRNA rat SIRT1 predicted (CAGAACCACCAAAGCGGAA) and 
Supersignal West Pico Cheminoluminescent Substrate were purchased from Thermo 
Fisher Scientific (ABgene, Epsom, UK). Primers were purchased from Eurogentec 
(Hampshire UK). Ultrasensitive mouse Insulin ELISA kit was purchased from 
Mercodia (Uppsala, Sweden). Reverse transcription kit was purchased from Promega 
UK (Southampton, UK). 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide 
(Ex527) was purchased from Tocris Bioscience (Bristol, UK). Non-esterified fatty 
acids (NEFA) assay kit was purchased from Wako Pure Chemical Industries (Osaka, 
Japan). 
 
2.2 Methods 
 
2.2.1 Cell Cultures 
 
All cell lines were cryopreserved at the Blizard Institute of Cell and Molecular 
Science, Barts and the London School of Medicine and Dentistry, Queen Mary 
University of London, in 1.5 ml vials (Sterilin Ltd, Houslow, UK) containing freezing 
media with a final concentration of 10% (v/v) DMSO, 10% (v/v) tissue culture 
medium [DMEM (25mM glucose)] and 80% (v/v) foetal bovine serum. Prior to 
culture, cells were removed from liquid nitrogen and thawed in a water bath 
maintained at 37 ° C. The contents of the vials were suspended in 10 ml of warmed 
tissue culture medium and centrifuged for 5 min at 1200 x g. Centrifugation resulted 
in a cell pellet that was re-suspended in fresh culture medium to give a cell 
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suspension. The cell suspension was transferred to a tissue culture flask (Falcon, 
Becton Dickinson, NJ, USA) and stored in an incubator at 37 ° C and at an 
atmosphere of 5% CO2 and 95% O2, until the cells had reached the required 
confluency for passage. 
 
2.2.1.1 H4IIEC3 hepatocyte cell line 
 
H4IIEC3 cells (rat hepatocyte cell line) obtained from the European Collection of 
Animal Cell Cultures (ECACC; ECACC no. 85061112) were used. The cell line was 
initially derived from the Reuber H-35 hepatoma, which was induced in AXC rat by 
the carcinogen N-2 fluoroenyldiacetamide [171]. Cells were cultured in DMEM 
containing 25mM of glucose (Appendix I.), non-essential amino acids and 
supplemented with 10% (v/v) foetal calf serum (FCS) (Appendix II.), 2 mM 
glutamate, 500 IU/ml penicillin and 100 µM streptomycin, in 95% O2 and 5% CO2, 
and incubated at 37° C. Cells were routinely passaged (when they were approximately 
90% confluent) as follows. Briefly, cells were washed with phosphate buffered saline 
(PBS) (Appendix III.) following aspiration of DMEM culture medium from the cells. 
Cellular detachment from tissue culture flasks was achieved using 5 ml of 0.05% 
trypsin (diluted in PBS), containing 0.02% ethylenediaminetetraacetic acid (EDTA). 
Cells were then re-suspended in a small amount of tissue culture medium (usually 5 
ml), transferred to a polypropylene tube (Ambion, Cambridgeshire, UK) and pelleted 
by centrifugation at 1200 x g for 5 min. The supernatant was discarded and 10 ml of 
fresh culture medium was added to the cells to create a cell suspension for 
experimental use. For experiments, cells were seeded at a density of 1.2 x 106 cells 
into 6-well flat-bottomed plates (9.5 cm2 growth area) (Falcon, Becton Dickinson, NJ, 
USA), creating a cell monolayer. Cells were then returned to culture and allowed to 
attach overnight as monolayers.  
 
Transient knockdown of target proteins was achieved using siRNA duplex 
technology. SIRT1 siRNA (target sequence: CAGAACCACCAAGCGGAA) and the 
scrambled siRNA sequence (negative control) were purchased from Dharmacon, 
USA. Transfection of H4IIEC3 was performed using Oligofectamine® (Invitrogen, 
USA) following the manufacturer’s instruction for transfection of adherent cells 
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seeded in 6-well plates. 1.2 x 106 cells/well were seeded in complete growth media 
(DMEM, 25 mM glucose) and incubated at 37°C in 95% O2 and 5% CO2. When cells 
were grown 25-30% confluent, a mix (A) of 7.5 μl siRNA duplexes (stock solution of 
20 μM) and 177.5 μl of serum-free, penincilin-streptomycin-free Optimem® 
(Invitrogen, UK) was prepared. In parallel, a mix (B) of 7.5 μl of Oligofectamine® 
and 7.5 μl of serum-free, penincilin-streptomycin-free Optimem® (Invitrogen, UK) 
was prepared. The two mixes were incubated for 10 min, at room temperature. 
Subsequently, the content of the tubes were mixed (total volume of 200 μl) and 
incubated for 25 min at room temperature. Cells were washed in 1X PBS solution and 
800 μl of Optimem® plus 200 μl of the transfection mix were added to each well and 
incubated for 4h at 37°C in 95% O2 and 5% CO2. Subsequently, 1ml of DMEM 
25mM glucose supplemented with 30% FCS was added to each well. The plates were 
incubated at 37°C in 95% O2 and 5% CO2 for 72h. Then, cells were washed in ice-
cold PBS, lysed in RLT buffer® (from RNeasy kit, Quiagen) containing β-
mercaptoethanol, and collected for RNA extraction, or lysed in RIPA buffer® (ready 
to use solution containing 150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) purchased from Sigma Aldrich 
(Guillingham, UK) and collected for protein extraction and measurement. 
 
2.2.1.2  L6 rat myoblast cell line 
 
L6 rat myoblasts were kindly provided by Dr. Tania Maffucci, Centre of Diabetes, 
Blizard Institute, Queen Mary University of London (UK). The L6 myogenic line was 
isolated originally by Yaffe from primary cultures of rat thigh muscle maintained for 
the first two passages in the presence of methyl cholanthrene [172].  Cells were 
cultured in DMEM containing 25mM of glucose, non-essential aminoacids and 
supplemented with 10% (v/v) foetal calf serum (FCS), 2 mM glutamate, 500 IU/ml 
penicillin and 100 µM streptomycin, in 95% O2 and 5% CO2, and incubated at 37°C. 
Cells were routinely passaged (when they were approximately 90% confluent) as 
follows. Briefly, cells were washed with PBS following the aspiration of DMEM 
culture medium from the cells. Cellular detachment from tissue culture flasks was 
achieved using 5 ml of 0.05% trypsin (diluted in PBS), containing 0.02% EDTA. 
Cells were then re-suspended in a small amount of tissue culture medium (usually 5 
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ml), transferred to a polypropylene tube (Ambion, Cambridgeshire, UK) and pelleted 
by centrifugation at 1,200 x g for 5 min. The supernatant was discarded and 10 ml of 
fresh culture medium was added to the cells to create a single cell suspension for 
experimental use. For experiments, cells were seeded at a density of 1.2 x 106 cells 
into 6-well flat-bottomed plates (9.5 cm2 growth area) (Falcon, Becton Dickinson, NJ, 
USA), creating a cell monolayer. Cells were then returned to culture and allowed to 
attach overnight as monolayers.  
 
After the experiments, described further in Chapter 4, section 4.2.1, cells were either 
lysed in RLT® buffer (from RNeasy kit, Quiagen) containing β-mercaptoethanol, and 
collected for RNA extraction and measurement, or lysed in ice-cold RIPA buffer 
(ready to use solution containing 150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% 
sodium deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) purchased from Sigma 
Aldrich (Gillingham, UK), and collected for protein extraction and measurement.  
 
2.2.1.3 3T3-L1 adipocyte cell culture 
 
Pre-adipocyte differentiation to mature adipocytes was carried out by Dr. Paul Caton, 
Centre for Diabetes, Blizard Institute, Queen Mary University of London. 
 
3T3-L1 preadipocytes were cultured (37ºC; 5% CO2) in DMEM 25 mM glucose 
supplemented with 10% BSC until confluent. Two days post-confluency 
(Differentiation day 0), to induce differentiation media was changed and replaced 
with DMEM/10% FCS, supplemented with insulin (1 μg/ml), dexamethasone (0.25 
mM) and isobutyl-1-methylxanthine IBMX (0.5 mM).  After 2 days (differentiation 
day 2), media was replaced with DMEM/10% FCS supplemented with insulin (1 
μg/ml). After 4 days (differentiation day 4) media was replaced with DMEM/10% 
FCS. All media contained 100 U/ml penicillin and 100 μg/ml streptomycin. 
Differentiation of pre-adipocytes to adipocytes was confirmed by measurement of 
PPARγ gene expression (qPCR). Treatments, carried out on differentiation day 8, 
were as follows; adiponectin (30 μg/ml), WY-14643 (10 μM) for 24 h. All treatments 
were carried out in DMEM containing 10% FCS. 
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2.2.1.4 Cell Counting 
 
For each experimental condition, cell viability was assessed using a haemocytometer, 
a counting chamber that was originally designed for performing blood cells counts. 
To prepare the counting chamber, the mirror-like polished surface was carefully 
cleaned with lens paper. The cover-slip was cleaned and then placed over the counting 
surface, prior to addition of the cell suspension into one of the V-shaped wells. The 
area under the cover-slip filled by capillary action and the mirrored surface was 
covered. The charged counting chamber was then placed on the microscope stage and 
the counting grid was brought into focus at low power. See Fig. 2.1. 
 
Figure 2.1 
 
 
 
Figure 2.1: Illustration of the counting chamber. 
 
2.2.1.5 Protein extraction from cultured cells 
 
Culture medium was removed and cells were lysed in ice-cold RIPA® buffer 
(containing 150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium deoxycholate, 
0.1% SDS, 50 mM Tris, pH 8.0), with added protease inhibitor (1:100; containing 
AEBSF, 104 mM; aprotinin, 80 μM; bestatin, 4 mM; E-64, 1.4 mM; leupeptin, 2 mM; 
pepstatin A, 1.5 mM). Cells were scraped and transferred to 1.5 ml Eppendorf tube 
then centrifuged at 8,000 x g for 15 min at 4 °C (Sigma 1-15K). The pellet was 
discarded, whilst the supernatant was transferred to a new 1.5 ml Eppendorf tube and 
sonicated at 4 °C for 3 x 10 sec pulses. Sonicated samples were centrifuged at 6,000 x 
g for 8 min at 4 °C in a refrigerated centrifuge. The resulting supernatant was 
transferred to a fresh 1.5 ml Eppendorf tube and stored at -20 °C and the pellet was 
discarded. 
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2.2.1.6 RNA extraction and quantification 
 
Total RNA was extracted from 3 x 106 monolayer cells, harvested as outlined in 
section 2.2.1.  
 
RNA was isolated from cultured cells using a QUIAGEN RNeasy Mini Kit® 
(Quiagen, West Sussex, UK). The kit purifies RNA through the addition of a 
specialized high salt buffer that promotes the binding of up to 100 μg of RNA (which 
must be longer than 200 bases) to a silica-based membrane. 
 
Approximately 350 μl of RLT buffer® containing β-mercaptoethanol (β-ME) (10 μl/ 
ml) were added to 3 x 106 cells per well. The solution was transferred to an RNase 
free Eppendorf tube and homogenized by vortexing (for 30 sec each sample). 350 μl 
of ethanol 70% were pipetted to each tube and the solutions were mixed well by 
pipetting, to provide the suitable binding conditions and to enable re-suspension of 
any precipitated material. Up to 700 μl of each sample, including any precipitate that 
might have been formed, were transferred to an RNeasy spin column® placed in a 2 
ml collection tube. The samples were centrifuged (centrifuge 1-15 K) at 20 – 25 °C 
for 15 sec, at 8,000 x g. The flow-through was discarded. 700 μl of RW1 buffer® were 
added to each RNeasy spin column® for washing of membrane-bound RNA. The 
samples were centrifuged (centrifuge 1-15 K) at 20 – 25 °C for 15 sec, at 8,000 x g to 
wash the membrane. The flow-through was discarded. 500 μl of RPE buffer® (diluted 
4:1 in 100% ethanol) were added to each RNeasy spin column®, to remove traces of 
salts, which might remain on the column due to buffers used earlier in the extraction 
protocol. The samples were centrifuged (centrifuge 1-15 K) at 20 – 25 °C for 15 sec, 
at 8,000 x g to wash the membrane. The flow-through was discarded. A further 500 μl 
of RPE buffer® was added to each RNeasy spin column®. The samples were 
centrifuged (centrifuge 1-15 K) at 20 – 25 °C for 2 min, at 8,000 x g to wash the 
membrane.  The RNeasy spin column® was carefully removed from the collection 
tube® to avoid contact with flow-through. Otherwise, carryover of ethanol could have 
occurred. The RNeasy spin column® was placed in a new 2 ml collection tube® and 
the old collection tube® was discarded with the flow-through. The RNeasy spin 
column® in a new collection tube was then centrifuged (centrifuge 1-15 K) at 20 – 25 
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°C for 1 min at 13,300 x g. The spin column was placed in a new 1.5 ml collection 
tube® and 40 μl of RNase-free water® were added directly in the RNeasy spin 
column® membrane. To elute the RNA, the tubes were centrifuged (centrifuge 1-15 
K) at 20 – 25 °C for 1 min at 8,000 x g. This last elution step was repeated, using the 
eluate previously obtained instead of fresh RNase-free water®, to have a higher RNA 
yield. The eluted RNA was retained from the collection tube, and the yield and purity 
of the RNA was assessed using a NanoDrop® ND-1000 spectrophotometer 
(NanoDrop Technologies, Delaware USA). Samples were diluted in RNase-free water 
to equalize their concentrations. 
 
2.2.2 Animals 
 
2.2.2.1 Skeletal muscle and liver specific AMPK knockout mice 
 
Female skeletal muscle-specific and liver specific AMPKα1/2-knockout (AMPK-/-) or 
wild-type control (WT) mice were maintained at Institute Cochin INSERM, Paris, 
France. Only female mice were used, because of the established sexual dimorphisms 
known to exist with respect to the responses to dietary changes [173].  
 
To obtain skeletal muscle specific AMPK-deficient mice (AMPKα1−/−α2fl/fl HSA-
Cre+ mice), AMPKα1−/−α2fl/fl mice were interbred with transgenic mice expressing the 
Cre recombinase under the control of the human skeletal actin (HSA) promoter, 
which is specifically expressed in differentiated multinucleated skeletal fibers [174].  
 
To obtain specific deletion of both catalytic subunits in the liver (AMPKα1α2LS−/−), a 
liver-specific AMPKα2-null mouse (AMPKα2−/−) was generated by crossing floxed 
AMPKα2 mice [175] with AlfpCre transgenic mice, which express Cre recombinase 
under control of the albumin and α-fetoprotein regulatory elements. Subsequently, a 
liver-specific AMPKα2 deletion was produced on an AMPKα1−/− background, by 
crossing liver-specific AMPKα2−/− mice with AMPKα1−/− mice [176]. Mice were 
genotyped by PCR on DNA extracted from a tail biopsy using specific primers for the 
Cre transgene and for the floxed AMPKα2, the deleted AMPKα1, and the wild-type 
AMPKα1 allele.  
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Genetic background is mixed C57Bl6J and 129Sv for muscle-specific knockout and 
for liver-specific, the mice have been backcrossed on C57Bl6J more than 5 times. 
 
Animals were maintained on a 12:12-h light-dark cycle (light from 7am to 7pm), with 
controlled temperature (22° C ± 2° C) and air conditioned environment, and received 
standard high-carbohydrate rodent chow obtained from SAFE (Scientific Animal 
Food & Engineering, Augy, France) (diet number A03) for mice and contained 69.2% 
of cereals, 20.2% vegetal protein, 6% animal protein and 4.6% of a variety of 
essential vitamins and trace elements. The nutritional composition of the diet was 
51.7% of carbohydrates, 21.4% of protein, 5.7% of minerals, 5.1% of lipids and 3.9% 
of fiber. Water was provided ad libitum.  
 
Muscle specific AMPK-/- and WT were sacrificed in the immediately post-absorptive 
state after 5 hours of fasting. Liver-specific AMPK-/- and WT mice were sacrificed 
immediately after the re-feeding period. All mice were sacrificed by cervical 
dislocation. Tissues were extracted and flash frozen in liquid nitrogen. Whole blood 
was collected to obtain plasma. 
 
AMPK knockout mouse studies were reviewed and approved (agreement no. 75-886) 
by the Directeur Départemental des Services Vétérinaires of the Préfecture of Police 
of Paris. All the procedures carried on using these samples were performed in 
accordance with the principles and guidelines established by the European 
Convention for the Protection of Laboratory Animals. 
 
2.2.2.2 C57BI/6 mice 
 
Male C57BI/6 were obtained from Charles River (Kent, UK) and maintained on a 
12:12-h light-dark cycle (light from 7am to 7pm), with controlled temperature (22° C 
± 2° C) and air conditioned environment, and received standard laboratory (Lab Diets, 
Testdiets UK) or experimental chow. Water was provided ad libitum.  
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Animal experiments were conducted in accordance with the Home Office regulations 
on the Operation of Animals (Scientific Procedures) Act 1986, published by HMSO, 
London. 
2.2.2.3 PPARα-null mice 
 
From Islam et al. [177], PPARα-null mice (PPARα-/-), bred onto a SV/129 genetic 
background, were kindly provided by Dr. J. Peters and Dr. F.J.Gonzalez [178] 
(National Institutes of Health, Bethesda, MD). Wild-type SV/129 mice (Charles 
River, UK) were used as controls. Male mice (14–20 weeks old) were housed (4 per 
cage) and maintained in a temperature controlled, air conditioned environment, 
subject to a 12-h light/dark cycle with the dark period beginning at 0300 h’. Mice 
were fed ad libitum with a standard diet unless specified. WAT was dissected from 
both wild type and PPARα-/- mice, which required them to be anaesthetized by an 
intraperitoneal injection of sodium pentobarbital (60 mg/ml in 0.9% NaCl; 1ml/kg of 
body weight i.p.). Specifically, epididymal fat pads were quickly excised, freeze-
clamped and stored in liquid nitrogen. 
 
2.2.2.4 Maternal low protein rat model 
 
Pregnant female Wistar rats (250 – 300 g; Charles River, Kent, UK) were randomly 
assigned to either control (control; 20% protein) or an isocaloric maternal low protein 
(MLP; 8%) diets (Hope Farms BV, Woerden, Netherlands) and maintained on the 
respective diet throughout pregnancy and lactation.  Pregnant dams fed the low-
protein diet did not exhibit any differences in caloric intake compared to controls.  
Despite this, MLP offspring weighed significantly less at 3 days of age than control 
offspring (28%; P<0.05). Male offspring were weaned at 24 days and maintained on 
standard rodent diet thereafter. Pregnant female rats and offspring were housed and 
maintained in a temperature controlled, air conditioned environment, subject to a 12-h 
light/dark cycle with the dark period beginning at 0700 h’. Controls and MLP 
offspring were killed at 8 weeks and visceral WAT depots were snap-frozen for 
analysis, whilst blood was collected for measurement of glucose and insulin.    
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2.2.2.5 Experimental animal dietary regimens and treatments 
 
2.2.2.5.1 Calorie restriction  
 
Female muscle specific AMPK-/- and WT ad libitum fed mice (AL) and calorie 
restricted mice (CR) were used in this experiments (17/group). Caloric restriction was 
conducted between 2.5  - 4 months of age and lasted for 10 weeks. Body weight 
changes over the period of CR were measured. Food was adjusted on a daily basis so 
that CR mice consumed 70% of the calories consumed by free feeding mice 
(calculated on the average of food intake during the last week before starting the 
caloric restriction protocol).  
 
2.2.2.5.2 Oral Glucose tolerance test (OGTT) 
 
To examine whole-body glucose homeostasis, female muscle specific AMPKα1/2 -/- 
and AMPKα1/2 +/+ ad libitum fed- and calorie restricted mice were used in this 
experiments (n=17/group). Mice were fasted overnight, followed by oral gavage of 
glucose (3 g/kg of body weight). Blood samples for glucose analysis were collected 
from the tail vein at 0, 20, 40, 60, 80 and 120 min after glucose gavage. Blood glucose 
concentration was measured in whole blood with an automatic glucose monitor 
(Glucotrend II; Roche Diagnostics). Serum insulin levels were measured in the blood 
samples collected during OGTT at time 0 and at time 20 min, using a specific ELISA 
(Linco, St Charles, MO).  
 
2.2.2.5.3 Insulin administration 
 
For investigations of insulin action, female muscle specific AMPKα1/2 -/- (n=10) and 
wild type control (n=10) ad libitum fed mice (AL, n=20) and calorie restricted mice 
(CR, n=20) were used in this experiments. Mice (n=10/group) received an 
intraperitoneal injection of insulin (1 Unit of insulin/kg of body weight) in vivo, 5 
minutes before sacrifice.  
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2.2.2.5.4 Immunihistochemistry 
 
Soleus and gastrocnemius CR femal specific AMPKα1/2-/- and AMPKα1/2+/+ muscles 
were embedded in cryomatrix and quickly frozen in isopentane cooled with liquid 
nitrogen. Cryostat sections (10 µm) were washed in PBS, permeabilized with 0.1% 
Triton X-100 and left for 1 hour in blocking solution (1x PBS, 1.5% goat serum, 0.1% 
Triton X-100). Rabbit poly-clonal antibodies directed against Laminin (Z0097, Dako) 
(1/100 dilution), and monoclonal antibodies against MyHCI (NOQ7.5.4D, Sigma) and 
MyHCIIA (SC-71, Santa Cruz biotechnology) were applied overnight at 4 °C to the 
treated sections. The next day, after three washes with 1× PBS containing 0.05% 
Tween-20, cryosections were incubated for 1 h with appropriate fluorescent 
secondary antibodies (Alexa Fluor 488 goat anti-rabbit IgG 1/1000 dilution, Alexa 
Fluor 594 goat anti-mouse IgG 1/1000 dilution, Invitrogen). After three washes with 
1× PBS containing 0.05% Tween 20, samples were mounted in Vectashield mounting 
medium. 
 
2.2.2.5.5 Fasting and re-feeding  
 
To assess the effects of fasting and re-feeding, female liver specific AMPKα1/2-/- 
(n=4) and AMPKα1/2+/+ (n=4) mice were fasted for 24 h with access to water ad 
libitum and then re-fed with a standard diet for a period of 4 h prior to sacrifice. In 
addition, C57BI/6 mice (n = 6) were either fed ad libitum or fasted overnight for 16 
hours.  
 
2.2.2.5.6 Feeding and fasting  
 
To assess the effects of feeding and fasting, C57BI/6 mice (n=6) were fasted 
overnight for 16 hours (fasted animals) prior to sacrifice while the others (controls; 
n=6) continued to be fed with a standard laboratory diet until sacrifice. Mice were 
anaesthetized by an intraperitoneal injection of sodium pentobarbital (60 mg/ml in 
0.9% NaCl; 1ml/kg of body weight i.p.) [177]. Livers were quickly excised, freeze-
clamped and stored in liquid nitrogen. 
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2.2.2.5.7 High fat diet 
 
Diets rich in saturated fat have been linked to obesity and development of T2DM. To 
examine this concept experimentally, eight-week old; male C57Bl/6 mice (n= 15) 
were fed with either a standard rodent laboratory chow (control) or an experimental 
high saturated fat diet (16 weeks; HF; AIN-76A w/11% Fat Energy/ Corn Starch/ 
Yellow, (diet number 58R0, TestDiet Richmond, IN USA), containing 11% saturated 
fat (high fat diet, n=15). See Table 2.1. Vitamin, mineral and amino acid content was 
equivalent in control and HF diet. Mice were sacrificed after 10 (Controls, n= 5 and 
HF, n=5) or 16 weeks (Controls, n=10 and HF, n=10) of administrated diet, by 
administration of anaesthetic, containing 100 mg/ml ketamine and 20 mg/ml xylazine, 
in a 2:1 ratio (2 ketamine: 1 xylazine), administrated at 1.5 ml/kg body weight. Liver 
tissue samples were quickly frozen in liquid nitrogen for protein and mRNA 
measurements. Blood was collected and centrifuged to obtain plasma for 
measurement of plasma glucose and insulin levels. 
 
Table 2.1  
 
Energy content  
Energy (Kcal/g)2 4.02 
Protein (%) 15.6 
Fat (ether extracts) (%) 10.9 
Carbohydrates (%) 73.5 
 
Table 2.1: Table showing the nutritional composition of the high fat diet. 
 
2.2.2.5.8 Nicotinamide mononucleotide (NMN) administration 
 
Mice were administered NMN (500 mg/kg/body weight; i.p.) or saline equivalent 16 h 
before sacrifice, to give four separate groups (n = 5/group); (A) Control + Saline; (B) 
Control + NMN; (C) HF + Saline; (D) HF + NMN. These experiments were 
conducted to assess the effects of amplification of the NAD+ biosynthetic salvage 
pathway. NMN is the reaction product of the enzyme nicotinamide mononucleotide 
phosphoribosyltransferase (NAMPT) [179]. NMN circulates systemically in mouse 
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plasma [179], suggesting that administration of NMN could promote NAD+ synthesis 
and thereby activate NAD-dependent enzymes such as SIRT1 and SIRT3.  
 
2.2.2.5.9 Metformin administration 
 
Eight-week old male C57Bl/6 mice (Charles River, Kent, UK) maintained on standard 
rodent diet were administered metformin (250 mg/kg/day; 7 days) or an equal volume 
of water daily by oral gavage. 
 
2.2.2.6 Protein extraction from liver, muscle and white adipose tissue 
samples 
 
Approximately 60 mg of tissue was homogenised with a tissue tearor/electronic 
homogeniser (EW-04750-55 Tissue TearorTM Homogeniser), previously washed with 
methanol, at moderate speed (speed 4 or 5) in 1 ml of ice cold RIPA® buffer (ready to 
use solution containing 150 mM NaCl, 1.0% IGEPAL® CA-630, 0.5% sodium 
deoxycholate, 0.1% SDS, 50 mM Tris, pH 8.0) purchased from Sigma Aldrich 
(Guillingham, UK), with protease inhibitor (containing AEBSF, 104 mM; aprotinin, 
80 μM; bestatin, 4 mM; E-64, 1.4 mM; leupeptin, 2 mM; pepstatin A, 1.5mM) diluted 
in 1:100, in a conical bottomed Falcon tube. Samples were homogenized for at least 
20 seconds or until all tissue was homogenized to create a uniformly homogenised 
solution. The homogenate was split into 1.5 ml Eppendorf tubes and centrifuged at 
5000 x g for 10 min at 4º C in a refrigerated centrifuge. The pellet was discarded and 
the supernatant transferred to a new 1.5 ml Eppendorf tube (placed on ice). Care was 
taken to avoid the upper fatty layer present in some samples, and only transfer the 
supernatant. Supernatatants were then sonicated for 3 x 10 sec pulses. Sonicated 
samples were centrifuged at 6000 x g for 8 min at 4 °C in a refrigerated centrifuge, 
producing a new cell lysate supernatant. The supernatant was transferred to a fresh 1.5 
ml Eppendorf tube and stored at -20 °C and the pellet was discarded. 
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2.2.2.7 RNA extraction and quantification 
 
Liver Tissue 
 
Cellular RNA was isolated using QUIAGEN RNeasy Midi Kit® (Quiagen, West 
Sussex, UK). The kit purifies RNA through the addition of a specialized high salt 
buffer that promotes the binding of up to 1 mg of RNA to a silica-based membrane. 
 
A tissue tearor/electronic homogeniser (EW-04750-55 Tissue TearorTM Homogeniser) 
was washed with methanol and rinsed with RNase-free water®.  Approximately 250 
mg of liver tissue from each sample was disrupted with the clean tissue tearor in 4 ml 
of RLT buffer®, containing β-mercaptoethanol (β-ME) (10 μl/ ml), in a 50 ml Falcon® 
tube. The lysates were centrifuged at 5,000 x g for 10 min, at 20 – 25 °C. After 
centrifugation a small pellet has been formed, accompanied by a fatty upper layer and 
an intermediary phase (or supernatant).  The supernatant of each sample was 
transferred to a new Falcon® tube by pipetting, avoiding transferring the fatty upper 
layer or the pellet. Transferring the pellet or the fatty layer might reduce the amount 
of RNA that binds to the membrane and could cause the spin column to clog. 4 ml (1 
volume) of ethanol 70% were pipetted to each tube and the solutions were mixed well 
by shaking vigorously, to provide the suitable binding conditions and to enable re-
suspension of any precipitated material. Up to 4 ml of each sample were transferred to 
an RNeasy midi column® placed in a 15 ml collection tube. The samples were 
centrifuged (centrifuge 40K) at 20 – 25 °C for 5 min, at 5,000 x g. The flow-through 
was discarded. The previous centrifugation step was repeated using the reminding 4 
ml of lysate. 4 ml of RW1 buffer® were added to each RNeasy midi column® for 
washing of membrane-bound RNA. The samples were centrifuged (centrifuge 40K) at 
20 – 25 °C for 5 min, at 5,000 x g to wash the membrane. The flow-through was 
discarded. 2.5 ml of RPE buffer® (diluted 4:1 in 100% ethanol) were added to each 
RNeasy midi column®, to remove traces of salts, which might remain on the column 
due to buffers used earlier in the extraction protocol. The samples were centrifuged 
(centrifuge 40K) at 20 – 25 °C for 2 min, at 5,000 x g to wash the membrane. The 
flow-through was discarded. A further 500 μl of RPE buffer® was added to each 
RNeasy spin column®. The samples were centrifuged (centrifuge 40K) at 20 – 25 °C 
for 5 min, at 5,000 x g to dry the RNeasy silica-gel membrane®.  The RNeasy midi 
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column® was carefully removed from the collection tube® to avoid contact with flow-
through. Otherwise, carryover of ethanol could have occurred. The RNeasy midi 
column® was placed in a new 15 ml collection tube® and the old collection tube® was 
discarded with the flow-through. To elute, 200 μl of RNase-free water® were pipetted 
directly in the RNeasy silica-gel membrane®. The columns were incubated at room 
temperature for 1 min. To elute the RNA, the tubes were centrifuged (centrifuge 40K) 
at 20 – 25 °C for 3 min at 5,000 x g. This last elution step was repeated, using the 
eluate previously obtained instead of fresh RNase-free water®, to have a higher RNA 
yield. The eluted RNA was retained from the collection tube, and the yield and purity 
of the RNA was assessed using a NanoDrop® ND-1000 spectrophotometer 
(NanoDrop Technologies, Delaware USA). Samples were diluted in RNase-free water 
to equalize their concentrations. 
 
Muscle tissue 
 
RNA extraction was performed according to the manufacturer (Quiagen, UK) 
instructions, using an RNeasy mini kit® for fibrous tissue (with proteinase K). A 
tissue tearor/electronic homogeniser (EW-04750-55 Tissue TearorTM Homogeniser) 
was washed with methanol and rinsed with RNase-free water®. Approximately 30 mg 
of tissue from each sample was homogenised at moderate speed (speed 4 or 5) in 300 
μl of RLT buffer®, containing β-mercaptoethanol (10 μl/ ml), in an RNase free 
Eppendorf round bottomed tube. Tissue was homogenized for, at least 20 seconds or 
until all tissue was homogenized. The homogenisation process was repeated until 
solution being uniformly homogenised. 590 μl of RNase-free water® were added to 
each lysate. Then, 10 μl of proteinase K solution were added to each previous solution 
and the solution was mixed thoroughly by pipetting. The solutions were incubated for 
10 min in a water bath, previously heated at 55 °C. After incubation, the solutions 
were centrifuged (centrifuge 1-15 K) at 20 – 25 °C for 3 min, at 10,000 x g. 
Approximately 900 μl of each supernatant were pipetted to a new RNase free 1.5 ml 
micro-centrifuge tube. 0.5 volumes (450 μl) of ethanol (100%) were added to each 
cleared lysate, and the solutions were mixed well by pipetting, to provide the suitable 
binding conditions and to enable re-suspension of any precipitated material. 700 μl of 
each sample, including any precipitate that might have been formed, were transferred 
to an RNeasy spin column® placed in a 2 ml collection tube. The samples were 
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centrifuged (centrifuge 1-15 K) at 20 – 25 °C for 3 min, at 8,000 x g. The flow-
through was discarded. The reminder 700 μl of each sample were transferred to the 
previous RNeasy spin columns® placed in a 2 ml collection tube®. The samples were 
centrifuged again (centrifuge 1-15 K) at 20 – 25 °C for 3 min, at 8,000 x g. The flow-
throw was discarded. 350 μl of RW1 buffer® were added to each RNeasy spin 
column® for washing of membrane-bound RNA. The samples were centrifuged 
(centrifuge 1-15 K) at 20 – 25 °C for 15 sec, at 8,000 x g to wash the membrane. The 
flow-through was discarded. For each column, 10 μl of DNase I stock solution were 
added to 70 μl of Buffer RDD®. The solution was gently mixed, inverting the tube, 
and briefly centrifuged to collect residual liquid from the sides of the tube. This 
DNase I incubation mix (80 μl) was directly added to the RNeasy spin column® 
membrane and placed on the bench-top (20 – 30 °C) for 15 min. 350 μl of RW1 
buffer® were added to each RNeasy spin column®. The samples were centrifuged 
(centrifuge 1-15 K) at 20 – 25 °C for 15 sec, at 8,000 x g to wash the membrane. The 
flow-through was discarded. 500 μl of RPE buffer®  (diluted 4:1 in 100% ethanol) 
were added to each RNeasy spin column®, to remove traces of salts, which might 
remain on the column due to buffers used earlier in the extraction protocol. The 
samples were centrifuged (centrifuge 1-15 K) at 20 – 25 °C for 15 sec, at 8,000 x g to 
wash the membrane. The flow-through was discarded. A further 500 μl of RPE 
buffer® was added to each RNeasy spin column®. The samples were centrifuged 
(centrifuge 1-15 K) at 20 – 25 °C for 2 min, at 8,000 x g to wash the membrane.  The 
RNeasy spin column® was carefully removed from the collection tube® to avoid 
contact with flow-through. Otherwise, carryover of ethanol could have occurred. The 
RNeasy spin column® was placed in a new 2 ml collection tube® and the old 
collection tube® was discarded with the flow-through. The RNeasy spin column® in a 
new collection tube was then centrifuged (centrifuge 1-15 K) at 20 – 25 °C for 1 min 
at 13,300 x g. The spin column was placed in a new 1.5 ml collection tube® and 40 μl 
of RNase-free water® were added directly in the RNeasy spin column® membrane. To 
elute the RNA, the tubes were centrifuged (centrifuge 1-15 K) at 20 – 25 °C for 1 min 
at 8,000 x g. This last elution step was repeated, using the eluate previously obtained 
instead of fresh RNase-free water®, to have a higher RNA yield. The eluted RNA was 
retained from the collection tube, and the yield and purity of the RNA was assessed 
using a NanoDrop® ND-1000 spectrophotometer (NanoDrop Technologies, Delaware 
USA). Samples were diluted in RNase-free water to equalize their concentrations. 
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White adipose tissue 
 
RNA extraction was performed according to the manufacturer (Quiagen, UK) 
instructions, using an RNeasy midi kit® for lipid tissue. 
A tissue tearor/electronic homogeniser was washed with methanol and rinsed with 
RNase-free water®. Approximately 300 mg of tissue from each sample was 
homogenised at moderate speed (speed 4 or 5) in 5 ml of QIAzol lysis reagent®, 
which immediately inactivates any RNases (to prevent RNA degradation), in an 
RNase-free Falcon tube. Tissue was homogenized for, at least 20 seconds or until all 
tissue was homogenized. The homogenisation process was repeated until solution 
being uniformly homogenised. The tubes were placed at the benchtop, at room 
temperature (15 - 25 °C) for 5 min. 1 ml of chloroform was added to the lysate and 
the mixture was vigorously shaken for the subsequent phase of lysate separation. The 
tubes were placed on the benchtop, at room temperature for 2-3 min. The lysate 
underwent centrifugation ate 5000 x g for 15 min, at 4 °C. After centrifugation, four 
layers could be observed: an upper, colourless, aqueous phase containing RNA; a 
white interphase; a lower, red, organic phase and an additional clear phase. The 
volume of the aqueous phase should be approximately 3 ml. This clear supernatant 
was transferred to another RNase-free Falcon tube and the other phases (fatty layer 
and pellet) were discarded. 1 volume (about 3 ml) of 70% ethanol was added to each 
cleared lysate. The solutions were immediately mixed by vortexing, to be able to 
provide the suitable binding conditions and to enable re-suspension of any 
precipitated material. 4 ml of each sample, including any precipitate that might have 
been formed, were transferred to an RNeasy Midi column® (which binds DNA and 
RNA) placed in a 15 ml collection tube. The samples were centrifuged (centrifuge 1-
15 K) at 20 – 25 °C for 5 min, at 5,000 x g. The flow-through was discarded from the 
collection tube. The reminder 2 ml of each sample were transferred to the previous 
RNeasy Midi columns® placed in 15 ml collection tube®. The samples were 
centrifuged once more (centrifuge 1-15 K) at 20 – 25 °C for 5 min, at 5,000 x g. The 
flow-throw was discarded. 4 ml of RW1 buffer® were added to each RNeasy Midi 
column® for washing of membrane-bound RNA. The samples were centrifuged 
(centrifuge 1-15 K) at 20 – 25 °C for 5 min, at 5,000 x g to wash the membrane. The 
flow-through was discarded. 2.5 ml of RPE buffer® (diluted 4:1 in 100% ethanol), 
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were added to each RNeasy Midi column®, to remove traces of salts, which might 
remain on the column due to buffers used earlier in the extraction protocol. The 
samples were centrifuged (centrifuge 1-15 K) at 20 – 25 °C for 2 min, at 5,000 x g to 
wash the membrane. The flow-through was discarded. A further 2.5 ml of RPE 
buffer® was added to each RNeasy Midi column®. The samples were centrifuged 
(centrifuge 1-15 K) at 20 – 25 °C for 5 min, at 5,000 x g to wash the membrane.  The 
RNeasy spin column® was carefully removed from the collection tube® to avoid 
contact with flow-through. Otherwise, carryover of ethanol could have occurred. The 
RNeasy Midi column® was placed in a new 15 ml collection tube® and the old 
collection tube was discarded with the flow-through. The RNeasy Midi column® in a 
new collection tube was then centrifuged (centrifuge 1-15 K) at 20 – 25 °C for 2 min 
at 5,000 x g. The column was placed in a new 15 ml collection tube® and 250 μl of 
RNase-free water® were added directly in the RNeasy Midi column® membrane. The 
columns were allowed to stand with RNase-free water for 1 min. To elute the RNA, 
the tubes were centrifuged (centrifuge 1-15 K) at 20 – 25 °C for 3 min at 5,000 x g. 
The eluted RNA was retained from the collection tube, and the yield and purity of the 
RNA was assessed using a NanoDrop® ND-1000 spectrophotometer (NanoDrop 
Technologies, Delaware USA). Samples were diluted in RNase –free water to 
equalize their concentrations. 
 
2.2.2.8 Plasma analysis 
 
Whole blood samples were collected in microcentrifuge tubes containing heparin as 
an anticoagulant. After collection, tubes were centrifuged at 1,000 x g for 10 min at 4° 
C. The top yellow plasma layer was transferred to a new tube and stored at -80° C.  
 
2.2.2.8.1 Glucose assay 
 
Glucose assay was performed according to the manufacturers instructions (Thermo 
Electro Corporation, Melbourne, Australia).  
 
The method utilised in this reagent is based on the hydrogen peroxide indicator 
reaction which couples 4-aminoantipyrine to a phenolic compound as first proposed 
by Trinder [180]. Glucose standards were prepared by labelling nine clean test tubes 
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from 0 - 9. 250 μl of ultrapure water were added to tubes 1-8. 500 μl of ultrapure 
water were added to tube 0. 250 μl of Glucose Standard® (1.441 g/dl) was added to 
tube 1 and this was mixed thoroughly. 250 μl of the solution in tube 1 was transferred 
to tube 2 and mixed thoroughly. This process was repeated for tubes 3 to 8. Tube 0 
has only ultrapure water and is used as blank. See Fig. 2.3. 
 
Figure 2.3 
 
 
 
Figure  2.3: Glucose assay curve. 
 
Duplicate glucose standards and plasma samples (2 l) were added into a clean, dry 
96-well micro-plate (Starlab, UK). 300 μl of the reagent (containing >15,000 U/l of 
glucose oxidase, >100 U/l of peroxidase, 0.5mmol/l of aminoantipyrine, 10 mmol/l of 
hydroxybenzoic acid and 119 mmol/l of phosphate buffer) were added to each well 
and mixed thoroughly. The plate was incubated for 30 min at room temperature. 
Absorbance was measured at 490 nm on an optical plate reader (Anthos Labtee HT3 
Version 1.21). Using a linear range of the standard curve from 0.0 mM to 40 mM 
(Figure 2.3), glucose was calculated and expressed as mM. 
 
2.2.2.8.2 Insulin ELISA 
 
Plasma insulin levels were assessed by specific insulin ELISA (Mercodia AB, 
Uppsala, Sweden). The ELISA is a solid two-site enzyme immunoassay with a 
colourimetric endpoint that is read spectrophotometrically. The assay is based on the 
direct sandwich technique in which two monoclonal antibodies are directed against 
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separate antigenic domains in the insulin molecule. All reagents and plasma samples 
were brought to room temperature before use. Enzyme Conjugate® (peroxidase 
conjugate mouse monoclonal anti-insulin) 1X, was prepared by mixing 5 µl of 
Enzyme Conjugate® 11x with 50 µl of Enzyme Conjugate Buffer®  (color coded blue) 
(1:10) for each sample. The Wash Buffer® was prepared by diluting 10 µl of Wash 
Buffer® 21x in 2000 µl redistilled water (1:20) for each sample. To prepare the 
calibration curve, duplicated aliquots (10 µl) of calibrator and sample were pipetted 
into a provided mouse monoclonal anti-insulin 96-well Coated Plate® (coted with 
anti-mouse insulin). 100 µl of an HRP-conjugated (Horse Radish Peroxidase) - 
conjugated anti-mouse insulin antibody (Enzyme Conjugate®) was added to the 
sample before incubating the plate on an orbital shaker (400 rpm) for 2 h, at room 
temperature. After 2 h, the wells were washed 5 times by adding 350 µl of Wash 
Buffer® to each well. After each wash, the wells were dried by firmly inverting 
against absorbent paper. After the final wash, 200 µl of chromogenic TMB® substrate 
(3,3’,5,5’-tetramethylbenzidine), was added to each well, and incubated at room 
temperature for 15 mins, protected from light. After 15 min, 50 µl of Stop Solution® 
(0.5 M H2SO4) was pipetted into each well, to stop the reaction. The plate was gently 
agitated for approximately 5 seconds to ensure mixing the substrate and Stop 
Solution®. Absorbance was measured at 450 nm, using an optical plate reader (Anthos 
Labtee HT3 Version 1.21). The equation obtained from the linear regression of the 
standard curve was used to calculate the concentration of insulin in ng/ml. See Fig. 
2.4. 
 
Figure 2.4 
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Figure 2.4: Insulin standard curve. 
 
2.2.3 Common Methods used for cells and tissue preparation and 
analysis 
 
2.2.3.1 Protein quantification 
 
Protein Concentrations were measured using the RC DC-BioRad protein assay system 
(BioRad, UK) – a colorimetric assay based on the method of Lowry [181]. The assay 
involves the reaction of the protein with an alkaline copper tartrate solution and Folin 
reagent (mixture of inorganic salts). Proteins (tyrosine and tryptophane residues) react 
with the Folin reagent promoting its reduction to produce a blue colour. The intensity 
of the colour is directly proportional to the concentration of the protein within the 
sample. Dilutions of bovine serum albumin (BSA) ranging from 0,0015625 – 2 mg/ml 
were prepared in dH2O and used as standards. Aliquots (5 µl) of standards and protein 
test samples (thawed on ice) were prepared in duplicate and pipetted into a clean, dry 
96-well micro-plate (Starlab, UK). 25 µl of reagent A (prepared previously by adding 
20 µl surfactant solution to 1ml alkaline copper tartrate solution) and 200 µl of Folin 
reagent were added to samples and standards, and the plate was incubated at room 
temperature for 15 minutes, with gently agitation. Absorbance was then measured at 
650 nm on an optical plate reader (Wallac 1420 Victor 2; Perkin-Elmer – company 
details). Using a linear range of the standard curve from 0.0 mg/ml to 25 mg/ml 
(Figure 2.7), sample protein was calculated and expressed as µg protein/µl. The 
protein concentration of each sample was established via extrapolation from the 
standard curve obtained by plotting the absorbance of the protein standards against 
their concentration, and protein concentrations of the samples determined from this. 
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Figure 2.7 
 
 
 
Figure 2.7: Graph illustrates a standard curve for the protein assay. 
 
2.2.3.2 Western blotting 
 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed as a modification of the method described by Laemmli [182]. Denatured 
proteins bind SDS and become negatively charged. The amount of SDS bound is 
usually proportional to the molecular weight of the protein and the polypeptide-SDS 
complex migrates through the gel according to the size of the polypeptide and not its 
charge. The separated proteins are transferred to a nitrocellulose membrane and 
probed with an appropriate antibody. 
 
2.2.3.2.1 SDS-PAGE gel electrophoresis 
 
After being extracted as detailed above, protein samples were separated by SDS-
PAGE on a 5%, 7.5% or 10% lower resolving gel (based on the size of the protein) 
and an upper 4.5% stacking gel. The gels were made by adding the reagents as listed 
below (see Table 2.3). 
 
Table 2.3  
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 Resolving gel 
5% 
Resolving gel 
7.5% 
Resolving gel 
10% 
Stacking 
gel 4% 
40%  (v/v) 
Acrylamide/bis 
2.5 ml 3.75 ml 5 ml 1 ml 
1.5M Tris-HCl 
pH 8.8 
5 ml 5 ml 5 ml  
0.5 M Tris-
HCL pH 6.8 
   2.5 ml 
10% (w/v) SDS 200 μl 200 μl 200 μl 100 μl 
dH2O 12.2 ml 10.95 ml 9.7 ml 6.35 ml 
TEMED 10 μl 10 μl 10 μl 10 ml 
10% (w/v) 
Amonium 
persulfate 
(APS) 
100 μl 100 μl 100 μl 100 μl 
Molecular 
weight 
57-212 kDa 36-94 kDa 16-68 kDa  
 
Table 2.3: Illustrates the required volume of reagents needed to make up the acrylamide gels. 
 
The gel, separated by two layers (the upper stacking gel and the lower 
resolving/running gel) had 1.5 mm of thickness. Gel apparatus was assembled (Bio-
Rad, Hemel Hempstead, UK) and the lower gel poured to 1 cm below the level of the 
gel comb. A thin layer of butan-2-ol (400 μl) was added to ensure that the gel front 
was level, to prevent the gel from drying out, and to remove any air bubble that might 
have been formed while the gel was being poured. The gel was then allowed to set for 
1 h. Once the lower gel had set, butan-2-ol was rinsed 3 times with distilled water. 
Water was removed using filter paper, and the upper stacking gel was poured and the 
comb was inserted. The gel was allowed to polymerize for 30 min and the comb was 
then removed.  
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Protein sample preparation  
Protein samples were mixed at a ratio of 1:1 with Laemmelli buffer (62.5 mM Tris-
HCl, pH 6.8; 2% (w/v) SDS, 40% (v/v) glycerol, 0.01% (w/v) bromophenol blue and 
10% (v/v) β-mercaptoethanol). Samples were vortexed and heated for 3 min at 100 °C 
to denature the proteins in the SDS sample buffer, containing β-mercaptoethanol as a 
reducing agent, giving them a uniform negative charge. The SDS binds consistently 
along the length of the proteins, equalizing the mass/charge ratio. As a result the 
proteins migrate towards the cathode separated primarily by molecular weight, which 
is important for later detection of the target protein.  Samples were then allowed to 
cool before loading onto a gel.  
 
SDS-PAGE electrophoresis was performed in a Bio-Rad Mini-Protean® kit (BioRad; 
California, USA) using 20 – 40 µg protein per lane, depending on the concentration of 
the protein and the well volume. Gels were electrophoresed in 1X running buffer 
(0.05 M Tris base, 0.384 M glycine and 0.1% (w/v) SDS) at 100 V for 20 min and 
then 150 V for 45 min or until the bromophenol blue gel front reached the bottom of 
the gel. Amersham, full-range rainbow molecular weight markers (12 000 – 225 000 
Da; GE Healthcare, UK) were run in parallel with unknown samples. 
 
2.2.3.2.2 Protein Transfer 
 
Following removal of the gel from the electrophoresis cassette, the upper stacking gel 
was removed. The top right hand corner of the lower gel was also removed, for 
orientation later. Proteins were transferred from SDS-PAGE gel to nitrocellulose 
Hybond membrane (GE Healthcare, UK) as described by Towbin (Towbin et al. 
1979), using a Bio-Rad Mini Trans-Blot® Electrophoretic Tranfer Cell (BioRad 
California, USA). Prior to transfer, SDS gels were equilibrated in transfer buffer (0.25 
mM TRIS, 0.19 mM glycine, 15% (v/v) methanol) for 30 min, whilst nitrocellulose 
membranes were soaked for 15 min in transfer buffer. Following this, each SDS-
PAGE gel with nitrocellulose membrane was placed in a transfer cassette between 
two sheets of 3 mm thick blotting paper, which had been pre-wetted in transfer buffer. 
The loaded cassettes were prepared in water and any air bubbles removed by rolling 
with a Pasteur pipette. The cassettes were placed into the transfer tank (Bio-Rad 
Transblot system; Richmond, CA, USA), containing transfer buffer pre-cooled at 4 
82 
ºC, with the nitrocellulose membrane side towards the cathode. The gel was then 
electro-eluted at 200 mA for 2h. The transfer was performed in the cold room to keep 
the gels cold as this process generated a lot of heat and the gels could melt if care was 
not taken. 
 
2.2.3.2.3 Immunodetection 
 
After transfer, membranes were rinsed in TNT buffer (2mM Tris-HCL, pH 7.6, 15 
mM NaCl, 0.01% Tween-20). After washing, non-specific hybridisation to the 
membrane was blocked by gentle mix for 1 h in 5% (w/v) blocking solution 
(consisting of 0.5 g of dried skimmed milk or BSA in 10 ml of TBS-Tween solution, 
per membrane). Membranes were washed 3 x 10 min periods in TBS-Tween buffer, 
with vigorous mixing. After washing, nitrocellulose membranes were incubated 
overnight on a shaking platform (gentle mix) at 4° C with primary antibody (1μl/ml) 
in a solution of 5% (w/v) BSA, dissolved in TBS-Tween buffer solution (see appendix 
XIV). After overnight incubation, the washing steps were repeated on a shaking 
platform at room temperature, followed by 1 h incubation with an appropriate 
secondary antibody. After incubation with the secondary antibody, the washing steps 
were repeated again with vigorous mixing (see appendix XIV).  
 
2.2.3.2.4 Visualisation 
 
To detect the protein bands, membranes were incubated for 5 min at room 
temperature in chemiluminescent reagent (Thermo Scientific Pierce ECL, Thermo 
Scientific USA) with gentle mixing. The system consists in an enhanced 
chemiluminescent substrate for detection of horseradish peroxidase (HRP) activity 
from antibodies and other Western blot probes. The HRP/H2O2 catalised oxidation of 
luminol in alkaline conditions takes place in the presence of chemical enhancers such 
as phenols. To detect the proteins, nitrocellulose Hybond membranes were exposed to 
blue-light sensitive autoradiography film (Hyperfilm ECL, GE Healthcare UK). The 
exposure time varied from 15 sec to 12 min depending on antibody and sample. 
Developement was then carried out using an automated Kodak developing machine. 
The densitometric readings of the resultant protein bands were analysed using 
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ImageJ® program (Image Processing and Analysis in Java). At least three independent 
western-blotting experiments were carried out for each antibody. 
 
2.2.3.3 Immunoprecipitation 
 
Immunoprecipitation (IP) was performed regarding to manufactures Catch and release 
v2.0 instruction manual. 
 
10X Catch and Release Wash Buffer® was diluted to 1X working concentration with 
Milli Q® water for incubation and all washes. Spin Columns®, Capture Tubes® and 
micro-centrifuge tubes were labelled. The snap-off bottom plug was removed from 
the Spin Columns® and saved for later use. The Spin Columns® were inserted in the 
Capture Tubes®. The screw-on cap of each Spin Column® was removed and the 
columns were centrifuged at 2,000 x g for 15-30 seconds to remove the resin slurry 
buffer. The resins in the Spin Columns® were washed twice with 400 μl of 1X Wash 
Buffer®. The Capture Tubes® were emptied and the bottom end of each Column was 
plugged with the snap-off bottom plug saved earlier.  
 
The volume of combined reagents was determined: 
a) 500 μg of cell lysate; 
b) 4 μg of the specific primary antibody and negative control antibody. 5-10 μl of 
whole antiserum; 
c) 10 μl of Antibody Capture Affinity Ligand®; 
d) Sufficient 1X Wash Buffer® to provide a total volume of 500 μl. 
 
With the bottom end of the Spin Column® plugged, the reagents were added in the 
following order: 
1) 1X Wash Buffer®; 
2) Cell Lysate; 
3) Specific primary antibody or negative control antibody; 
4) Antibody Capture Affinity Ligand® 
 
Using the screw-on caps, the top of the Columns were capped and the columns were 
incubated overnight in a rotator, at 4° C. After incubation, the snap-off bottom plugs 
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were removed and discarded. The Columns were placed in the Capture Tubes®; the 
screw-on caps were removed and the Tubes were centrifuged at 2,000 x g for 15-30 
seconds to collect the flow-through. The flow-through was transferred to a new 
micro-centrifuge tube and saved for Western Blot analysis (it could have been useful 
for trouble-shooting, if necessary). 
 
The Columns were washed 3X with 400 μl of 1X Wash Buffer®, spinning at 2,000 x g 
for 15-30 seconds, for each wash. The Columns were placed into fresh Capture 
Tubes®. 70 μl of 1X Denaturing Elution Buffer® containing β-mercaptoethanol were 
added to each Spin Column®.  The Columns were centrifuged at 2,000 x g and saved 
for Western Blot analysis. 
 
2.2.3.4 Reverse transcription-polymerase chain reaction 
 
2.2.3.4.1 Reverse transcription 
 
In reverse transcription PCR, RNA strands are reverse transcribed into cDNA, using 
the enzyme reverse transcriptase extracted from avian myeloblastosis virus, HIV or 
moloney murine leukemia virus. Reverse transcriptase requires a double stranded 
primer that allows 5’ to 3’ cDNA synthesis.  Several types of primers are available 
such as random primers or gene specific primers. We, however, employ random 
primers as they convert all the mRNA and as a result several genes can be measured 
on one sample. Since the goal of the RT-PCR is to synthesise certain amount of 
mRNA into an equal amount of cDNA, the analysis is just one cycle.  
 
Reverse Transcription was carried out according to manufacturer’s instructions 
(Promega, UK). Complementary DNA (cDNA) was generated from RNA templates 
(500 – 1000 ng). Reverse transcription was carried out in a reaction mix containing 5 
mM MgCl2, 10X Reverse transcription buffer (10 mM Tris-HCL, pH 9, 50 mM KCL, 
0.1% Triton X-100, 1 mM deoxyribonucleotide triphosphates (dNTP), 1U/ml 
recombinant RNase inhibitor (RNAsin), 15 U/µg RNA AMV reverse transcriptase 
and 0.5 µg//µl RNA random primers). Reverse transcription reactions were carried 
out in 20 µl volumes at 37 ° C for 1 h, 70 ° C for 15 min. See table 2.4 
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Table 2.4 
 
Reagent Quantity/tube in µl 
MgCl2 4 
Reverse Transcriptase buffer 2 
dNTP 2 
RNAsin 0.5 
Random Primers 0.72* 
Reverse Transcriptase 1.2* 
Nuclease Free H2O 4.4 
Total Amount: 15 
 
Table 2.4 Illustrates the reagents used for RT-PCR and their quantity. 
*The amount of these reagents depends on the RNA concentration in the sample. The numbers given 
equals to an RNA yield of 144.6ng/µl.  There is added 5 µl of RNA to the 15 µl of the mixed solution.  
To calculate the amount of Random primers and Reverse transcriptase the total amount of RNA to be 
added (723ng) is divided by 1000 = random primers (0.72µl). 0.72 is then multiplied with 25 and 
divided with 15 = reverse transcriptase (1.2µl). RNAsin is added to inhibit any RNAse activity. 
 
15 µl of the reagent mix shown in table 2.4 were added to a 200µl thin walled RNAse 
free Eppendorf tube, and 5µl RNA sample was added. The Eppendorf tube was then 
placed in a PCR machine and set to the following program: The reverse transcription 
reaction was at 37°C for 1 hour where the RNA is converted into cDNA. Initially the 
random primers bind the complementary RNA- strands. Then the reverse transcriptase 
binds where the primers are annealed and extends the template. Following this, 
samples were incubated at 75°C for 15 min to denature the reverse transcriptase. 
Samples were then cooled to 4°C until the PCR machine was switched off. This step 
is to ensure preservation of the cDNA until the samples were transferred to the -20°C 
freezer. 
 
2.2.3.4.2 Polymerase chain reaction 
 
Quantitative reverse transcription polymerase chain reaction (qRT-PCR) was carried 
out using sequence specific primers (all Eurogentec, UK) using either Sybr green 
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(Invitrogen, UK) or Taqman methodology (Eurogentec, UK). The sense and anti-
sense primers sequence and PCR cycle used are shown in Appendix XV. The reaction 
mix (16 l), containing master mix (ThermoScientific, UK), forward and reverse 
primers, probe (Sybr green or Taqman) and nuclease-free water was prepared as 
described below and added, along with cDNA sample (4 l), to a 96 well-plate 
(MicroAmp® Optical Reaction Plate with Barcode, Applied Biosystems, UK). The 
plate was mixed and centrifuged briefly to force the solution to the bottom of the 
wells and to eliminate any air bubbles, prior to running of qPCR reaction.  
 
Table 2.5  
 
Reagents 
Final concentration 
Amount/well  (µl) 
SYBR Green 
Amount/well  (µl) Taqman 
Absolute QPCR mix (+ ROX) 
1x 
10 10 
Forward primer (300 nM) 1 1* 
Reverse Primer (300 nM) 1 1* 
Probe (25/100nM) 1 1* 
Nuclease-free H20 3 4.7 
Sample DNA (5 ng/μl) 4 4 
 
Table 2.5 Illustrates the reagents used, for qRT-PCR with SYBR Green and Taqman as detectors, and 
the volume needed.  * For 18S gene, use 0.1 μL of probe, forward and reverse primer. Samples were 
analysed in duplicate in reactions containing 1X QPCR mix, 100 nM of ROX reference Dye, 300 nM 
forward and reverse primers, 100 nM probe, 20 ng (5ng/µl) cDNA sample and nuclease-free water to a 
final volume of 20 µl. 18S ribosomal RNA was measured as a control gene, using a commercial 
Taqman assay (Applied Biosystems, USA). 
 
The RT-PCR reaction was run using a 7500 Real-Time PCR System (Applied 
Biosystems, US). The RT-PCR thermal cycling program was set up as listed below, in 
Table 2.6. 
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Table 2.6 
 
 Temperature Time Number of 
cycles 
 50°C 2 min 1 
Enzyme activation 95°C 15 min 1 
Denaturation 95°C 15 sec 40 
Annealing/Extension 60°C 60 sec  
 
Table 2.6: RT-PCR thermal cycling programme. 
 
The volume was set 20 µl as this was the amount present in the tubes. A dissociation 
curve was added at the end of the last PCR cycle, as a control of the amplified 
product. Then the set-up was saved and the PCR started. An incubation step of 50°C 
for 2 min was added to the cycling programme before activation of DNA polymerase. 
During the activation step, DNA polymerase is heat-activated at 95°C for 15 min: hot-
start PCR. The hot-start eliminates secondary structures and straightens the DNA, in 
addition, preventing any DNA amplification prior to the first thermal cycle of the real 
time PCR. The denaturation step was performed at 95°C for 15 seconds and caused 
DNA melting of the DNA template by disrupting the hydrogen bonds between 
complementary bases, yielding single-stranded DNA molecules. The annealing and 
extension step was performed at 60°C for 1 minute and allowed annealing of the 
primers to the single-stranded DNA template. The polymerase bound to the primer-
template hybrid and begun DNA formation. At this step the DNA polymerase 
synthesized a new DNA strand complementary to the DNA template strand by adding 
dNTPs that are complementary to the template in 5' to 3' direction, condensing the 5'-
phosphate group of the dNTPs with the 3'-hydroxyl group at the end of the nascent 
(extending) DNA strand. Exponential amplification of the specific DNA fragment 
happened. After the PCR is finished, a relative quantification study is opened and the 
saved data is opened using the programme. This is where the CT values are set and 
then imported into Microsoft Excel®. The CT value is based on the fact that a large 
amount of a specific gene within a sample will cause the sample to reach the cut off 
point in an earlier cycle compared to samples where the gene is less expressed. This 
principle is used when calculating the gene expression.   
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A relative quantification is done, where the calculations of the fold increase or 
decrease in gene expression is based on the calculations from Livak et al. [183]. In 
short ΔCT= CT Sample - CT reference gene. ΔΔCT= ΔCTsample – ΔCT control (e.g. 
non-mated mouse). Then use the formula to calculate the gene expression relative to 
the control. 
 
The dissociation curve is used to control the accumulated DNA. Since SYBR Green is 
not sequence specific, the product of the PCR has to be verified. The verification 
consists of dissociation curve, which records the melting temperature of the DNA. 
The DNA should have the same melting temperature in all the samples, if there is 
deviation it indicates the presence of primer dimers or accumulation of another gene. 
This could happen if primers had homology with other genes. And primer dimers 
occur when there are complementarities between the forward and reverse primer. An 
example of a dissociation curve is shown in Figure 2.8. 
 
Figure 2.8  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8: Illustration of a dissociation curve. There doesn’t seem to be much deviation, indicating no 
or very little presence of primer dimers and that the same gene has been amplified in all the samples. 
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2.2.3.4.3 Analysis 
 
Results were analysed using GeneAmp software (Applied Biosystems, USA). A 
threshold level was set during the linear, exponential amplification phase of the 
logarithmic amplification plot. The quantity of cDNA/mRNA present in the unknown 
samples was then calculated using the standard curve at the point where the threshold 
crossed the amplification plot. 
 
A housekeeping gene that is expressed at a constant level in most cell types, 18S, was 
used as an endogenous control to normalize the expression pattern of each gene. The 
mean sample content of the product of interest was divided by the respective mean 
level of 18S reference RNA for each sample. The mean average of these values for 
the control (untreated) sample was then calculated. Each sample was then divided by 
the mean average of the control sample to produce a value for each sample relative to 
the control. Results were then expressed as fold-increase in mRNA/cDNA level, 
relative to the control sample.  
 
2.2.3.5 Statistical Analysis 
 
All data are expressed as mean ± SEM. Statistical comparisons were carried out using 
Graphpad Prism (GraphPad Software) and StatView. Statistical differences were 
evaluated by unpaired t-test or one-way analysis of variance (ANOVA), followed by a 
Newman-Keuls, Tuckey post-hoc or Fisher’s post-test where appropriate. Statistical 
differences were accepted as P<0.05. 
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Chapter: 
3. Studies on the effect of experimental diets on the regulation of hepatic 
lipogenesis. 
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3.1 Introduction 
 
AMPK and SIRT1 play important roles in the maintenance of hepatic lipid 
homeostasis, via PPARα-mediated regulatory effects on lipogenesis and fatty acid 
oxidation, as well as regulating hepatic glucose homeostasis via direct effects on 
insulin signaling and gluconeogenesis [19, 88, 184, 185]. Recent studies have 
suggested that PPARα – AMPK – SIRT1 interact to form a complex regulatory 
feedback network controlling glucose and lipid metabolism in the liver [149, 163, 
164]. However, this system is not well understood, particularly with respect to 
potential interactions between AMPK and SIRT1 (Chapter 1, section 1.6.1.7). In 
addition, the effects of hepatic SIRT1 are also controversial, with various studies 
reporting contrasting effects of SIRT1 on lipogenesis and gluconeogenesis [128, 130-
132, 186]. 
 
This chapter aims to characterise the putative AMPK-SIRT-PPAR regulatory 
network in liver. This will be done by using the following in vivo models; (a) 
alterations in nutritional status viz. starvation (where the hepatic capacity for 
gluconeogenesis and fat oxidation is increased), (b) re-feeding after starvation (which 
suppresses hepatic glucose production and fat oxidation), and (c) in the well-fed state, 
where the glucose supply is ample, insulin levels are high, and incoming FA are 
predominantly esterified rather than oxidized. In addition, comparisons will be made 
between ad libitum feeding of control rodent diet and a diet enriched with saturated 
fat, which affect hepatic glucose production and fat metabolism.  Finally, to elucidate 
further the potentially complex interplay between AMPK with the PPARs and SIRTs 
in regulating hepatic metabolism, we utilized (f) AMPK null mice and (g) SIRT1 
knockdown H4IIEC3 cells. Studies described in this chapter were performed in liver 
(a key tissue for glucose and lipid homeostasis) where SIRT1 has previously been 
reported to activate AMPK [148].  
 
 
3.2 Materials and methods 
 
To examine the effects of experimental diets and nutritional status on regulation of 
hepatic lipid homeostasis, the following in vivo models were utilised; C57BI/6 fasted 
and fed mice, liver specific AMPK-/- fasted and refed mice and high fat fed C57BI/6 
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mice (these models are described in detail in the general methods chapter; Chapter 2, 
sections: 2.2.2.1 and 2.2.2.2; animal diets and treatments described on Chapter 2, 
section 2.2.2.5) 
 
All the procedures carried on using these samples were performed in accordance with 
the principles and guidelines established by the European Convention for the 
Protection of Laboratory Animalsof Animals (Scientific Procedures) Act 1986, 
published by HMSO, London.  
 
Culture, treatment and transfection of the hepatocyte cell line, H4IIEC3 (Chapter 2, 
section 2.2.1.1), western blotting (Chapter 2, section 2.2.3.2), immunoprecipitation 
(Chapter 2, section 2.2.3.3), qRT-PCR (Chapter 2, section 2.2.3.4) and plasma 
analysis (Chapter 2, section 2.2.2.8) were conducted as described in the general 
methods section. 
 
3.3 Results 
3.3.1 Effects of 24h starvation on hepatic lipid homeostasis 
 
The liver is the central metabolic organ that regulates several key aspects of lipid 
metabolism including fatty acid β-oxidation, lipogenesis, and lipoprotein uptake and 
secretion, in response to nutritional and hormonal signals [187]. During the fed state, 
dietary glucose stimulates insulin secretion from the pancreas, increasing hepatic 
lipogenesis and lipoprotein secretion. Conversely, upon fasting, hepatic fatty acid 
oxidation is enhanced [188, 189]. C57BI/6 mice were either starved for 24h or fed a 
control diet to provide context for the later studies on specific AMPK-/-  liver (fasted 
or refed). 
3.3.1.1 Plasma glucose and insulin levels were reduced by fasting 
Plasma glucose levels were decreased in fasted compared to fed mice (30%; P 
<0.001; Fig. 3.1A).  Plasma insulin levels were decreased in fasted mice relative to 
fed mice (40 %; P<0.01; Fig. 3.1B). 
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Figure 3.1 
 
A                                                                 B 
 
 
Figure 3.1 Plasma glucose and insulin concentrations in fed or fasted mice. Mice were either killed at 
the mid-point of the dark phase on day 5 (fed) or starved for 24 h after 5 days of maintenance on the 
standard diet. Blood samples were collected for measurement of plasma glucose (A) or plasma insulin 
(B). Results are expressed as means ± SEM. n = 8 mice in each group. Statistically significant effects 
of fasting are indicated by **P<0.01 and ***P<0.001. 
 
3.3.1.2 Lipogenic gene expression is suppressed by fasting. 
SREBP1 and stearoyl-CoA desaturase-1 (SCD-1) are key lipogenic genes, whose 
expression is up regulated in liver under lipogenic conditions, including insulin 
stimulation and high-carbohydrate feeding. Consistent with this, starvation (24 h) of 
control mice resulted in a marked decline in both SREBP1 (93%; P<0.001) and SCD-
1 (71%) gene expression (Fig. 3.2A and 3.2B, respectively). Studies have reported a 
key role for X-box binding protein 1 (XBP1) in induction of hepatic lipogenic genes, 
including SCD1 [190]. In liver, starvation-induced decreases in lipogenic gene 
expression were not associated with a decline in XBP1 mRNA or protein expression 
(Fig. 3.2B). On the contrary, XBP1 was 2-fold increased (P<0.001) relative to fed 
samples.  
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Figure 3.2 
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Figure 3.2: Expression of genes regulating hepatic lipogenesis (SREBP1, SCD1) and the mammalian 
XBP1 in liver of fasted and fed mice. Mice were either killed at the mid-point of the dark phase on day 
5 (fed) or starved for 24 h after 5 days of maintenance on the standard diet. Gene expression for 
SREBP-1 (A), SCD1 (B) and XBP1 (C) were measured in liver by qRT-PCR. Representative Western 
blots for XBP-1 protein expression in liver (C) of mice sampled in the fed or 24 h-fasted state are also 
shown. Results are expressed as means ± SEM. Statistically significant effects of fasting are indicated 
by ***P<0.001. 
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3.3.1.3 Effects of fasting on PGC-1α and PDHK4 expression. 
PPARα is a key regulator of hepatic FA oxidation [88]. In addition, the nuclear 
receptor co-activator PGC-1α participates in regulating glucose and lipid metabolism 
in liver by interacting with PPARα [86]. Hepatic PGC-1α gene expression was 
significantly increased in WT starved compared with fed mice (Fig. 3.3A), as is 
consistent with its role in coordinating the response of hepatic nutrient handling to 
starvation. Protein expression of PGC-1α was also enhanced by fasting. 
 
The gene expression of PDHK4 (encoded by PDK4 gene), a regulatory kinase that 
inactivates PDC, blocking glucose oxidation and thereby forcing fat oxidation, is 
PPARα [185].  As expected, fasting also elevated hepatic PDK4 
expression, with a greater (3.2-fold; P<0.01) increase in protein expression (Fig. 
3.3B) than gene expression.   
 
Figure 3.3 
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Figure 3.3: Gene and protein expression of key regulators of lipid (PGC-1α) and glucose (PDK4) 
oxidation in liver of fasted and fed mice. Mice were either killed at the mid-point of the dark phase on 
day 5 (fed) or starved for 24 h after 5 days of maintenance on the standard diet before being killed. 
Gene expression for PGC-1α (A) and PDHK4 (B) were measured in liver by qRT-PCR. Representative 
Western blots for PGC-1α (A) and PDHK4 (B) protein expression in liver sampled in the fed or 24 h-
fasted state are also shown. Results are expressed as means ± SEM. Statistically significant effects of 
fasting are indicated by *P<0.05. n = 6-8 mice. 
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3.3.1.4 Effects of fasting on SIRT1, SIRT3 and GCN5 expression. 
Nutrient-mediated control of PGC-1α activity is tightly correlated with its acetylation 
state [139]. Here we measured SIRT1 and GCN5 to understand how the nutrient 
regulation of PGC-1α activity previously seen (Fig. 3.3) squares with the regulation of 
its acetylation state. SIRT1 gene expression was markedly up regulated in response to 
fasting in livers of WT mice, with a concomitant 15-fold increase in SIRT1 protein 
expression (**P<0.01) (Fig. 3.4A).  In contrast, hepatic GCN5 gene expression was 
unaffected by fasting, although there was a 2.6-fold increase (*P<0.05) in GCN5 
protein expression (Fig. 3.4B), suggestive of post-transcriptional control.   
 
Acetylation targets most enzymes in most metabolic pathways including those 
occurring within mitochondria, such as the Krebs cycle and mitochondrial β oxidation 
[191].  SIRT3 is localized in the mitochondrial matrix, where it regulates the 
acetylation levels of metabolic enzymes [109], and its expression is up-regulated in 
liver in response to starvation, leading to promotion of FA oxidation [130]. Starvation 
increased hepatic SIRT3 gene expression (~3.2-fold; **P<0.01) (Fig. 3.4C). 
 
Figure 3.4 
 
A                                                                B 
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C                                                                  
 
 
Figure 3.4: Response of gene and protein expression of the deacetylases SIRT1 and SIRT3 and 
acetylase GCN5 to fed or fasted conditions. Mice were either killed at the mid-point of the dark phase 
on day 5 (fed) or starved for 24 h after 5 days of maintenance on the standard diet, before being killed. 
Gene expression for SIRT1 (A), GCN5 (B) and SIRT3 (C) were measured in liver by qRT-PCR. 
Representative Western blots for SIRT1 (A), GCN5 (B) and SIRT3 (C) in liver of mice sampled in the 
fed or 24 h-fasted state are also shown. Results are expressed as means ± SEM (n = 6-8 mice). 
Statistically significant effects of fasting are indicated by **P<0.01. 
 
3.3.2 Effects of AMPK deletion 
 
According to the previous results described in this chapter, the SIRT1-PGC-1α-SIRT3 
lipolytic axis is induced by fasting, whereas lipogenesis is decreased. In the liver, 
SIRT1 has been reported to activate AMPK [148]. Lee et al. have reported that, in the 
liver, SIRT1 is directly phosphorylated and inactivated by AMPK [192]. These 
findings, together with evidence that AMPK and SIRT1 share the common activators 
(including fasting), actions and target molecules [149], led us to examine the effect of 
AMPK deficiency in SIRT1 target molecules, during fasting and after refeeding 
(which suppresses hepatic glucose production and fat oxidation). 
3.3.2.1 Loss of AMPKα1 and α2 subunit decreases AMPK protein 
expression in liver 
As expected, Western blot analysis (Fig. 3.5) confirmed reduced hepatic AMPK 
protein levels in AMPK -/- mice compared to WT, under fed conditions. Western 
blotting revealed that, consistent with lower total AMPK expression, AMPK 
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phosphorylation on Thr172 is 80%  (**P<0.01) decreased in livers of AMPK-/- mice 
compared to WT mice (Fig. 3.5). 
 
Figure 3.5 
 
Figure 3.5: Western blot analysis showing decreased phospho-AMPK-thr172 protein expression in 
AMPK knockout fed livers. Values are represented as means ± SEM (n=8). **P< 0.01 vs. +/+. -/- = 
AMPK α1/2 knockout mice. +/+ = WT mice. 
 
3.3.2.2 SIRT1 gene expression is decreased in mice after re-feeding 
AMPK increases SIRT1 activity by increasing cellular NAD+ levels [151] or by 
increasing NAMPT activity [150]. Like SIRT1, AMPK is activated by glucose 
deprivation [19]. A 24h period of fasting in mice promoted an increased expression of 
SIRT1 mRNA and protein in liver (Fig. 3.4). In mouse embryonic fibroblasts (MEF), 
Wang and his collaborators have shown that SIRT1 activity is impaired by AMPK 
inhibition [193]. In the present study SIRT1 gene expression was analyzed in livers of 
WT and AMPK-/-mice, fasted for 24h, or after refeeding. SIRT1 gene expression was 
about 98% decreased (*P<0.05) in refed animals, but there were no significant 
changes between WT and AMPK-/- livers (Fig. 3.6A).  
 
Enzymatic activity of SIRT3 promotes oxidative phosphorylation. Mitochondrial 
proteins of SIRT3 knockout mice are hyperacetylated and cellular ATP levels of such 
animals are reduced in high-energy tissues in, for example, the liver [159]. Loss of 
SIRT3 appears to decrease mitochondrial substrate oxidation and results in more 
intensive glycolysis [194]. In line with these observations, SIRT3 knockout attenuates 
oxygen consumption, while overexpression increases it [113, 195]. The effect of 
SIRT3 deficiency on ATP production is further aggravated by fasting, underlying its 
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reliance on NAD+ [167]. In this study, we analysed SIRT3 gene expression in livers 
of WT and AMPK-/-, under 24h fasting conditions or after a 4h-refeeding period. 
SIRT3 gene expression did not change with AMPK knockout. However there is a 
marked difference in SIRT3 gene expression between the fasted-refed state (~75% vs. 
fasted, *P<0.05, Fig. 3.6B). 
 
Figure 3.6 
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Figure 3.6: Relative gene expression of SIRT1 (A) and SIRT3 (B) vs. 18S gene expression in mice 
fasted for 24h (fasted) or re-fed with a standard diet for a period of 4h (re-fed). qRT-PCR was 
performed to measure mRNA expression of SIRT1 and SIRT3 gene. Values are represented as means ± 
SEM (n=8). *P< 0.05 vs. fasted +/+.  -/- = AMPK α1/2 knockout mice. +/+ = WT mice. 
 
3.3.2.3 Hepatic gene expression of the gluconeogenic enzymes PEPCK 
and G6Pase were suppressed in livers of re-fed AMPK-/- mice. 
SIRT1 deacetylates and activates PGC-1α, resulting in increased gluconeogenesis 
[129]. According with this, a decreased activity of SIRT1 could impair the expression 
(and thus, potentially, activity) of the gluconeogenic enzymes: phosphoenolpyruvate 
carboxykinase (PEPCK) (encoded by PCK1 gene) and glucose-6-phosphatase 
(G6Pase) [196]. In this study, we investigated the gene expression of the 
gluconeogenic enzymes to better understand the effect of AMPK-/- and nutritional 
status on gluconeogenesis in the liver. As expected, the expression of gluconeogenic 
genes were decreased (PCK1 was 75% decreased, *P<0.05) in re-fed livers (Fig. 3.7A 
and B), after a fasting period. There were no significant differences in the responses to 
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re-feeding between AMPK-/-, when compared to WT, indicating that AMPK plays no 
effect in repressed gluconeogenesis upon re-feding.  
 
Figure 3.7 
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Figure 3.7: qRT-PCR showing reduced mRNA expression of gluconeogenic enzymes in livers of mice 
after a 4h period of re-feeding (re-fed), comparing to 24h fasted animals (fasted). Relative gene 
expression of G6Pase (A); PCK1 (PEPCK) (B) vs. 18S gene. Values are represented as means ± SEM 
(n=8). *P< 0.05 vs. fasted +/+.  -/- = AMPK α1/2 knockout mice. +/+ = WT mice. 
 
 
3.3.2.4 Acetylation levels of PGC-1α in AMPK -/- liver 
AMPK and SIRT1 are metabolic sensors that can increase each other's activity [149].  
AMPK increases SIRT1 activity, resulting in deacetylation and activation of the 
activity of one downstream SIRT1 target: PGC-1α [151]. In this study we aimed to 
understand the role of the SIRT1-PGC-1α axis in AMPK-/- liver, by 
immunoprecipitating PGC-1α, followed by a western blot to reveal the acetylated 
lysine protein residues in the purified PGC-1α proteins. PGC-1α had decreased 
mRNA expression in refed animals (Fig. 3.10A), a result that correlates with SIRT1 
gene expression under the same conditions. Interestingly, PGC-1α was found to be 
less acetylated in lysine residues in livers of the AMPK deficient animals (~25%, 
*P<0.05, ±P<0.05) although, there is less acetylation in re-fed conditions than in 
fasting conditions for 24h (~20%, *P<0.05) (Fig.3.8A and 3.8B).  
 
 
 
 
103 
Figure 3.8 
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Figure 3.8: qRT-PCR showing PGC-1α gene expression vs. 18S gene (A); Western blot analysis 
showing acetylation levels on lysine residues of PGC-1α (B) in AMPK-/- and WT animals fasted for 
24h (fasted) or refed for a 4h period (refed). Values are represented as means ± SEM (n=4). *P< 0.05 
vs. fasted +/+; **P<0.01 vs. fasted; ±P<0.05 vs. +/+. -/- = AMPK α1/2 knockout mice. +/+ = WT mice. 
 
3.3.3 Studies in hepatocyte cell culture: Effects of SIRT1 silencing  
 
AMPK and SIRT1 are reported to exert similar effects on diverse processes such as 
cellular fuel metabolism, inflammation, and mitochondrial function [149]. Several 
lines of evidence suggest that these similarities occur because AMPK and SIRT1 both 
regulate each other and share many common target molecules [118]. Since we have 
previously studied the effects of AMPK knockout in the liver, we speculated that 
SIRT1 knockdown in liver cell line (H4IIEC3) could show that there is a possible 
feedback loop between SIRT1 and AMPK. In this context we studied the effects of 
SIRT1 knockdown in liver metabolism, in vitro using H4IIEC3 liver cell line. 
 
3.3.3.1 SIRT1 siRNA decreased SIRT1 gene expression in H4IIEC3 
cells. 
Cells were transfected with SIRT1 siRNA to knockdown SIRT1 protein and gene 
expression. Cells transfected with SIRT1 siRNA had lower expression of SIRT1 
mRNA, although this result was not significant (Fig. 3.9A). However, the knockdown 
is similar in magnitude to that observed in AMPK-/- mice, so allows for a good 
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comparison with the in vivo situation. A significant reduction in PGC-1α (target of 
SIRT1) gene expression was observed (~98%, ***P<0.005 vs. siRNA Scr) in cells 
transfected with SIRT1 siRNA comparing to the scrambled sequence siRNA (Fig. 
3.9B). 
 
Figure 3.9 
 
A                                                       B           
 
 
 
Figure 3.9: Relative gene expression of SIRT1 (A) and PGC-1α (B) vs. 18S gene. mRNA expression of 
SIRT1 and PGC-1α was analyzed by qRT-PCR. Values are represented as means ± SEM (n=4 
repetitions). ***P< 0.005 vs. Control.  siRNA. Scr = Control or scrambled sequence; siRNA SIRT1 = 
SIRT1 knockdown cells for 72h. 
 
3.3.3.2 SIRT1 silencing causes decreased AMPK activation 
To better understand the possible feedback loop existing between SIRT1 and AMPK 
we investigated AMPK phosphorylation at Thr172, when cells were subjected to 
SIRT1 knockdown. AMPK phosphorylation on Thr172 was 10% decreased 
(**P<0.005) in SIRT1 knockdown cells, when compared to the scrambled sequence 
(control) (Fig. 3.10). 
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Figure 3.10 
 
A                                                             B 
 
 
 
Figure 3.10: Western blot analysis showing that phospho-AMPK- thr172 (MW: 63 kDa) protein is 
decreased as a consequence of SIRT1 knockdown, in H4IIEC3 cells. (A) Representative western blot. 
(B) Graph analysis of the representative western blot. Values are represented as means ± SEM (n=4 
repetitions). ***P< 0.005 vs. Control.  siRNA Scr = Control or scrambled sequence; siRNA SIRT1 = 
SIRT1 knockdown cells for 72h. 
 
3.3.3.3 Gluconeogenic  genes differ in their responses to SIRT1 siRNA 
As stated previously, SIRT1 deacetylates and activates PGC-1α, resulting in increased 
gluconeogenesis [129]. We speculated that SIRT1 knockdown could impair gene 
expression of the gluconeogenic enzymes (PEPCK, encoded by PCK1 gene, and 
G6Pase) [196]. PEPCK gene expression was 90% reduced (*P<0.05) in response to 
SIRT1 knockdown (Fig.3.11A), whereas G6Pase gene expression tended to increase 
under the same conditions (Fig.3.11B).  
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Figure 3.11 
 
A                                                             B 
 
 
Figure 3.11: qRT-PCR analysis showing PCK1 (A) mRNA expression and G6Pase (B) mRNA 
expression in control cells compared to SIRT1 knockdown cells. Values are represented as means ± 
SEM (n= 2 to 4 repetitions). *P< 0.005 vs. Control.  siRNA Scr = Control or scrambled sequence; 
siRNA SIRT1 = SIRT1 knockdown cells for 72h. 
 
3.3.3.4 SIRT6 is regulated by SIRT1 
Like SIRT1, SIRT6 is a nuclear NAD+ dependent deacetylase, known to prolong the 
lifespan of organisms and delay the aging process (and age related diseases such as 
T2DM), by repairing the DNA damage [197]. We studied the effect of SIRT1 
knockdown in SIRT6 gene expression. SIRT6 protein and gene expression were 
decreased in SIRT1 knockdown H4IIEC3 cells. SIRT6 mRNA is 80% decreased 
when compared to the control group (*P<0.05, Fig. 3.12). 
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Figure 3.12 
 
A                                                             B 
 
  
 
Figure 3.12: Decreased expression and activity of SIRT1 decreases SIRT6 protein and gene expression. 
Western Blot analysis showing decreased SIRT6 (MW: 37 kDa) protein expression in SIRT1 
knockdown cells (A); qRT-PCR analysis showing a significant decrease of SIRT6 mRNA expression 
in SIRT1 knockdown cells (B). Values are represented as means ± SEM (n=4 repetitions). *P< 0.005 
vs. Control.  siRNA Scr = Control or scrambled sequence; siRNA SIRT1 = SIRT1 knockdown cells for 
72h. 
3.3.4 Effects of high-fat feeding and NMN treatment 
 
We have previously seen that AMPK deficiency decreases the SIRT1 target gene 
(PGC-1α) expression and that this is related to decreased gluconeogenesis, upon 
fasting. Re-feeding (which suppresses gluconeogenesis) abrogates the effect of 
AMPK deficieny in liver. However, in H4IIEC3 cells, when SIRT1 is knockdown, 
there is a decreased protein and gene expression of AMPK. According with the 
studies developed in AMPK-/- liver and in H4IIEC3 cells, we speculate that there is a 
feedback loop between AMPK and SIRT1 in the liver and that this feedback loop 
regulates hepatic gluconeogenesis, depending of the nutritional status. To better 
understand how the nutritional status infuences SIRT1 target genes in regulating 
hepatic metabolism, we have also studied mice fed a high fat diet with or without 
NMN administration. NMN is the percurso of NAD+ [179] and thereby (potentially) 
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increases SIRT1 activity by increasing NAD+ availability [198], which could affect 
hepatic metabolism. High fat diet is very low in fat, when compared to other studies, 
because I am interested in the effects of a small increase in dietary fat, to better mimic 
what happens in human occidental diet. 
 
Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in 
hepatic steatosis and inflammation [133]. On the other hand, SIRT1 is significantly 
reduced in non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet in rats 
[199]. The aim of this aspect of the project was to investigate the effects of high fat 
feeding on hepatic SIRT1 expression and determine how, by exposing tissues to the 
NAD+ precursor NMN and thereby (potentially) increasing SIRT1 activity by 
increasing NAD+ availability, could affect hepatic metabolism and hepatic insulin 
sensitivity.  
 
3.3.4.1 The effect of high fat feeding on body weights 
Significant changes in body weight occurred during the high fat diet for 16 weeks (but 
not for 10 weeks) comparing to animals that were fed with a control diet for the same 
period (Table 3.1A). After intraperitoneal NMN administration (500 mg/kg body 
weight), 16h before sacrifice, mice tend to lose weight, although control + NMN mice 
gained weight (**P<0.05) (Table 3.1B).  
 
Table 3.1 
 
A 
 
 10 weeks of diet 16 weeks of diet 
 Control HF Control HF 
Initial weight (g) 24.0 ± 0.5 23.9 ± 1.2 24.1 ± 0.6 24.0 ± 1.4 
Final weight (g) 28.5 ± 0.6 29.1 ± 2.0 31.4 ± 1.0 35.4 ± 3.0 
Weight gained (g) 4.5 ± 0.7 5.2 ± 2.0 7.3 ± 1.3 11.4 ± 3.9** 
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B 
 
Administration of 
NMN after 16 
weeks of 
HF/Control diet 
Control 
Vehicle 
Control + 
NMN 
HF Vehicle HF + NMN 
Weight gained (g) -0.52± 0.43 0.46 ± 0.67 -0.74 ± 0.45 -0.26 ± 0.34 
 
 
Table 3.1. A: Animal characteristics of C57Bl/6 mice on control diet for 10 or 16 weeks (Control) or 
11% saturated fat diet for 10 or 16 weeks (HF). Values are represented as means ± SEM (n= 5 or 10 
mice per group). **P <0.005 vs. controls. The equality of variances was studied in Leven test (**P 
<0.009). A t-test was used for independent samples. B: Weight gained on a control diet for 16 weeks 
after administration (or not) of 20 mg of NMN 24h prior sacrifice. Vehicles = not administrated with 
NMN. +NMN = intraperitoneal injection of 20 mg of NMN.  
 
3.3.4.2 Glucose and insulin plasma levels upon high fat feeding 
In addition to promoting glucose storage, insulin inhibits the production and release of 
glucose by the liver by blocking gluconeogenesis and glycogenolysis [5]. Inslin and 
glucose plasma levels were assessed in the liver of HF fed mice to understand how a 
moderate high fat diet affect the glucose homeostasis in the liver. Plasma glucose 
levels were significantly decreased in HF + NMN mice compared to HF mice (20%; 
*P<0.05; Fig. 3.13A).  Plasma insulin levels did not change significantly between HF 
and the control group (Fig. 3.13B). 
 
Figure 3.13 
 
A                                                                   B 
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Figure 3.13: Plasma glucose (A) and insulin (B) concentrations in high fat fed mice or controls. HF = 
high fat diet for 16 weeks. NMN = intraperitoneal injection of 500 mg/kg body weight of NMN at 16 
hours prior to tissue sampling. Results are expressed as means ± SEM. n = 5 mice in each group. 
Statistically significant effects of HF diet are indicated by **P<0.01. 
 
3.3.4.3 High fat feeding increases SIRT1 protein expression in liver  
Previous studies have reported that high-fat feeding decreases SIRT1 gene expression 
in mice fed on high fat diet (60% energy from fat) [126]. In the present investigations, 
in which mice were maintained on a high-saturated fat diet (11% fat) for 16 weeks, 
high-fat feeding was associated with a modest increase in SIRT1 protein expression.  
A representative blot is shown in Fig. 3.14A. Quantification of the data (Fig. 3.14A) 
indicated that, although there was some variation between individual mice, SIRT1 
protein expression increased in response to high-fat feeding relative to controls.  
 
To assess the effects of modulating SIRT1 activity in HF mice, NMN (500 mg/kg 
body weight) was administered by intraperitoneal injection to control and high-fat fed 
mice 16 hours prior to tissue sampling. NMN administration had little effect on 
SIRT1 protein expression in livers of control mice maintained on standard diet (Fig. 
3.14). In contrast, the administration of NMN to high-fat fed mice was associated with 
increased SIRT1 protein expression. The highest protein expression of SIRT1 was 
observed in high-fat-fed mice treated with NMN, approximately 6.0% higher levels of 
expression than seen in control mice that had not been treated with NMN. It can be 
concluded that high-fat feeding increases SIRT1 protein expression, an effect 
exaggerated by treatment with NMN (Fig. 3.14).  
 
Figure 3.14                                                        
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Figure 3.14: A representative Western blot of the protein SIRT1 (MW: 110 kDa) and the control β-
actin (MW: 45 kDa) are displayed in control and high fat fed animals (HF), with or without NMN 
administration. HF = high fat diet for 16 weeks. NMN = intraperitoneal injection of 500 mg/kg body 
weight of NMN at 16 hours prior to tissue sampling. mRNA expression levels measured using qRT-
PCR. n=3. 
 
3.3.4.4 High fat feeding increases Akt activity in liver 
PI3K/Akt pathway is considered to be the major effector of insulin action. Akt 
phosphorylation at Ser473 is required for its activation [51, 200]. Protein levels of 
phosphor-(Ser473)-Akt were increased in livers of high-fat fat mice compared with 
control mice on standard diet, suggesting increased Akt activity as protein expression 
of total (unphosphorylated and phosphorylated Akt) was unchanged (Fig. 3.15).  
Protein expression of phospho-Akt also increased with NMN treatment in control 
mice, but the effect of NMN treatment to increase phospho-Akt expression (i.e. Akt 
activity) did not appear to be additive with that of HF feeding (Fig. 3.15).  This 
contrasts with effects of high-fat feeding and NMN to increase SIRT1 protein 
expression (Fig. 3.14). 
 
Figure 3.15 
                                                             
 
 
 
 
Figure 3.15: Western blot analysis of phospho-Akt-ser473 (MW 56 kDa) in control and high fat fed 
animals (HF), with or without NMN (500 mg/kg body weight) administration as intraperitoneal 
injection, at 16 hours prior to tissue sampling; total Akt (MW 56 kDa) and the control protein: β -actin 
(MW 45 kDa) were also measured to compare changes in phospho-Aktser473. As the density of the 
control and total-Akt bands are similar across the gel, changes witnessed in the levels of phospho-Akt-
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ser473 are due to its activation state. HF = high fat diet for 16 weeks. NMN = intraperitoneal injection of 
20 mg of NMN. 
 
3.3.4.5 High fat feeding and NMN treatment have opposite effects on 
IRS-1 tyrosine phosphorylation in liver  
Akt activation in livers of high-fat fed mice was unexpected (Fig. 3.15) as high-fat 
feeding is thought to cause tissue insulin resistance [201]. The intracellular actions of 
insulin are initiated by tyrosine phosphorylation of IRS-1 (Shulman 2000). Therefore, 
to confirm that Akt activation in response to high-fat feeding reflects increased insulin 
action, protein levels of tyrosine-phosphorylated IRS-1 were compared in livers of 
high fat fed and control mice, with or without NMN treatment. In contrast to Akt 
phosphorylation, tyrosine phosphorylation of IRS-1 was decreased by HF feeding 
(Fig. 3.16). This effect was reversed by NMN administration, with led to increased 
IRS-1 tyrosine phosphorylation in NMN treated HF fed mouse livers (Fig. 3.16). 
Levels of IRS-1 tyrosine phosphorylation were similar in NMN-treated control mice 
and NMN-treated high-fat-fed mice (Fig. 3.16).  
 
Figure 3.16                                                        
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: Western blot of the eluted phosphorylated tyrosine on IRS1 following an 
immunoprecipitation assay in control and high fat fed animals (HF), with or without NMN (500 mg/kg 
body weight) administration as intra-peritoneal injection, at 16 hours prior to tissue sampling. HF = 
high fat diet for 16 weeks. NMN = intra-peritoneal injection of 500 mg/kg body weight of NMN. 
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3.3.4.6 Variations in PGC1α and PCK1 gene expression induced by high-
fat feeding and NMN treatment 
As indicated from decreased IRS-1 tyrosine phosphorylation, mice maintained on HF 
diet showed a modest decrease in insulin signalling; however, Akt activity was 
paradoxically increased. It was therefore investigated whether this dietary 
manipulation caused increases in gene expression of the gluconeogenic genes PCK1 
and PGC1a, which would be consistent with decreased insulin sensitivity. Consistent 
with reduced insulin sensitivity, PGC-1α (Fig. 3.17A) and PCK1 (Fig. 3.17B; ~3-fold, 
*P<0.05) mRNA levels were increased in HF fed mice compared to control.  
 
NMN administration increased IRS-1 tyrosine phosphorylation in both control and 
high-fat fed mice, suggesting enhanced insulin sensitivity. Consistent with an NMN-
mediated improvement in hepatic insulin sensitivity, NMN treatment decreased gene 
expression of PCK1 and PGC1α to control levels. NMN did not afect gene expression 
of either PGC-1α or PCK in control mice. The patterns of responses of SIRT1, PGC-
1α and PEPCK to high-fat feeding and NMN-treatment are strikingly similar. 
 
Figure 3.17 
 
A                                                              B 
 
Figure 3.17: Relative expression of PGC-1α (A) and PCK1 (B) vs. 18S gene in control and high fat fed 
animals (HF), with or without NMN (500 mg/kg body weight) administration as intra-peritoneal 
injection, at 16 hours prior to tissue sampling. mRNA expression levels of PGC-1α and PCK1 
measured using qRT-PCR. Data are means ± SEM, n=4. *P<0.05 vs. control; #P<0.05 vs. control + 
NMN. HF = High fat diet. 
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3.3.4.7 Variations in phospho-AMPK and phospho-ACC protein 
expression induced by high-fat feeding and NMN treatment 
AMPK and SIRT1 both respond to glucose scarcity with increased activity and both 
enzymes suppress FA synthesis whilst promoting FA oxidation.  High-fat feeding 
caused concomitant increases in protein expression of phospho-AMPK and phospho-
ACC (Fig. 3.18), indicative of increased AMPK activity. Although this is not very 
clear on the blot, the density analysis of the western blot shows a correlation between 
the two. NMN-treatment of control mice lowered phspho-AMPK-thr172 protein 
expression (Fig. 3.18).  Although this suggests lowered AMPK activity, protein 
expression of phosphoACC-ser218 was too variable between samples to draw a firm 
conclusion (Fig. 3.18).  NMN did not have a significant effect on either phospho-
AMPK-thr172 or phopsho-ACC-ser218 protein expression in livers of HF fed mice. 
 
Figure 3.18 
 
A 
 
 
 
 
 
 
 
    B                                                                 C 
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Figure 3.18: Western blot analysis of phospho-AMPK (MW 63 kDa) and phospho-ACC (MW 215 
kDa) (A) in control and high fat fed animals (HF), with or without NMN (500 mg/kg body weight) 
administration as intraperitoneal injection, at 16 hours prior to tissue sampling. Β-actin (MW: 45 kDa) 
was used to verify that the samples were equally loaded; Quantified data of the western blot for p-
AMPK (B); Quantified data of the western blot for p-ACC (C). HF = high fat diet for 16 weeks. NMN 
= intraperitoneal injection of 500 mg/kg body weight of NMN. 
 
3.4 Discussion 
 
In the present study, liver specific AMPK-/- mice show decreased SIRT1 gene 
expression and SIRT1 knockdown cells have lower levels of PGC-1α gene expression 
and AMPK protein expression, suggesting a feedback loop between SIRT1 and 
AMPK, where SIRT1 deacetylates and activates AMPK through an upstream kinase 
of AMPK (perhaps LKB1), leading to AMPK activation; AMPK depletion, on the 
other hand, inhibits SIRT1 activity in the liver, under normal fed conditions. 
Gluconeogenesis gene expression could be regulated by the amount of glucose in the 
media (in addition to SIRT change). Since our H4IIEC3 cells were cultured in a 
media containing glucose, this could have affected the results about gluconeogenic 
gene expression. In the future, it would be interesting to study LKB1 acetylation 
levels together with SIRT1 activity, and NAMPT gene and protein expression in 
AMPK knockout livers of fasted mice, refed after a 24h period. 
 
We investigated the expression of metabolically important genes encoding key 
regulators of lipid and glucose oxidation in liver, in vivo and in vitro. Fasting was 
employed as a metabolic challenge associated with an increased demand for supply of 
FA for oxidation. We found that in the liver, there was a fasting-induced reduction in 
the expression of lipogenic genes targeted by insulin (SREBP-1 and its target, SCD1). 
XBP-1 gene expression is, however, increased possibly due to decreased activity of 
SCD-1. Paton & Ntambi found that SCD-1 activity is required for efficient cholesterol 
esterification to monounsaturated fatty acid (MUFA) and that loss of its activity 
increases XBP-1-mediated free cholesterol synthesis [202]. XBP-1 induction may also 
be related to induction of endoplasmic reticulum stress and the activation of unfolded 
protein response (UPR), which can be induced by fasting [203], and involves XBP1 
[204]. SIRT3 and PGC-1α gene expression were up-regulated in liver in response to 
fasting, which is important for increased fat oxidation under these conditions. The 
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increased PGC-1α gene expression might be a result of increased SIRT1 gene 
expression under the same conditions. Expression of SIRT3 in the liver is induced by 
PGC-1α through a mechanism involving estrogen-related receptor alpha (ERRα) 
[205]. SIRT3 dependent deacetylation of LCAD promotes β-oxidation [167]. SIRT1-
PGC-1α-SIRT3 axis during fasting is important to prevent chronic mitochondrial 
protein hyperacetylation and reduced LCAD activity [167]. Decreased fatty acid 
oxidation due to decreased LCAD activity would eventually lead to obesity, insulin 
resistance and metabolic disorders [106, 206, 207]. 
 
Previous studies have shown that NAMPT-mediated NAD+ biosynthesis is 
compromised by high fat diet and aging, contributing to the pathogenesis of T2DM.  
The same authors have also provided proof of the concept that promoting NAD+ 
biosynthesis by administering NMN, a key NAD+ intermediate, can be an effective 
intervention to treat the pathophysiology of diet- and age-induced T2DM [208]. In our 
study, high fat diet tended to increase SIRT1 expression, bur the results were not 
statistically significant. Short term NMN administration did not have a significant 
effect of high fat feeding in SIRT1 gene expression, although, SIRT1 protein 
expression seems to be increased in HF fed plus NMN treated animals. Measuring 
SIRT1 activity with an enzymatic kit would be interesting to understand how SIRT1 
activity is affected by diet. The mechansism by which NMN is transported into cells 
currently remains unknown; metabolic tissues and organs seem to utilize NMN and 
convert it to NAD+ efficiently [208]. Therefore, an adequate and consistent supply of 
this key NAD+ intermediate must be critical to maintain normal hepatic insulin 
sensitivity, in part through increased SIRT1 activity. Interestingly, HF mice, but not 
controls, lose weight after short term NMN administration. This can be explained 
either by possible increased lipolysis in HF mice, associated to NMN administration 
or by starvation as a result of NMN administration. It is possible that animals do not 
eat as much after the injection of NMN, possibly because NMN affects appetite 
mechanism for high fat diets. Further investigation is required to explain the loss of 
weight under these circumstances. To assess beneficial and possible adverse effects of 
NMN more comprehensively, it would be interesting to measure long-term NMN 
supplementation experiments in different dietary conditions (i.e. fasting, feeding, high 
fat feeding). It will be also of great interest to examine whether the effects of NMN 
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are synergistic with those of small chemical SIRT1 activators (e.g. AROS) [209], 
particularly in aged, diabetic individuals. 
 
Studies performed in vitro have shown that resveratrol inhibited the phosphorylation 
of IRS1-Ser307, which is a marker of insulin resistance [210], indicating that 
resveratrol (SIRT1 activator) improves insulin signalling [211]. In agreement with 
this, SIRT1 overexpression increased the phosphorylation of Akt, a downstream target 
of insulin signalling, in muscle cells and HEK293 cells, whereas the inhibition of 
SIRT1 induced the opposite response [211]. High fat feeding impairs tyrosine-
phosphorylation of IRS-1, which indicates that high fat could impair insulin 
signalling. In contrast, in the liver, NMN treatment seems to increase IRS-1 tyrosine 
phosphorylation, perhaps ameliorating insulin-signalling pathway even in high fat fed 
animals. I suggest that NMN administration increases SIRT1 activity through 
increased NAD+ and this, in turn, improves insulin signalling through phosphorylation 
of tyrosine residues in IRS1. This could increase Akt gene expression in response to 
IRS1 decrease as a compensatory effect, which could explain Akt activation in livers 
of high-fat fed mice. 
 
AMPK is reported to activate SIRT1 in skeletal muscle by increased NAMPT 
concentrations or through increased β oxidation [150, 151]. A recent study has shown 
that a relative deficiency in carbohydrate intake or, albeit less likely, a relative excess 
of fat intake (in the absence of caloric deprivation) is sufficient to activate the AMPK-
SIRT1-PGC1α energy-sensing cellular network in human skeletal muscle [212]. A 
similar mechanism could happen in the liver of high fat fed animals, where PGC-1α 
was increased in a significant way and AMPK and SIRT1 tended to be increased. In 
this chapter, the effect of fasting in increasing SIRT1-PGC1α axis is abrogated by the 
loss of AMPK. The acetylation levels of PGC-1α are significantly decreased in liver 
specific AMPK-/- mice, suggesting that AMPK has an effect in SIRT1 mediated PGC-
1α acetylation and activation. PGC-1α’s activation of gluconeogenic gene expression 
is dependent upon its acetylation state, which is controlled not only by the deacetylase 
SIRT1, but also by the acetyltransferase GCN5 [137, 138]. Nevertheless, whether 
other chromatin modifiers - particularly other sirtuins - can modulate PGC-1α 
acetylation is currently unknown.  
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Finally, it seems like SIRT6 is SIRT1 dependent. SIRT6 mRNA expression is 
decreased under SIRT1 knockdown conditions in H4IIEC3 cells. Since SIRT1 and 
SIRT6 are both nuclear, is possible that SIRT1 activates SIRT6 through deacetylation 
or that SIRT1 absence leads to SIRT6 inactivation. Dominy et al [107] have reported 
that SIRT6 strongly controls PGC-1α acetylation. Surprisingly, SIRT6 induces PGC-
1α acetylation, through interaction and modification of GCN5, leading to GCN5 
enhanced activity. Decreased acetylation levels of PGC-1α in AMPK-/- mice could be 
either because AMPK negatively regulates SIRT1 target genes, or because decreased 
activity of SIRT6 through decreased SIRT1 gene expression could impair PGC-1α 
acetylation status. Further studies with SIRT1 activity kit would be important to better 
understand this pathway.  
 
In summary, fasted mice display an oxidative profile (enhanced expression of 
oxidative genes: PGC-1α, SIRT1 and SIRT3), with decreased plasma glucose and 
insulin levels, together with decreased expression of the lipogenic genes SREBP1 and 
SCD-1. High fat feeding impairs tyrosine-phosphorylation of IRS-1, possibly due to 
decreased SIRT1 activity, which could impair insulin signalling. Mice fed with a high 
fat diet had no significant changes in their weight gained, which possibly explains the 
difficulty of achieving statistically significant results to suggest an oxidative or 
lipogenic profile. It is possible that the diet was less apelative, and if so, HF mice 
have not had eaten as much as the controls. SIRT1 and AMPK seem to be involved in 
a reciprocal activation in liver, but further studies need to be done to better understand 
the link between these proteins. 
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Chapter: 
4. Studies on the roles of the SIRT1-AMPK regulatory axis in skeletal 
muscle in vivo and using L6 myoblasts 
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The studies described in this chapter have been published on Life Sciences: 
Silvestre MFP, Viollet B, Caton PW, Leclerc J, Sakakibara I, Foretz M, Holness MC, 
Sugden MC. (2014) The AMPK-SIRT signaling network regulates glucose tolerance 
under calorie restriction conditions. Life Sci 100(1)55-60. 
 
4.1 Introduction 
 
Chapter 3 has shown that, in the liver, AMPK deficiency decreases SIRT1 gene 
expression, and SIRT1 deficient H4IIEC3 cells have lower levels of PGC-1α gene 
expression and AMPK protein expression, suggesting a feedback loop between these 
two proteins (AMPK and SIRT1). In skeletal muscle this interaction remains unclear, 
but given the function of skeletal muscle as the major site of glucose uptake, this 
signalling network is potentially of great importance. 
 
Calorie restriction (CR) has been shown to protect against onset age-related diseases 
[100, 213], in part through improvement of glucose tolerance and insulin signalling, 
and to reduce mortality linked to T2DM and cardiovascular diseases [214-218]. Of its 
target tissues, skeletal muscle is the major site of insulin-stimulated glucose disposal 
[219] and AMPK has important acute metabolic actions in this insulin-responsive 
tissue, such as LCFA oxidation (lipid-lowering effect), glucose uptake and glucose 
and glycogen breakdown (glucose-lowering effect) [19, 220, 221]. However, in 
marked contrast to the effects of AMPK, insulin suppresses fat oxidation and 
stimulates glycogen, lipid and protein synthesis and may often oppose the actions of 
AMPK [222, 223].  Interestingly, common actions of AMPK and insulin are also 
observed, in particular, stimulation of glucose uptake into skeletal muscle [38]. It has 
been recently established that AMPK acts as the prime initial sensor for fasting-
induced adaptations in skeletal muscle and that SIRT1 downstream signalling is 
blunted in the absence of AMPK [166]. 
 
The research described in this chapter aims to understand the mechanisms by which 
AMPK and SIRT1 may interact to regulate glucose tolerance in skeletal muscle 
during CR. To clarify whether altered AMPK signalling could be associated with 
altered skeletal muscle metabolism, particularly with respect to SIRT1 expression or 
action, we analysed muscle-specific AMPKα1/2 knockout (AMPK -/-) using CR and 
starvation as manipulations to modify glucose tolerance. In addition, L6 cells (skeletal 
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muscle myoblasts) were employed to determine regulatory interactions between 
AMPK and SIRT1. 
 
4.2 Methods 
 
Female skeletal muscle-specific AMPK-/- or WT mice were maintained on CR (CR-
AMPK-/-; WT-AMPK-/-) or ad libitum (AL-AMPK-/-; AL-AMPK-/-) feeding regimes 
at Institute Cochin INSERM, Paris, France. Animal studies described in Chapter 2, 
Section 2.2.2.1 were reviewed and approved (agreement no. 75-886) by the Directeur 
Départemental des Services Vétérinaires of the Préfecture of Police of Paris. Mice 
were subjected to calorie restriction (30%) or ad libitum feeding (Chapter 2, section 
2.2.2.5.1), and whole body glucose homeostasis and insulin sensitivity were assessed 
by an oral glucose tolerance test (oral gavage of glucose; 3 mg/kg/body weight) 
(Chapter 2, section 2.2.2.5.2) and insulin administration (5 minutes before sacrifice; 1 
Unit of insulin/kg of body weight) (Chapter 2, section 2.2.2.5.3) respectively, as 
described in the general methods. Immunohistochemistry was performed as described 
in Chapter 2, section 2.2.2.5.4. 
 
All the procedures carried on using these samples were performed in accordance with 
the principles and guidelines established by the European Convention for the 
Protection of Laboratory Animals. 
 
Culture and treatment of the skeletal myoblast cell line, L6 was performed as 
described in Chapter 2, section 2.2.1.2. When cells had reached 70 – 80% confluency, 
they were either kept in the same medium (termed “fed cells”) or incubated in either 
serum-free DMEM (without FCS) or Hank’s Balanced Salt Solution (HBSS) with 
calcium and magnesium, (Appendix IV.) for 3.5 hours (termed “starved cells”).  Fed 
and starved cells were incubated with 1 ml of media containing SIRT1 inhibitor 
for a further 30 minutes with insulin (100 nM) and/or recombinant mouse globular 
ibodies-online GmbH, Germany). 
Research has shown that gAcrp30 is more active than Acrp30 in mediating increased 
activity of AMPK and PPARα [224]. Negative controls consisted of 1ml of media 
containing an equal concentration of dimethyl sulphoxide (DMSO).  
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Western blotting (Chapter 2, 2.2.3.2), immunoprecipitation (Chapter 2, 2.2.3.3) and 
qRT-PCR (Chapter 2, 2.2.3.4) were conducted as described in the general methods 
section. 
 
All data are expressed as mean ± SEM. Statistical comparisons were carried out using 
Graphpad Prism and StatView. Statistical differences were evaluated by unpaired t-
test, two-way or one-way analysis of variance (ANOVA), followed by a Newman-
Keuls, Bonferroni’s or Fisher’s post-test where appropriate. Statistical differences 
were accepted as P<0.05. 
 
4.3 Results 
 
Studies of effects of AMPK deficiency in vivo using AMPK KO mice 
 
Here we investigated the role of AMPK in the insulin-sensitizing effect of calorie 
restriction and in the NAMPT-SIRT1 pathway, in skeletal mixed hindlimb muscle in 
vivo. We used skeletal muscle specific AMPK-/- under ad libitum fed (AL) conditions 
or after CR (30% of the food consumed by AL mice, for 10 weeks), with or without in 
vivo administration of insulin (1 Unit/kg of body weight). 
 
4.3.1 Loss of AMPKα1 and -2 subunits decreases AMPK protein 
expression in skeletal muscle of AL and CR-fed mice 
Skeletal muscle AMPK protein levels were undectable in AL- and CR-AMPK-/- mice 
(Fig. 4.1). Moreover, levels of AMPK activity, denoted by phosphorylation on Thr172, 
were abolished in skeletal muscle of AL- and CR-AMPK-/- mice compared to AL-WT 
and CR-WT respectively (Fig. 4.1A).  
 
Acetyl CoA Carboxylase (ACC) is a down stream target of AMPK, where by AMPK 
inhibits ACC activity through phosphorylation on Ser218 [225]. Enhanced ACC 
phosphorylation at Ser218 in skeletal muscle of CR-WT is clearly lost in AMPK-/- mice 
(Fig. 4.1A).  
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AL-AMPK-/- mice gained similar weight over 10 weeks compared to AL-WT mice 
and body weight reduction in CR-WT and CR-AMPK-/- was also comparable (Fig. 
4.1B).   
 
Taken together, these data demonstrate that these mice are suitable for study of the 
effects of reduced skeletal muscle AMPK signalling. 
 
Figure 4.1 
 
A 
 
B 
 
  
 WT AMPK
-/-
 
 AL CR AL CR 
Initial weight (g) 18.52 ± 2.4 21.0 ± 2.3 17.33  ± 1.4 21.16 ± 2.7 
Final weight (g) 22.34 ± 2.9 20.25 ± 1.0 21.33 ± 1.2 20.44 ± 2.6 
Weight gain (g) 3.82 ± 1.3 -0.8 ± 2.3*** ### 4.0 ± 2.3 -0.72 ± 0.75*** 
### 
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Figure 4.1: (A) Representative western blot of total AMPK and phospho-AMPK-thr172 protein (MW: 
63 kDa) and of total ACC and phospho-ACC-ser218 protein (MW: 215 kDa). AL = mice fed ad 
libitum; CR = calorie restricted mice (30% caloric restriction); -/- = AMPK α1/2 knockout mice; +/+ = 
WT mice. (B) Weight gained after 10 weeks of AL vs. CR treatment. Data are presented as means ± 
SE. ***P<0.001 vs. AL +/+, ###P<0.001 vs. AL -/-, n= 4-5 per group.  
 
4.3.2 AMPKα1/2 knockout impairs CR-mediated improvements in all 
body glucose tolerance 
To assess the effects of the experimental diets and AMPK-/- on whole body glucose 
tolerance we utilized an oral glucose tolerance test (OGTT). There were no significant 
differences in basal fasting plasma glucose and insulin levels between the four groups 
(Fig. 4.2A and 4.2C). However, CR-WT mice displayed improved glucose tolerance, 
where blood glucose levels were significantly lower 20 – 40 minutes post-glucose 
injection, compared to AL-WT (*P<0.05) (Fig. 4.2A and 4.2B). Notably, this effect 
was lost in CR-AMPK-/- mice, demonstrating that skeletal muscle AMPK is required 
for mediating the beneficial effects of CR on glucose tolerance. Interestingly, glucose 
levels peaked at 40 minutes-post glucose injections in CR-AMPK-/-, but at 20 minutes 
post-glucose in AL-AMPK-/- mice, perhaps indicating subtly different mechanisms of 
action. The early raised blood glucose levels were lost between 60 – 120 minutes, and 
blood glucose returned to basal levels after 120 minutes in all four groups (Fig. 4.2A). 
CR-WT mice did not display increased plasma insulin levels after 20 minutes 
compared to AL-WT and AL-AMPK-/-, indicating that the improvements in glucose 
tolerance relative to these groups were likely mediated by increased peripheral insulin 
sensitivity, rather than elevated pancreatic insulin secretion (Fig. 4.2C). However, 
plasma insulin was slightly reduced in CR-AMPK-/- mice compared with the other 
three groups, suggesting that AMPK deficiency in CR may lead to lower insulin 
secretion (Fig. 4.2C).  
 
In order to demonstrate that improved glucose tolerance following CR is not a result 
of a shift in fiber type, we have counted the number of myosin heavy chain I and 
myosin heavy chain IIA fibers in WT and AMPK-/- soleus and gastrocnemious 
muscle, under CR conditions. No changes were observed in the number of fibers in 
gastrocnemius and soleus muscle from  CR-WT and CR-AMPK-/-  mice. (Fig. 4.2D 
and 4.2E). 
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Figure 4.2 
 
A                                                                 
 
B                                                                  C 
  
D                                                                  E 
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Figure  4.2: (A) Glycaemia after intra-peritoneal administration of glucose (3g/kg of body weight) (B); 
Area under the curve data (C); plasma glucose and insulin levels measured after 5-hours fasting and 20 
min after oral gavage of glucose (3g/kg of body weight). Data are means ± SE (n=17-23); 
Quantification of immunostaining for MyHC I and MyHC IIA in gastrocnemius (C) and soleus (D) 
from CR-WT and CR-AMPK-/- mice. Results are presented as mean ± SEM (n = 3); *P< 0.05, 
**P<0.01 significantly different from AL-WT. AL = ad libitum fed mice; CR = calorie restricted mice 
(30% caloric restriction); -/- = AMPK α1/2 knockout mice. +/+ = WT mice. 
 
4.3.3 NAMPT gene expression in skeletal muscle is suppressed by 
AMPK deletion in fed mice, an effect blunted by CR 
Several studies have reported that NAMPT plays a protective role against various 
types of stresses [226]. These effects are thought to occur in part due to the NAD+ 
biosynthetic activity of NAMPT, which results in activation of NAD+-dependent 
sirtuin enzymes, particularly SIRT1 [227]. AMPK has been reported to induce 
NAMPT with consequent raised NAD+ levels and increased SIRT1 activity [150]. We 
studied NAMPT gene expression in order to better understand the possible link 
AMPK-NAMPT-SIRT1 in CR. Loss of AMPKα1/2 subunits greatly decreased 
skeletal-muscle NAMPT mRNA expression in AL mice (~75% vs. AL AMPK +/+, 
**P<0.01) (Fig. 4.3). CR also suppressed skeletal-muscle NAMPT gene expression in 
WT mice (~75% vs. AL AMPK +/+, **P<0.01).  Skeletal-muscle NAMPT gene 
expression levels were comparable in AL AMPK KO mice, CR WT mice and CR 
AMPK KO mice (~75% vs. AL AMPK +/+, **P<0.01).  This data shows that 
deficiency in AMPK and CR separately lower skeletal muscle NAMPT expression, 
but AMPK deficiency does not lead to further NAMPT mRNA decrease in CR mice 
(Fig. 4.3). 
 
Figure 4.3                                                       
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Figure 4.3: qRT-PCR showing NAMPT mRNA expression in CR and AL mice (AMPK-/- and WT)  
mice vs. 18S gene. Values are represented as mean ± SEM (n=4-6 per group). **P<0.01 vs. +/+ AL 
mice. AL = mice fed ad libitum; CR = calorie restricted mice (30% caloric restriction);  -/- = AMPK 
α1/2 null mice. +/+ = WT mice. 
 
4.3.4 SIRT1, SIRT6 and SIRT3 gene expression tend to be suppressed 
by AMPK deletion in skeletal muscles of AL fed mice  
Previous studies have reported that SIRT1 activity is disrupted by AMPK inhibition 
[193]. To further examine these findings in vivo, with the aim of determining the 
mechanisms responsible for the altered glucose tolerance described above, SIRT1 
gene expression was analyzed in skeletal muscle of WT and AMPK-/- mice, fed AL or 
CR. Loss of AMPK decreased SIRT1 mRNA expression in skeletal muscle of AL fed 
animals (Fig. 4.4A). However, in contrast, SIRT1 gene expression was unchanged in 
both CR-WT and CR-AMPK -/- mice (Fig. 4.4A).  
 
A study has shown that in mice, absence of SIRT6 enhances insulin signalling and 
activation of Akt, leading to hypoglycemia and this is associated with increased 
membrane association of GLUT1 and GLUT4, which enhances glucose uptake [228]. 
In our previous studies in H4IIEC3 liver cell line (Chapter 3), we have shown that 
SIRT6 gene and protein expression is suppressed when SIRT1 is knockdown. In this 
chapter we measured SIRT6 gene expression to better understand if this dependence 
is tissue-specific and what are the consequences of this possible interaction to glucose 
homeostasis.  Skeletal-muscle SIRT6 gene expression was moderately suppressed by 
AMPK deficiency, both in AL-fed mice and CR mice (c.f. SIRT1 gene expression, 
where the effect of CR is blocked by AMPK deficiency) (Fig. 4.4 B).  
 
CR also induces the expression of SIRT3, particularly in brown adipose tissue (BAT) 
[113]. However, during CR in mice, cellular NAD+ levels and the NAD+/NADH ratio 
fluctuate significantly depending on tissue type, suggesting that sirtuins have tissue-
specific responses to CR. Nevertheless, it appears that SIRT1 regulates energy 
metabolism and physical responses to CR, while SIRT3 is able to mediate CR-
associated reduction of oxidative damage [109]. In muscle tissue we assessed SIRT3 
mRNA. SIRT3 mRNA showed decreased gene expression in CR-AMPK-/- mice when 
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compared to CR-WT (~80%, ±±±P<0.001). AL mice did not exhibit differences in 
SIRT3 gene expression between WT and AMPK-/- mice (Fig 4.4C).  
 
In summary, CR did not increase sirtuins’ gene expression. In AL fed mice, AMPK 
deficiency caused a modest decrease in SIRT1 and SIRT6, but did not affect SIRT3. 
Under CR, all sirtuins have decreased gene expression when AMPK is deficient. 
SIRT6, and in a less extension, SIRT1 have modest decreases, while SIRT3 shows a 
significant marked decreased mRNA expression. 
 
Figure 4.4 
 
A 
 
B                                                                       C 
 
Figure 4.4: qRT-PCR showing A) SIRT1, B) SIRT6 and C) SIRT3 mRNA expression in AL and CR 
mice (AMPK-/- and WT) vs. 18S gene.  Data are  presented as mean ± SEM (n=4-6 per group), 
±±±P<0.01 vs. +/+ CR; AL = mice fed ad libitum; CR = calorie restricted mice (30% caloric 
restriction); -/- = AMPK α1/2 knockout mice. +/+ = WT mice. 
 
4.3.5 PGC- 1α gene and protein expression and acetylation status 
In skeletal muscle, PGC-1α target genes for FA oxidation are induced by the 
deacetylase SIRT1, whilst GNC5 has been reported to acetylate and suppress PGC-1α 
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activity in skeletal muscle and in liver [139]. PGC-1α controls the transcription of 
SIRT3 to activate thermogenesis in brown adipose tissue [229] and to suppress ROS 
production in the mitochondria [205]. SIRT6 has not been reported to interact with 
PGC-1α. According with these facts, and because SIRT6 changes were minimal in 
response to AMPK deficiency and CR, we speculated that PGC-1α gene and protein 
expression would occur in parallel with changes in SIRT1 and/or SIRT3 expression. 
Acetylation status was also assessed to verify whether SIRT1-dependent of PGC-1α 
was disturbed by changes in SIRT1 gene expression. Skeletal-muscle PGC-1α gene 
expression was similar in AL-WT mice and AL-AMPK-/- mice. It has been reported 
that gene and protein expression of PGC-1 in mouse skeletal muscle is enhanced by 
fasting [130] and, in the present experiments, PGC-1α gene expression was 
substantially increased in CR-WT mice compared with AL-AMPK-/- mice (~3-fold vs. 
AL-WT, **P<0.01). The absence of AMPK led to ablation of CR-mediated increases 
in PGC-1α gene expression (<75% vs. CR-WT, ±±P<0.01) (Fig. 4.5A). The marked 
increase in PGC-1α gene expression elicited by CR -WT mice was not, however, 
accompanied by any marked change in PGC-1α protein. 
 
PGC-1α protein is deacetylated by SIRT1, and thus suppression of SIRT1 activity 
would be predicted to increase PGC-1α protein acetylation. When deacetylated, PGC-
1α is activated and acts as a master regulator of mitochondrial biogenesis [151] PGC-
1α protein was therefore immunoprecipitated and probed with anti–acetyl-lysine 
antibody to assess the acetylation level of PGC-1α (Fig. 4.5B). Skeletal-muscle PGC-
1α acetylation was modestly (30%) but significantly (*P<0.05) increased in AL-
AMPK-/- mice compared with AL-WT mice, and substantially (0.5-fold, *P<0.05) 
increased in CR-WT animals compared with AL-WT mice (>0.5-fold vs. AL AMPK 
+/+, *P<0.05). The absence of AMPK completely abrogated the CR-dependent 
increase in PGC-1α protein acetylation (~30% vs. CR –WT,  ± P<0.05).  
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Figure 4.5 
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Figure 4.5: A: qRT-PCR analysis showing PGC-1α mRNA expression vs. 18S gene. B: 
Immunoprecipitation followed by western blotting analysis showing acetylation levels of PGC-1α in 
lysine residues (MW: 130 kDa), compared to total PGC-1α. Data are presented as mean ± SEM (n=4-6 
per group), **P<0.01 vs. +/+ AL, ±±P<0.01 vs. +/+ CR, *P<0,05 vs. +/+ AL, ±P<0.05 vs. +/+ CR. AL 
= mice fed ad libitum; CR = calorie restricted mice (30% caloric restriction); -/- = AMPK α1/2 null 
mice. 
 
4.3.6 Loss of AMPK α1/2 attenuates insulin-mediated activation of Akt  
It has been reported that, in vascular smooth muscle cells, tyrosine (Tyr) 
phosphorylation of IRS-1 is negatively regulated by serine794 phosphorylation of IRS-
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1 by activated AMPK [230].  We therefore postulated that lack of AMPK might affect 
Tyr phosphorylation of IRS-1 in skeletal muscle. Thus, we analyzed the Tyr 
phosphorylation level of skeletal-muscle IRS-1 through immunoprecipitation (Fig. 
4.6A). In WT mice, total IRS-1 protein expression in skeletal muscle of AL mice was 
increased by insulin stimulation, but decreased in CR mice. AMPK deficiency did not 
exert any major effect on total-IRS-1 protein expression. CR and acute insulin 
treatment did not exert additive effects on IRS-1 tyrosine phosphorylation (Fig. 4.6A).  
 
AL- and CR-WT mice exhibited remarkable increases in skeletal-muscle Akt Ser473 
phosphorylation in response to insulin (~2-fold vs. basal, *P<0.05; ±P<0.05) (Fig. 
4.6B). This demonstrated increased Akt activation since total-Akt protein was 
unchanged. The response of Akt-ser473 phosphorylation to insulin treatment was 
greatly attenuated in AMPK-/- mice (~63% vs. AMPK +/+, P<0.05), (Fig 4.6B). 
 
Figure 4.6 
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Figure 4.6: A: Immunoprecipitation followed by western blot analysis showing IRS tyrosine 
phosphosphorylation at tyrosine residues, compared to total IRS-1 protein expression (MW: 180 kDa). 
B: western blot analysis showing insulin-dependent Akt phosphorylation on ser473 in AL animals. β-
actin (MW: 45 kDa) was used to verify that the samples were equally loaded.  Data shown are 
presented as mean ± SEM (n=4-6 per group), *P<0.05 vs. +/+ AL mice, P<0.05 vs. -/- AL mice, 
±P<0.05 vs. +/+ CR mice. AL = mice fed ad libitum; CR = calorie restricted mice (30% caloric 
restriction); -/- = AMPK α1/2 null mice. +/+ = WT mice. 
 
Studies with L6 rat myoblasts 
 
Cultured L6 myoblasts were used to dissect out inter-relationships between AMPK 
and SIRT1 in more detail, since direct effects of activators and inhibitors on muscle 
cells could be identified. Adiponectin and insulin were used in these experiments as 
activators of AMPK and insulin signalling (including Akt phosphorylation), 
respectively. The SIRT1 inhibitor Ex527 was added to inhibit SIRT1 activity.  
 
4.3.7 Serum starvation augments phospho-AMPK protein expression 
but suppresses Akt phosphorylation in L6 myoblasts 
Preliminary experiments indicated that AMPK-Thr172 phosphorylation status in L6 
myoblasts was greatly influenced by the incubation medium selected.  As shown in 
Fig. 4.7A, serum starvation, which mimics starvation/CR in vivo regarding AMPK 
activation, markedly increased phospho-AMPK-Thr172 protein expression, without 
affecting total AMPK expression, indicative of AMPK activation.   
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In marked contrast, serum starvation greatly suppressed Akt-Ser473 phosphorylation 
(Fig. 4.7A), an effect reversed by the addition of insulin (Fig 4.7B).  Thus, AMPK 
activation by serum starvation correlates with decreased insulin signalling. 
 
Figure 4.7 
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B 
 
Figure 4.7: A: Western blot showing increased expression of total-AMPK and phospho-AMPK-Thr172 
(MW: 63 kDa), total Akt and phospho-Akt-ser473 (MW: 56 kDa) in in serum starved (3.5 h) samples. β-
actin (MW: 45 KDa) was used to verify that the samples were equally loaded. B: western blot analysis 
on serum starved L6 myoblasts, showing that insulin (100 nM) for 30 min markedly reverses the effect 
of serum starvation on Akt phosphorylation on Ser473.  
 
4.3.8 SIRT1 inhibition downregulates AMPK in starved L6 myoblasts 
In Chapter 3, I have shown the suppressor effect of SIRT1 knockdown in AMPK 
protein expression in H4IIEC3 liver cell line. Ex527 is known to inhibit SIRT1 gene 
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expression in different cell types [231, 232]. qRT-PCR indicated significant mRNA 
expression of SIRT1 in starved L6 myoblasts, which was completely suppressed by 
the addition of the SIRT1 inhibitor Ex527  (~100% vs. control, **P<0.01; Fig.4.8A). 
The impact of SIRT1 inhibition on AMPK expression and activity was analyzed. 
Although AMPK total protein was unaffected by this manoevre, cells cultured in 
HBSS demonstrated significant down regulation of phosphor-AMPK-Thr172 protein 
expression (~0.5-fold vs. control, *P<0.05) suggesting that SIRT1 activity correlated 
positively with AMPK activation by phosphorylation, contrasting with the inverse 
relationship between AMPK activation and Akt activation (Fig. 4.8B).  A similar 
result was obtained in serum-starved cells (Fig.4.8C) (Fig. 4.8B).  
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Figure 4.8: A: Changes in L6 SIRT1 mRNA level after culture with SIRT1 inhibitor, Ex527 (20 mg/ml 
of media), for 3.5 h. B and C: representative western blot of total AMPK and phospho-AMPK at Thr172 
(MW: 63 kDa) changes in cells cultured with Ex527 (20 mg/ml of media) for 3.5h comparing to 
control cells [cells cultured in HBSS (serum-free, 1mM glucose) for 3.5h] (B) or comparing to control 
cells [cultured in serum-free DMEM (serum-free, 25 mM glucose) for 3.5h (C). Total AMPK did not 
change between inhibit cells or control cells [cells cultured in HBSS (serum-free, 1mM glucose) for 
3,5h (B). Blots were repeated 3 times with qualitatively similar results. β-actin (MW: 45 kDa) was used 
to verify that the samples were equally loaded. Data are means ± SE, *P<0.05 vs. control. 
 
 
4.3.9 Effect of adiponectin on phosphoAMPK-Thr172 protein expression 
in serum-starved L6 myoblasts  
It has been reported that adiponectin can activate AMPK [233, 234] and can regulate 
PGC-1α activity through AMPK/SIRT1 [152].  We therefore investigated whether 
adiponectin-dependent AMPK activation (indicated by phosphorylation of AMPK on 
Thr172) is also affected by SIRT1 inhibition by Ex527.  Adiponectin did not affect 
total AMPK protein expression but an effect of adiponectin to increase 
phosphorylation of AMPK at Thr172 in L6 myoblasts was evident in the absence of 
serum. In the absence of adiponectin, the SIRT1 inhibitor Ex527 decreased AMPK at 
Thr172 phosphorylation. In contrast, adiponectin-dependent phosphorylation of AMPK 
in serum- starved L6 myoblasts was little affected by SIRT1 inhibition by Ex527 (Fig. 
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4.9A). As discussed earlier, ACC is phosphorylated on Ser218 by active AMPK [225] 
and so it was anticipated that increased phosphorylation of AMPK-Thr172 would be 
accompanied by increased ACC2-Ser218 phosphorylation.  However, this was not 
found to be the case.  Neither ACC-Ser218 phosphorylation nor total-ACC protein 
expression was affected by adiponectin or Ex527, under conditions where AMPK-
Thr172 phosphorylation was marginally increased (Fig. 4.9B). 
 
Figure 4.9 
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Figure 4.9: A) Representative western blot of the effect of adiponectin (1g/l for 30 min) and SIRT1 
activator Ex527 (20mg/ml media for 3,5h) treatment under serum-free conditions in total AMPK and 
phospho-AMPK-thr172 (MW: 63 kDa); B) Western blot analysis showing the effect of SIRT1 inhibitor 
Ex527 (20 mg/ml of media for 3,5h) in ACC phosphorylation at ser218 protein expression and total 
ACC protein expression (MW: 215 kDa) in serum starved cells for 3,5h treated or not with adiponectin 
(1g/l for 30 min). β-actin (MW: 45 KDa) was used to verify that the samples were equally loaded. 
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4.3.10 Effect of insulin and adiponectin combined treatment on AMPK 
thr172 phosphorylation in L6 myoblasts 
Insulin and AMPK have opposite effects on adipogenesis and adipocyte glucose 
uptake, although, effects of AMPK activation to suppress adipogenesis and adipocyte 
glucose uptake are beneficial in metabolic diseases (such as T2DM) associated with 
obesity since they attenuate expansion of the adipose tissue mass and the development 
of obesity [19]. A further series of studies, shown in Fig. 4.10A, investigated effects 
of adiponectin and insulin in combination on AMPK activity. Adiponectin and insulin 
added together tended to increase AMPK phosphorylation (Fig. 4.10). 
 
Figure 4.10 
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Figure 4.10: Western blot analysis showing the effect of insulin and adiponectin combined treatments 
on AMPK (MW: 63 kDa) phosphorylation at thr172. Adiponectin = 1 g/l for 30 min in serum starved 
cells (3,5h of serum starvation); insulin = 100 nM treatment for 30 minutes in serum starved cells (3,5h 
of serum starvation). Ex527 treatment = 20 mg/ml of media for 3,5h. β-actin (MW: 45 kDa) was 
used to verify that the samples were equally loaded. 
 
4.4 Discussion 
 
CR-mediated improvement in whole body glucose tolerance is partly dependent on 
skeletal muscle AMPK activity. WT mice fed a CR diet displayed improved glucose 
tolerance, whilst this effect was ablated in the absence of skeletal muscle AMPK. 
These effects did not reflect differential effects in weight gain, since CR induced a 
significant body weight loss in WT and AMPK-/- mice.  
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The insulin sensitising effects of CR were reduced in AMPK-/- mice, suggesting that 
those effects are dependent in part on AMPK α1/2. AMPK phosphorylates and 
activates the insulin receptor, providing a direct link between AMPK and the insulin-
signalling pathway. Moreover, given the known interaction between AMPK and 
mTORC-S6K1, these data suggest that a disrupted inactivation of mTORC-S6K1 
signalling pathway contributes to the impaired insulin sensitizing effects of CR in 
AMPK-/- mice [235]. This pathway promotes energy conservation and survival of 
muscle exposed to severe glucose deprivation [236]. The ablation of CR-mediated 
insulin sensitization observed in AMPK-/- mice resulted in a consequent impairment in 
glucose tolerance. Studies have shown that acute inhibition of mTORC-S6K1 
pathway, in cultured adipocytes, induces glucose uptake [237]. In our studies, is 
possible that AMPK-/--mediated activation of mTORC-S6K1 suppresses glucose 
uptake in CR muscle. AMPK-induced improvements in skeletal muscle insulin 
signalling result in increased blood glucose uptake into skeletal muscle [238, 239]. In 
addition, AMPK activity also promotes skeletal muscle glycogen synthesis capacity 
by increased glycogen synthase activity [221, 240], thus lowering blood glucose 
levels. Therefore, impaired glucose tolerance in CR-AMPK-/- mice likely occurs via 
both impaired glucose uptake and reduced glycogen storage in skeletal muscle, which 
are in turn mediated by impaired insulin signaling at the receptor level.  
 
In addition to decreased skeletal muscle glucose tolerance, we also observed reduced 
serum insulin levels 20 minutes-post OGTT glucose infusion in CR-AMPK-/- mice. 
This suggests that first-phase glucose-stimulated insulin secretion (GSIS) from 
pancreatic β-cells is partially suppressed when AMPK is absent from skeletal muscle. 
Therefore, these data highlight the intriguing possibility for a mechanism by which 
crosstalk between insulin-sensitive tissues and pancreatic islets might occur. In 
particular myokines produced by an AMPK-dependent process may be important for 
regulation of β-cell insulin secretion in response to CR. This opens very interesting 
therapeutic perspectives. To date, only a few myokines, which are released from 
skeletal muscle and influence function of other tissues, have been identified [241]. 
Further studies on β-cells of muscle specific AMPK-/- mice must be done to better 
understand this pathway. 
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A key role for the enzyme NAMPT in protecting the body against age-induced T2D 
has been demonstrated [208]. NAMPT has also been reported as an important 
regulator of pancreatic insulin secretion and glucose homeostasis [130, 179]. In this 
study we demonstrated that the AMPK deficiency and inactivation in skeletal muscle 
is associated with changes in NAMPT expression and SIRT1 activity (as evidenced 
by PGC-1α deacetylation). Moreover, we also show that SIRT1 activity seems to be 
decreased when AMPK is lacking, which suggest that SIRT1 and AMPK may be 
linked, possibly through AMPK-mediated NAMPT expression. These findings are 
largely in agreement with other studies [150, 151], that have described links between 
skeletal muscle AMPK-SIRT1. Fulco et al. (2008) described a pathway where AMPK 
activates SIRT1 through increased NAMPT activity. They have used glucose 
restricted skeletal myoblasts with AMPK activation [150]. Canto et al (2009) also 
report a link between muscle AMPK and SIRT1, using the AMPK activator AICAR. 
However this study found no role for NAMPT in mediating this link [151]. According 
with this study, AMPK increases NAD+/NADH ratio through increased mitochondrial 
 oxidation. In our studies, decreased AMPK activity in CR fed mice was also related 
to decreased PGC-1α and decreased SIRT3 gene expression, suggesting reduced 
mitochondrial  oxidation. According with this, both NAMPT and  oxidation could 
play a role in AMPK-depenent SIRT1 activation. The decrease of SIRT1 mRNA 
expression in skeletal muscle of AL-fed AMPK-/- mice was no longer observed when 
mice were subjected to CR, suggesting that caloric restriction plays an important role 
in protecting skeletal muscle from the effects of decreased SIRT1 expression 
(impaired insulin signalling and impaired glucose uptake), probably caused by a lack 
of AMPK [141]. The compromised SIRT1 activity in AMPK-/- mice abolished the 
SIRT1 dependent deacetylation of PGC-1α in AL fed mice. This down regulation of 
PGC-1α activity compromises its function on glucose and lipid metabolism [242]. 
Decreased PGC-1α gene expression possibly the reason by which AMPK deficiency 
decreases glucose uptake. The mechanism by which reduced PGC-1α leads to glucose 
uptake remains unknown. We suggest a mechanism based on a study from Michael et 
al. 2001, where PGC-1 mediates the increase in GLUT4 expression, in large part, by 
binding to and coactivating the muscle-selective transcription factor MEF2C [243]. 
According with this, decreased PGC-1α gene expression would lead to decreased 
GLUT4 expression and decreased glucose uptake. The fact that SIRT1 gene 
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expression did not change in CR conditions between WT and AMPK-/- is interesting, 
since previous studies have reported that CR leads to increased SIRT1 protein and 
gene expression [110]. However, our findings are consistent with some previous 
reports, where SIRT1 gene and protein expression have been reported to be 
unaffected by CR in skeletal muscle and adipose tissue [126].  
 
Our study showed that a reduced activity of SIRT1 in AMPK-/- mice decreases SIRT6 
protein and gene expression, suggesting that SIRT6 activity is positively regulated by 
SIRT1. Xiao et al. found that 60% of SIRT6-/- animals had very low levels of blood 
glucose and died shortly after weaning. Feeding the mice with glucose-containing 
water increased blood glucose and rescued 83% of mutant mice, suggesting that the 
hypoglycemia is a major cause for the lethality. They showed that SIRT6 deficiency 
results in more abundant membrane association of GLUT1 and GLUT4, which 
enhances glucose uptake. The authors further demonstrated that SIRT6 negatively 
regulates Akt phosphorylation at Ser473 and Thr308 through inhibition of multiple 
upstream molecules, including insulin receptor, IRS1, and IRS2. The absence of 
SIRT6, consequently, enhances insulin signalling and activation of Akt, leading to 
hypoglycemia. These data uncover an essential role of SIRT6 in modulating glucose 
metabolism through mediating insulin sensitivity [228]. Controversially, in our 
experiments, we found that reduced SIRT6 possibly due to reduced AMPK-mediated 
SIRT1 expression was associated with non-significant enhanced glucose plasma 
levels upon CR.   
 
Changes in SIRT3 correlate with changes in PGC-1α. Expression of SIRT3 in the 
liver is induced by PGC-1α through a mechanism involving estrogen-related receptor 
alpha (ERRα) [205]. We have previously seen (Chapter 3) that SIRT1-PGC-1α-
SIRT3 axis during fasting is important to prevent chronic mitochondrial protein 
hyperacetylation and reduced LCAD activity. Decreased fatty acid oxidation due to 
decreased LCAD activity would eventually lead to obesity, insulin resistance and 
metabolic disorders [106, 206, 207]. Is possible that a similar mechanism exists in 
skeletal muscle, where the SIRT1-PGC-1α-SIRT3 axis maintains mitochondrial β 
oxidation during CR to protect the body from metabolic disorders. Interestingly, 
SIRT3 and PGC-1α have also been reported to play an important role in aging. Joseph 
et al. (2012) have shown that levels of SIRT3 and PGC-1α were significantly reduced 
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(50%) in two groups of elderly participants (high- and low-functioning based on the 
Short Physical Performance Battery test) when compared to young [244]. Jing et al 
(2011) have shown decreased insulin-stimulated IRS-1 phosphorylation in SIRT3-/- 
mice, which was paralleled by a reduction in insulin-stimulated Akt and Erk 
phosphorylation. This impaired insulin signalling in skeletal muscle was reflected at 
the whole-body level through GTT, with significantly higher glucose levels in the 
SIRT3-/- mice at 60 min [169]. Taken together, these data indicate that SIRT3-/- mice 
display impaired insulin action and a lower rate of oxygen consumption with 
increased oxidative stress in skeletal muscle. Interestingly, in our studies, decreased 
SIRT3 expression correlates with higher glycaemia at 40 in CR-AMPK-/- mice, 
suggesting impaired insulin signalling under these circumstances. 
 
Investigation of the effects of AMPK activation by adiponectin in L6 myoblasts 
 
It is known already that AMPK responds to a requirement to increase cellular ATP 
production and/or to conserve available ATP [159], leading to an early cell cycle 
arrest [245]. It has been reported that the polyphenol resveratrol arrests cell cycling 
through AMPK activation and promotes apoptosis through inhibition of Akt 
signalling pathways [245]. According with the results obtained in L6 myoblasts, we 
speculate that starvation or depletion of essential proteins can cause a fast depletion of 
ATP and this effect is counter balanced by an increased phosphorylation of AMPK on 
Thr172, in order to conserve the ATP available. In this context, Akt is modestly 
inhibited to reduce gene expression and proliferation and to promote cell arrest, 
protecting the cells against starvation. This effect is reversed by insulin, which is an 
anabolic protein.  
 
SIRT1 inhibition down regulates AMPK activity in L6 myoblasts, which led us to 
hypothesise that a possible feedback loop might exist between these two proteins, 
where AMPK regulates SIRT1 activity through NAMPT concentrations and, on the 
other hand, SIRT1 regulates AMPK possibly through LKB1 deacetylation [66]. 
Further studies on LKB1 acetylation levels need to be done, to fully characterise this 
pathway. 
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Adiponectin is an anti-diabetic and anti-atherogenic adipokine and plasma 
adiponectin levels are decreased in obesity, insulin resistance and T2DM [246]. 
Adiponectin-dependent AMPK phosphorylation is not affected by the SIRT1 inhibitor 
Ex527. However, when adiponectin is not present, SIRT1 inhibition causes a modest 
reduction of AMPK phosphorylation on thr172. It is possible that adiponectin 
abrogates the link between SIRT1 and AMPK, previously discussed in this chapter.  
 
In summary, AMPK deficiency impairs the beneficial effects of CR on skeletal 
muscle glucose tolerance. This may occur through loss of direct AMPK effects on the 
insulin signaling machinery. Alternatively, downstream effects of AMPK deficiency 
are also likely to involved decreased activation and expression of NAMPT and the 
sirtuin enzymes, particularly SIRT1, but also SIRT3 and SIRT6 impairement, of 
which all lead to reduced insulin signalling, culminating in lower glucose uptake. In 
addition, decreased AMPK in skeletal muscle might lead to impaired glucose-induced 
insulin secretion (GIIS) signalling in pancreatic β-cells, reducing blood insulin 
content observed during GTT. This may occur through changes in AMPK-mediated 
myokine signalling, or as a result of increased glucolipotoxicity, occurring as a result 
of lower AMPK-mediated glucose uptake in skeletal muscle. AMPK and SIRT1 seem 
to be involved in a feedback loop that maintain fatty acid oxidation in a perfect level 
to protect muscle from the metabolic disorders during CR/fasting conditions. It is 
possible that adiponectin abrogates the link between SIRT1 and AMPK, activating 
AMPK ability to inhibit ACC and, as a consequence, allowing fatty acid oxidation 
and protecting the cells from the excessive anabolic signalling, caused by insulin, in 
fasting/CR conditions. Increased fatty oxidation would increase NAD+/NADH, 
leading to increased SIRT1 gene expression. Further studies on LKB1 acetylation 
levels and NAD+/NADH ratio must be done to better understand the feedback loop 
between SIRT1 and AMPK. 
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Chapter: 
5. A key role for interferon regulatory factors in mediating early life 
metabolic defects in male offspring of maternal protein restricted rats 
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The studies described in this chaper were accepted for publication on Hormone 
and Metabolic Rsearch: Silvestre MFP, Kieswich J, Yaqoob MM, Holness MJ, 
Sugden MC, Caton PW. (2014) A key role for interferon regulatory factors in 
mediating early life metabolic defects in male offspring of maternal protein restricted 
rats (2014). Horm Metab Res 46(4):252-8. 
 
5.1 Introduction 
 
An adverse intra-uterine environment has also been implicated as a potential 
trigger for development of obesity in later life [247-249].  Examples of poor maternal 
nutrition include maternal consumption of diets high in saturated fat or a diet low in 
protein [247, 250]. Maternal consumption of a low protein (Maternal Low Protein; 
MLP) diet results in offspring with a low birth weight in humans and animal models 
[250]. Moreover, there exists a strong positive correlation between low birth-weight 
and the development in later life of obesity, insulin resistance and type 2 diabetes 
[251]. Epidemiological and experimental evidence suggests that an imbalance 
between prenatal (e.g. maternal protein restriction) and post-natal (e.g. excess dietary 
carbohydrate) nutrition can predispose to development of obesity [247]. In agreement, 
children exposed to growth-restricted conditions during development exhibit 
increased adiposity in childhood and later life [252], whilst the offspring of rats fed a 
low-protein diet display a greater predisposition to develop obesity and related 
metabolic disorders in response to high-fat feeding compared to controls [247, 251].  
This phenomenon, termed the ‘thrifty phenotype’, suggests that fetal malnutrition may 
lead to physiological changes that programme the fetus for survival in what it predicts 
to be a poor nutritional environment.  This evolutionary programming is less 
advantageous when food is abundant, potentially predisposing to obesity [251]. 
However, the underlying mechanisms responsible for this programming of obesity 
have yet to be described.  
 
Recent studies have identified the immunoregulatory proteins, interferon regulatory 
factors 3 and 4 (IRF3 and IRF4) as key regulators of adipocyte function [253, 254]. 
IRF4 increases during adipocyte differentiation and functions to repress adipogenesis 
and lipogenesis and induce lipolysis in white adipose tissue. IRF4 expression is 
repressed by insulin, and consequently IRF4 levels are reduced in insulin resistant 
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mouse models, as well as being elevated during fasting and reduced during re-feeding. 
Adipocytes lacking IRF4 display increased expression of lipogenic genes including 
fatty acid synthase (FAS; gene code: Fasn) and sterol regulatory-element binding-
protein 1 (SREBP1).  Moreover, IRF4 knockout mice have larger adipocytes, are 
obese and develop T2DM. Less is known about the regulation of IRF3 [253, 254]. 
 
To further examine the early life mechanistic changes following exposure to an 
adverse intra-uterine environment responsible for onset of obesity and metabolic 
syndrome in later-life, we examined the role of IRF3 and IRF4 in the MLP model of 
fetal programming. Further to this, we investigated novel mechanisms involved in 
regulation of IRF3 and IRF4 in adipocytes and white adipose tissue. 
 
5.2 Methods 
 
We obtained visceral adipose tissue from the following in vivo models; (a) PPAR 
null mice, (b) offspring of rats fed a maternal-low protein diet (MLP rats), and (c) 
control mice administered metformin (these models are described in detail in the 
general methods; Chapter 2, sections 2.2.2.3, 2.2.2.4 and 2.2.2.2 respectively; 
metformin administration described in Chapter 2, section 2.2.2.5.9) 
 
All the procedures carried on using these samples were performed in accordance with 
the principles and guidelines established by the European Convention for the 
Protection of Laboratory Animals (Scientific Procedures) Act 1986, published by 
HMSO, London.  
 
Culture, treatment and transfection of the adipocyte cell line, 3T3-L1 (Chapter 2, 
section 2.2.1.3), western blotting (Chapter 2, section 2.2.3.2), qRT-PCR (Chapter 2, 
section 2.2.3.4) and plasma analysis (Chapter 2, section 2.2.2.8) were conducted as 
described in the general methods section. 
 
Results are expressed as mean ± SEM.  Statistical comparisons were obtained using 
GraphPad (GraphPad Software, CA, USA).  Statistical differences were calculated 
using an unpaired t-test. 
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5.3 Results 
 
5.3.1 Metabolic data for MLP offspring 
Pregnant dams fed a low-protein diet did not exhibit any differences in food intake 
compared to controls (data not shown).  Despite this MLP offspring weighed 
significantly less at 3 days of age than control litter mates (28%; P<0.05).  After 8-
weeks consumption of standard rodent diet, MLP offspring displayed no changes in 
fasting insulin (16.0   
Additionally, no changes in fasting plasma glucose levels were found in MLP 
offspring (4.36  0.13 mmol/l) compared to control (4.11  0.21 mmol/l), whilst 
glucose area under the curve (AUC) analysis for glucose tolerance tests resulted in 
non significant increased AUC values for MLP (9.76  1.29 mmol/L/min) compared 
to control (7.45  0.79 mmol/L/min) (Fig. 5.1). 
 
Figure 5.1 
 CON MLP P value 
Fasting Glucose (mM) 4.11 ± 0.13  4.36 ± 0.21  0.33 
Fasting Insulin (μU/ml) 14.4 ± 1.3 16 ± 3.21 0.65 
Glucose – AUC (mmol/L/min)  7.54 ± 0.79  9.76 ± 1.29 0.16 
 
Figure 5.1: Table showing serum insulin and glucose changes between control and MLP rats fed a 
standard rodent diet during 8 weeks. Values are Mean ± SEM, n = 8. 
 
5.3.2 MLP offspring display altered adipogenic and lipogenic gene 
expression 
Whilst no significant changes in metabolic data were observed at this early stage in 
the MLP rats, it is possible that mechanistic changes may occur during this early-life 
period, which would predispose to later development of metabolic disease. Therefore, 
by focussing on altered lipogenesis and adipogenesis in white adipose tissue, we next 
attempted to identify early-life metabolic changes which would likely lead to onset of 
the established later-life metabolic defects induced by MLP.  IRF3 and IRF4 are 
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recently identified repressors of adipogenesis and lipogenesis [253, 254]. Gene 
expression of IRF3 and IRF4 was markedly reduced in white adipose tissue of MLP 
rats compared to controls (Fig. 5.2A and 5.2B). These changes occurred in parallel 
with increased mRNA expression of SREBP1c, elevated mRNA and protein levels of 
FASN as well as increased ACC protein (Fig. 5.2C, 5.2D and 5.2E), consistent with a 
role for IRF4 in repressing transcription of these genes. This data implies that early 
life changes in IRF3 and IRF4 occur in MLP rats and may contribute to increased risk 
of development of obesity and metabolic syndrome in later life.  
 
Figure 5.2 
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Figure 5.2: Reduced IRF levels in white adipose tissue of MLP offspring.  Visceral WAT was isolated 
from 8-week old offspring of MLP and control Wistar rats (n = 6). Gene expression of (A) Irf3, (B) 
Irf4, (C) Srebp1c and (D) Fasn. (E) Protein levels of FASN and ACC.  Western blots are 
representative. Data are expressed as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001 vs. control. 
MLP = Maternal low protein diet (8% low-protein vs. 20% control diet during pregnancy and 
lactation); Offspring were maintained on standard diet after weaning (3 weeks) and then killed at 8 
weeks. 
5.3.3 IRF3 and IRF4 supression is associated with adiponectin signaling 
Previous studies have demonstrated that insulin exerts regulatory control of IRF4, 
whilst less is known about IRF3 regulation in the context of obesity and metabolic 
syndrome. Insulin was reported to repress IRF4 expression in vitro in adipocytes and 
in vivo under fed conditions, and in obese, hyperinsulinaemic rodent models [253]. 
However, despite marked reductions in IRF3 and IRF4 expression, we did not observe 
significant changes in serum insulin levels in our models (Fig. 5.1A). This suggested 
the existence of an alternative regulatory mechanism controlling IRF4, and potentially 
IRF3, in white adipose tissue.  Adipokines, such as adiponectin, are bioactive peptides 
secreted from adipose tissue, which exert metabolic control over a number of insulin 
sensitive tissues, including, in an autocrine manner, adipose tissue. We next 
investigated potential alterations in adiponectin signalling in MLP rats, with aim of 
determining alternative mechanisms of IRF3 and IRF4 regulation. Remarkably, we 
found that mRNA levels of adiponectin (ADIPOq; Fig. 5.3A) and adiponectin 
receptor 1 (AdipoR1) and receptor 2 (AdipoR2) were dramatically suppressed in MLP 
rats by ≈90% relative to control (Fig. 5.3B and 5.3C), suggesting that impaired 
adiponectin signalling may lead to decreased IRF3 and IRF4 expression.  To 
investigate this further, we used the 3T3L1 adipocyte cell line. Consistent with 
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impaired adiponectin signalling and reduced IRF expression in the white adipose 
tissue of MLP rats, incubation of 3T3L1 adipocytes with adiponectin led to increased 
mRNA levels of IRF3 and IRF4 (Fig. 5.3D and 5.3E). This suggests that, in addition 
to insulin, adiponectin provides an additional level of regulatory control over IRF3 
and IRF4 in white adipose tissue.  
 
Figure 5.3 
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Figure 5.3: Impaired adiponectin signalling in white adipose tissue of MLP offspring leads to reduced 
IRF levels.  Visceral WAT and serum were isolated from 8-week old offspring of MLP and control 
Wistar rats (n = 6); mRNA levels of (A) AdipoQ, (B) AdipoR1, and (C) AdipoR2 in white adipose 
tissue. 3T3- /ml; 24 h) and mRNA levels of (D) Irf3 
and (E) Irf4 were measured by qPCR. Data are expressed as mean ± SEM. * P < 0.05, *** P < 0.001 
vs. control. 
 Adiponectin regulates IRF3 and IRF4 through AMPK and PPAR
Adiponectin, via signalling through adiponectin receptor 1 (AdipoR1) and receptor 2 
(AdipoR2) has been reported to exert metabolic effects through activation of the 
energy sensing enzyme AMPK and the nuclear receptor PPARα [60].  Both AMPK 
and PPARα play important roles in regulating lipogenesis and fatty acid oxidation 
[133, 244, 255]. Consistent with observed reductions in adiponectin and AdipoR1 
expression, MLP rats also displayed decreased protein levels of phospho(Thr172)-
AMPK (Fig. 5.4A).  Since phosphorylation at Thr172 leads to AMPK activation, this 
observation suggests reduced AMPK activity in MLP rats.  In addition, protein levels 
of phospho(Ser79)-ACC, a downstream target of AMPK, were also reduced in MLP 
offspring compared to control (Fig. 5.4A).  Total protein levels of AMPK were 
unchanged, demonstrating that decreased AMPK activation did not occur because of 
MLP-induced reductions in total protein. In contrast, total-ACC protein levels were 
elevated in MLP mice, reflecting increased lipogenesis, changes that are consistent 
with increased lipogenic gene expression (Fig. 5.2E). Furthermore, reflecting 
decreased AdipoR2 expression, we also observed decreased mRNA levels of PPARα 
in MLP rats, compared to control (Fig. 5.4B). Transcriptional modulation by PPARα 
154 
requires the presence of the PGC1α. Consistent with this, PGC1α mRNA levels were 
also suppressed in MLP rat adipose tissue (Fig. 5.4C). 
 
Figure 5.4 
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Figure 5.4: Reduced AMPK and PPARα signalling in white adipose tissue of MLP offspring.  Visceral 
WAT was isolated from 8-week old offspring of MLP and control Wistar rats (n = 6); (A) protein 
levels of phospho(Thr.172)-AMPK, total-AMPK and phospho(Ser79)-ACC; mRNA levels of (B) Pparα 
and (C) Pgc1α.Western blots are representative. Data are expressed as mean ± SEM. ** p < 0.01, *** P 
< 0.001 vs. control. MLP = Maternal low protein diet (8% low-protein vs. 20% control diet during 
pregnancy and lactation); Offspring were maintained on standard diet after weaning (3 weeks) and then 
killed at 8 weeks. 
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5.3.5 The potential role of Adiponectin-AMPK-PPAR  signalling in 
regulating IRF3 and IRF4 
To further analyse the potential role of adiponectin-AMPK-PPARα signalling in 
regulating IRF3 and IRF4 expression, we initially used 3T3L1 adipocytes. Use of 
3T3L1 adipocytes allowed for specific examination of IRF4 regulation in a model 
lacking macrophages, which may influence results given the role of IRF4 in immune 
regulation [256]. Adipocyte differentiation was confirmed by measurement of mRNA 
levels of PPARγ (data not shown). Treatment of differentiated adipocytes with 
WY14643, a potent PPARα agonist, had no effect on IRF3 mRNA (Fig. 5.5A) but did 
induce expression of IRF4 (Fig. 5.5B). We further analysed these putative signalling 
mechanism using PPARα knockout mice, which displayed ≈90% reduction in PPARα 
mRNA levels in white adipose tissue, together with a marked reduction in PGC1α 
mRNA levels (Fig. 5.5C and 5.5D). Significantly, in PPARα knockout mice the 
normal IRF4 responses to fasting and feeding were disrupted (Fig. 5.5E). Consistent 
with previous reports [253], IRF4 levels were induced by fasting in WT mice. 
However, this effect was blunted in PPARα knockout mice, where IRF4 levels were 
reduced in fasted compared to fed mice. Similar to MLP rats, PPARα knockout mice 
also displayed reduced IRF4 levels (Fig. 5.5F), together with raised levels of ACC 
and SREBP1c (Fig. 5.5G-H), indicative of elevate lipogenesis and adipogenesis in 
white adipose tissue. Taken together, these results indicate that an adiponectin-
PPARα signalling pathway induces IRF4 mRNA expression in white adipose tissue. 
Moreover, this pathway is dysregulated in response MLP, and this may in part 
mediate the metabolic defects associated with this MLP. 
 
Figure 5.5 
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Figure 5.5: Adiponectin-PPARα signalling induces IRF4 expression in white adipose tissue. 3T3-L1 
adipocytes were treated with WY14643 (WY) Irf3 and (B) Irf4 
were measured by qPCR. Visceral WAT and serum were isolated from 8-week old PPARα knockout 
and control mice (n = 6); mRNA levels of (C)  (D) , (E – F) Irf4, (G) Srebp1c were 
assessed by qPCR. (H) Protein levels of ACC. Western blots are representative. Data are expressed as 
mean ± SEM. * P< 0.05, **P<0.01, *** P < 0.001 vs. control (FED); ### P<0.001 v. control (FAST). 
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5.3.6 Adiponectin-AMPK signalling may regulate IRF3 in white adipose 
tissue 
In contrast to IRF4, IRF3 was unaffected by PPARα agonist in vitro, indicating an 
alternative regulatory mechanism for IRF3 (Fig. 5.5A). Since adiponectin induced 
both IRF3 and IRF4, but PPARα regulated IRF4 only, we reasoned that AMPK, 
another target of adiponectin, may exert regulatory control over IRF3. To test this, we 
used metformin, as a known activator of AMPK [257], rather than for its actions as an 
anti-diabetic treatment. Administration of metformin to control mice led to significant 
induction of IRF3 (Fig. 5.6A) but had no effect on IRF4 mRNA levels (Fig. 5.6B), 
implying that adiponectin-AMPK signalling selectively induces IRF3 in white 
adipose tissue. 
 
Figure 5.6 
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Figure 5.6: Adiponectin-AMPK signalling may regulate IRF3 expression in white adipose tissue. 
Visceral WAT was isolated from 8-week old C57Bl/6 mice administered metformin (250 mg/kg/day; 7 
days) or saline equivalent (n = 6); mRNA levels of (A) Irf3 and (B) Irf4 were measured by qPCR. Data 
are expressed as mean ± SEM. * P < 0.05, vs. control. 
 
5.4 Discussion 
 
We report here that expression of IRF3 and IRF4, two key repressors of adipogenesis, 
are reduced in offspring of rats fed a protein-restricted diet during pregnancy and 
lactation, in parallel with no changes in fasting insulin and glucose levels.  Human 
epidemiological studies have consistently reported that exposure to an adverse 
intrauterine environment, such as protein-restriction, leads to an increased risk of 
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development of obesity, T2DM and cardiovascular disease in later life [249, 251, 
252]. Experimental model studies have reported that MLP offspring gain more 
weight, have increased susceptibility to development on metabolic syndrome and 
display impaired adipocyte function when placed a high fat diet [247, 258, 259]. 
However the underlying regulatory mechanisms driving these processes are yet to be 
fully elucidated. Our data provides evidence that a loss of ability to efficiently repress 
adipogenesis and lipogenesis, as a result of marked early-life reductions in IRF3 and 
IRF4, may contribute to impaired adipocyte function and increased risk of obesity in 
later life. Whilst metabolic changes observed in this model are mild, the early life 
mechanistic changes reported here would likely make a key contribution to the 
expected, and previously reported, metabolic deterioration likely observed in these 
animals in later life.  
 
Previous studies have described that IRF4 expression and function is suppressed by 
insulin, and that as a result, IRF4 expression is lower in white adipose tissue depots 
obtained from rodent models characterised by insulin resistance; HFD, ob/ob and 
db/db mice [253]. Despite this well characterised role of insulin, our MLP model 
displayed a marked reduction in IRF3 and IRF4, without significant changes in serum 
insulin. Instead, our data point the involvement of the adiponectin-PPARα and 
adiponectin-AMPK signalling pathways in the regulation of IRF4 and IRF3 
respectively. Adiponectin is a bioactive adipokine expressed at high levels and 
secreted from adipose tissue [260]. Adiponectin exerts metabolic regulatory effects 
via autocrine, paracrine and endocrine function, through the receptors adipoR1 and 
adipoR2, which in turn activate AMPK and PPARα  [60, 260]. Conversely, PPARα 
agonists have been reported to upregulate adiponectin and AdipoR1 and AdipoR2, 
whilst adiponectin is suppressed in PPARα knockout mice [261]. PPARα is a 
transcription factor for genes involved in lipolysis and fatty acid oxidation and 
PPAR null mice maintained on a high-fat diet become more obese than WT [262]. 
Despite suppression of insulin levels and increases in FA supply, PPARα-deficient 
mice exhibit an impaired ability to adequately up-regulate hepatic FA oxidation in 
response to fasting [263]. Insulin resistance induced by excess of non-esterified FA 
and circulating TAG can be corrected by the administration of PPARα activators by 
actions to promote removal of intracellular lipid through tissue FA oxidation [93]. 
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PPARα is activated under calorie restriction, increasing the expression of genes 
encoding mitochondrial FA oxidation enzymes, thereby increasing the capacity for 
FA oxidation and intracellular lipid clearance [163]. AMPK activation occurs in 
response to a rise in AMP associated with metabolic stresses that interfere with ATP 
production (e.g., hypoxia or calorie restriction/glucose deprivation) or accelerated 
ATP consumption (e.g., muscle contraction), so as to preserve or maintain tissue 
function [19]. Therefore, AMPK also plays an important role in regulating lipid 
homeostasis in adipose tissue, having been shown to inhibit lipogenesis and during 
the longer-term increase lipolysis [255]. The fact that PPARα levels and other 
oxidation genes (PGC-1α) and proteins (AMPK) are suppressed in MLP rats, while 
lipogenic genes are enhanced (SREBP-1c and FAS), suggest that these mice may 
develop a similar phenotype to PPARα-/- mice, and that the MLP phenotype may be a 
direct result of reduced PPARα levels, leading to increased IRF4 levels. Under both 
conditions, fatty acid oxidation is decreased and lipogenesis is enhanced, again 
potential involving an IRF-mediated mechanism. Several mechanisms for these 
actions of AMPK and PPARα have been described. Our data suggests a further 
mechanism of action, namely via induction of IRF3 and IRF4, and consequent 
repression of lipogenesis and induction of lipolysis in white adipose tissue. These 
changes were in turn regulated by adiponectin, and these signalling pathways were all 
impaired in MLP rats.  
 
In addition to specific effects on lipolysis and lipogenesis, low levels of IRF4 may 
also reflect poorly differentiated adipocytes, since IRF4 is expressed only in fully 
differentiated adipocytes. Poorly differentiated adipocytes are often present in obesity 
and can lead to hypoxia, inflammation and an altered adipokine profile, including 
lower adiponectin levels [264]. Dysregulation of these processes are linked to onset of 
T2DM. Moreover, reduced adiponectin levels occurring as a result of poor 
differentiation, may represent an initial cause of the impaired adiponectin signalling 
observed in MLP mice. Alternatively, this mechanism of impaired adiponectin 
signalling may induce a feed-forward loop, with further reductions in adiponectin 
signalling and consequent worsening of the MLP phenotype. In addition, whilst 
adiponectin has been reported to induce PPARα, the reverse has also been 
documented, with adiponectin upregulated by PPARα agonists and suppressed in 
white adipose tissue of PPARα knockout mice [261]. Thus, suppressed PPARα levels 
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in MLP mice may contribute to further impairment of adiponectin signalling and 
consequent exacerbation of the MLP phenotype. Further studies are required to 
determine the exact mechanistic interactions by which PPARα regulates IRF4.  
 
In addition to an established role in adipocytes, IRFs are present in macrophages and 
infiltrating lymphocytes. IRF4 is essential for the function and homeostasis of both 
mature B and mature T lymphocytes. IRF4-deficient mice exhibited a profound 
reduction in serum immunoglobulin concentrations and impaired T lymphocyte 
function [265]. The altered IRF levels could potentially represent reduced immune 
infiltrate into the white adipose tissue. Further research is needed to clarify this. 
However, given the increased inflammation and macrophage recruitment observed in 
response to reduced adiponectin levels in other studies [260], a reduced immune 
infiltrate  seems unlikely, instead suggesting a specific role for adipocyte-IRF3 and 
IRF4 in this model. 
 
In summary, we propose that in early life in response to protein restriction, 
adiponectin signalling is impaired leading to reduced activity of PPARα and AMPK, 
which in turn lead to decreased levels of IRF3 and IRF4. This would lead to an 
inability to repress adipogenesis and lipogenesis, and confer increased susceptibility 
to development of an obese phenotype in later-life.  
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6.1 Reciprocal interaction between SIRT1 and AMPK 
 
SIRT1 expression was reduced in the liver and skeletal muscle of liver-specific and 
skeletal muscle-specific AMPK-/- mice, respectively. Moreover, SIRT1 knockdown 
or inhibition in cultured hepatocytes or skeletal myoblasts lowered AMPK levels and 
activity. This suggests that SIRT1 and AMPK may be linked, possibly by changes in 
NAD+/NADH ratio [151]. However, the decrease of SIRT1 in skeletal muscle of AL-
fed AMPK-/- mice was no longer observed when mice were subjected to CR, 
suggesting that caloric restriction plays an important role in protecting skeletal muscle 
from the effects of decreased SIRT1 expression (which include impaired insulin 
signalling and impaired glucose uptake), probably caused by a lack of AMPK [141]. 
In WAT, decreased SIRT1 protein expression in MLP-offspring was also associated 
with decreased AMPK activity.  AMPK activation by serum starvation correlates with 
a modestly decreased Akt phosphorylation, in L6 myoblasts (Chapter 4). Starvation or 
depletion of essential proteins can cause a fast depletion of ATP and this effect is 
counter balanced by an increased phosphorylation of AMPK on thr172, in order to 
conserve the ATP available [266]. In this context, Akt is inhibited to reduce gene 
expression and proliferation and to promote cell arrest, protecting the cells against 
starvation. Insulin administration reverses this pathway, promoting anabolism [3]. 
 
Our results suggest a feedback loop between SIRT1 and AMPK, where, in skeletal 
muscle, AMPK activates SIRT1 through increased β oxidation. In fact, in our studies, 
decreased PGC-1α and SIRT3 gene expression levels (regulators of increased β 
oxidation) correlated with decreased SIRT1 in AMPK-/- muscle. Hirschey et al. have 
shown that mice lacking SIRT3 display an abnormal oxidizing capacity during fasting 
in liver, skeletal and cardiac muscle and brown adipose tissue, possibly due to 
hyperacetylation of the SIRT3 target, LCAD [167]. In parallel with these results, ATP 
levels were also lower in livers of mice lacking SIRT3 [167]. It is likely that the 
AMPK-SIRT1-PGC-1α-SIRT3 axis during fasting/CR is important to prevent chronic 
mitochondrial protein hyperacetylation and reduced LCAD activity. Decreased fatty 
acid oxidation due to decreased LCAD activity would eventually lead to obesity, 
insulin resistance and metabolic disorders [206, 207].   
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In the liver, SIRT1 has been reported to activate AMPK, possibly through 
deacetylation and activation of an upstream kinase of AMPK (perhaps LKB1); 
AMPK depletion, on the other hand, inhibits SIRT1 activity, under normal fed 
conditions. In the the present studies, SIRT1 knockdown H4IIEC3 cells revealed 
decreased levels of PGC-1α gene expression and AMPK protein expression, where 
liver specific AMPK deficient mice had lower expression of SIRT1 mRNA, decreased 
PGC-1α gene expression and impaired gluconeogenesis. Our results, in line with 
previous studies, reveal that there is a possible feedback loop between SIRT1 and 
AMPK. In the future, it would be interesting to study LKB1 acetylation levels 
together with SIRT1 activity in AMPK knockout livers of fasted mice, re-fed after a 
24h period. Further studies will also focus on changes in NAD+/NADH ratio together 
with SIRT1 activity in muscle specific AMPK-/-. Identification of potential therapeutic 
targets through elucidation of novel mechanisms of metabolic regulation of AMPK 
complementing, for example, deacetylation catalyzed by the sirtuins, may prove to be 
important for the treatment of T2DM and other metabolic disorders associated with 
aging. Reduced mTORC1 activity, either as a consequence of dietary restriction or 
direct inhibition, extends lifespan in numerous lower and higher organisms [19]. 
Thus, exploration of the connections between AMPK, the SIRTs and mTORC1 
presents a line of enquiry of huge potential relevance to T2DM and related metabolic 
disorders.  
 
6.2 Adiponectin targeting obesity-related T2DM  
 
In chapter 4, we have seen that adiponectin modestly increases AMPK 
phosphorylation on thr172, which is related to stimulate fatty oxidation, through the 
adiponectin receptors, AdipoR1 and AdipoR2 [224, 267]. Adiponectin abrogates the 
link between SIRT1 and AMPK, activating AMPK ability to inhibit ACC and, as a 
consequence, allowing fatty acid oxidation and protecting the cells from the excessive 
anabolic signalling, caused by insulin, in fasting conditions. MLP-offspring display 
reduced expression of IRF3 and IRF4, in association with increased lipogenic gene 
expression in WAT (increased SREBP1 and FAS). IRF3 and IRF4 suppression may 
lead to obesity and T2D on MLP-offspring [253]. IRF3 and IRF4 are increased by 
adiponectin, through activation os AMPK and PPARα, respectively. This pathway 
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represses adipogenesis and lipogenesis, and confers protection against the 
development of an obese/diabetic phenotype.  
 
6.3 Hepatic and muscular lipogenesis as a response to nutritional status 
 
The decrease of SIRT1 mRNA expression in skeletal muscle of AL-fed AMPK-/- mice 
was no longer observed when mice were subjected to CR, suggesting that caloric 
restriction plays an important role in protecting skeletal muscle from the effects of 
decreased SIRT1 expression (impaired insulin signalling and impaired glucose 
uptake), probably caused by a lack of AMPK [141]. The fact that SIRT1 gene 
expression did not change in CR conditions between WT and AMPK-/- is interesting, 
since previous studies have reported that CR leads to increased SIRT1 protein and 
gene expression [110]. However, our findings are consistent with some previous 
reports, where SIRT1 gene and protein expression have been reported to be 
unaffected by CR in skeletal muscle and adipose tissue [126]. 
 
Chapter 3 described convincing evidence that fasted liver display an oxidative profile, 
even though, free cholesterol synthesis (mediated by XBP-1) is increased. The 
AMPK-SIRT1-PGC-1α-SIRT3 pathway has been suggested (in this thesis) to control 
fatty acid oxidation during fasting. Because the fatty acid oxidation pathway is a 
major contributor to the regulation of cellular energy balance, especially during 
fasting [268], the upregulation of this pathway and the increase in cellular NAD+ that 
both occur during the transition to fasting  could work in synergy to maximally induce 
the deacetylation of LCAD, and subsequent increase its activity and fatty acid 
oxidation output. 
 
6.4 AMPK-SIRT1 axis improves insulin-signaling pathway 
 
Studies performed in vitro have shown that resveratrol inhibits the phosphorylation of 
IRS1-ser307 and IRS2-thr348, which are markers of insulin resistance [210], indicating 
that resveratrol (SIRT1 activator) improves insulin signalling [211]. In agreement 
with this, SIRT1 overexpression increases the phosphorylation of Akt, a downstream 
target of insulin signalling, in muscle cells and HEK293 cells, whereas the inhibition 
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of SIRT1 induced the opposite response [211]. In our studies performed in liver, Akt 
was modestly increased under high fat conditions, which was unexpected since high 
fat feeding is known to cause tissue insulin resistance [269]. Although, is important to 
verify that in our studies, high fat feeding was not associated to weight gain, possibly 
because mice did not eat as much as the controls. This is one of the possibly reasons 
why high fat diet did not cause insulin resistance. Our studies have also shown that 
NMN treatment seems to increase IRS-1 tyrosine phosphorylation, perhaps 
ameliorating insulin-signalling pathway even in high fat fed animals. It is possible 
that NMN administration increases NAD+ availability to activate SIRT1 [270, 271], 
which in turn, improves insulin-signalling pathway. The mechanism through which 
SIRT1 improves insulin signalling remains unclear. However Wang et al. found that 
SIRT1 deficiency in the liver decreases phospho-Akt-ser473 due to a reduced level of 
Rictor, a critical component of mTORC2, thereby underscoring an important role for 
SIRT1 in maintaining activity of mTORC2 complex and providing a mechanism how 
the hepatic insulin resistance caused by liver specific loss of SIRT1 eventually spread 
to other insulin-sensitive tissues/organs [272]. Changes in SIRT/AMPK (seen above, 
section 6.1) would likely induce lipogenesis and potential lipotoxicity mediated 
impaired insulin signalling. Increased fatty acid delivery through high fat diet and 
decreased fatty acid oxidation due to impaired SIRT1/AMPK signalling would led to 
lipid accumulation within hepatocytes, which inhibits tyrosine phosphorylation of 
IRS-1. Inhibition of tyrosine phosphorylation of IRS-1 follows serine phosphorylation 
of critical sites on IRS-1 and inhibits binding and activation of PI3K [273]. A number 
of different serine kinases could be responsible for serine phosphorylation of IRS-1. 
Candidates include members of the novel protein kinase C family, which may be 
activated by accumulation of lipid intermediates [273]. Further are required to fully 
carachterise the signalling mechanisms involved.  
 
AMPK phosphorylates and activates the insulin receptor, providing a direct link 
between AMPK and the insulin-signalling pathway [236]. In our studies we have 
provided a primary evidence that insulin-dependent Akt phosphorylation on ser473 is 
impaired on AMPK deficient muscle, suggesting that AMPK is crucial for insulin-
dependent Akt phosphorylation on ser-473 (Chapter 4). We already knew that in the 
liver SIRT1 stimulates insulin signalling through Akt (Chapter 3). It is possible that, 
in muscle, similarly to what happens in the liver, AMPK deficiency is impairing 
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NAMPT activity, which decreases SIRT1 activity due to a lack of NAD+ and this, in 
turn, results in impaired acetylation of Rictor and impaired mTORC2/Akt signalling, 
known to promote hyperglycemia, oxidative damage and insulin resistance [272] (Fig. 
6.1).  
 
Figure 6.1 
 
 
Figure 6.1: AMPK-mediated SIRT1 activity on insulin signaling pathway. Lack of AMPKα (catalytic 
subunit), but not AMPKβ or AMPKγ, results in decreased NAMPT activity, which culminates in 
decreased SIRT1 activity. Reduced activity of SIRT1 leads a higher acetylation of Ritctor (part of the 
complex mTORC2), which results in decreased Akt phosphorylation on ser473.  
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AMPK-induced increase in skeletal muscle and liver insulin signalling pathway 
results in higher blood glucose uptake [238, 239]. In addition, AMPK activity also 
improves skeletal muscle and liver glycogen synthesis capacity by increased glycogen 
synthase activity [220, 240], enhancing blood glucose disposal, allowing faster 
glycaemia reduction. Thus, decreased AMPK in skeletal muscle might account for 
impaired glucose-induced insulin secretion (GIIS) signaling in pancreatic β-cells, 
reducing blood insulin content observed during GTT. Therefore, these data provide 
some evidence for a mechanism by which the crosstalk between insulin-sensitive 
tissues and pancreatic islets might occur. Further studies on β-cells of muscle specific 
AMPK -/- mice must be done to better understand this pathway.  
 
Decreased PGC-1α gene expression is possibly the reason by which AMPK 
deficiency decreases glucose uptake. We suggested a mechanism for this, based on a 
study from Michael et al. 2001, where PGC-1 mediates the increase in GLUT4 
expression, in large part, by binding to and coactivating the muscle-selective 
transcription factor MEF2C [243]. According with this, decreased PGC-1α gene 
expression would lead to decreased GLUT4 expression and decreased glucose uptake. 
Another possibility is that decreased PGC-1α gene expression affects SIRT3 gene 
expression and this, in turn, would impair glucose uptake and insulin signaling. 
SIRT3-/- mice display impaired insulin action and a lower rate of oxygen consumption 
with increased oxidative stress in skeletal muscle [169]. In our studies, decreased 
SIRT3 expression correlates with higher glycaemia in CR-AMPK-/- mice, suggesting 
impaired insulin signalling under these circumstances. 
 
6.5 SIRT3 and SIRT6 
Research has yet to be undertaken to establish the intermediate steps with enzymes 
and transcriptional regulators involved in the activation of PPARα by SIRT3. 
Changes in SIRT3 correlate with changes in PGC-1α. Expression of SIRT3 in the 
liver is induced by PGC-1α through a mechanism involving estrogen-related receptor 
alpha (ERRα) [205]. We have seen that in liver and skeletal muscle SIRT1-PGC-1α-
SIRT3 axis during fasting/CR is important to prevent chronic mitochondrial protein 
hyperacetylation and reduced LCAD activity. SIRT3 plays an important role in 
diabetes through regulation of mitochondrial oxidation, reactive oxygen species 
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production, and insulin resistance, in insulin sensitive tissues. It is another important 
therapeutic target for T2DM. 
 
SIRT6 is SIRT1 dependent. SIRT1 knockdown H4IIEC3 cells exibit decreased gene 
and protein expression of SIRT6. Since SIRT1 and SIRT6 are both nuclear, is 
possible that SIRT1 activates SIRT6 through deacetylation or that a lack of SIRT1 
leads to SIRT6 inactivation. Dominey et al [107] have reported that SIRT6 strongly 
controls PGC-1α acetylation. Surprisingly, SIRT6 induces PGC-1α acetylation, 
through interaction and modification of GCN5, leading to GCN5 enhanced activity 
[107]. Decreased acetylation levels of PGC-1α in AMPK-/- livers could be either 
because AMPK negatively regulates SIRT1 target genes, or because decreased 
activity of SIRT6 through decreased SIRT1 gene expression could impair PGC-1α 
acetylation status. Further studies on SIRT1 activity would be important to better 
understand this pathway. Under conditions of normal glucose availability, SIRT6 
represses expression of key enzymes, diverting pyruvate towards the mitochondrial 
citric acid cycle (TCA) for efficient ATP production [274]. According with this and 
based on our experiments, we can predict that SIRT6 can be involved in the pathway 
through which SIRT1 activates AMPK, with increased ATP production. Further 
studies involving SIRT6 acetylation levels and SIRT1 activity could help to 
understand better this mechanism.  
 
6.6 Mechanism of IRF3 and IRF4 on the development of obesity-related T2DM 
in MLP-offspring 
 
Previous studies have shown that MLP leads to telomere shortening and increased 
markers of cell senescence in rat islets [275]. MLP-offspring display reduced PGC-1α 
and reduced PPARα (both SIRT1 targets [133]) together with reduced SIRT1 protein 
expression. These observations suggest that maternal protein restriction can affect 
major metabolic pathways implicated in regulation of lifespan at a young age, which 
may explain the impact of maternal diet on longevity. 
 
MLP mice are prone to development of obesity and insulin resistance [276]. MLP-
offspring display reduced expression of adiponectin and adiponectin receptors 
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(Chapter 5). In agreement, phospho-AMPK protein expression and AMPK-dependent 
ACC phosphorylation were also reduced in our studies (Chapter 5), as well as PPARα. 
Our data supports the theory that MLP-offspring display impaired fatty oxidation and 
increased lipogenesis. 
 
Adipose-specific IRF4 knockdown leads to increased lipogenesis and repressed 
lipolysis and, as a consequence, adipose-specific IRF4 downregulation leads to 
development of obesity and T2DM in mice [253]. IRF4 is required for lipolysis, at 
least in part due to direct effects on the expression of adipocyte triglyceride lipase and 
hormone-sensitive lipase. These studies establish a link between IRF4 and the 
disposition of calories in adipose tissue, with consequences for systemic metabolic 
homeostasis [253]. In Chapter 5, IRF4 but not IRF3 was enhanced in fasted adipose 
tissue. We can, therefore, conclude that IRF4 represses adipogenesis under fasting 
conditions. MLP-offspring display reduced expression of IRF3 and IRF4, in 
association with increased lipogenic gene expression in WAT (Chapter 5). IRF3 and 
IRF4 suppression may lead to obesity on MLP-offspring. A study using Dams fed a 
low- (8%) protein diet during pregnancy and lactation to induce growth restriction in 
the offspring has shown that MLP-offspring undergo an age-dependent loss of 
glucose tolerance and insulin resistance resistance and by 17 mo of age have frank 
diabetes (reviewed in [277]). The level of protein restriction is a mild insult to the 
animals, because it results in only a modest reduction in birth weight and does not 
affect litter size. The offspring are weaned onto a standard diet containing 20% 
protein. These animals were compared to control offspring born to mothers fed a 
control diet containing 20% protein. The differences in protein expression occur prior 
to development of insulin resistance, suggesting that they are not consequences of 
hyperinsulinemia or hyperglycemia but play a role in determining future susceptibility 
to insulin resistance, cardiovascular disease, and T2DM. According to our studies, 
IRF3 and IRF4 suppression on MLP-offspring could be one of the mechanisms by 
which these rat model develop obesity-related insulin resistance, due to repression of 
fatty oxidation and enhanced lipogenesis. Further studies need to be done, using IRF3 
and IRF4 agonists (perhaps AMPK and PPARα activators) to better understand if the 
overexpression of these genes could prevent the metabolic dysfunctions seen in MLP-
offspring. 
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It is already established that the offspring of rats fed a low-protein diet display a 
greater predisposition to develop obesity and related metabolic disorders in response 
to high-fat feeding compared to controls [277, 278].  It is also known that PPARα-/- 
mice develop steatosis in liver and muscle on fasting because increased adipocyte 
lipolysis is not matched by augmented FA oxidation. On the other hand, insulin 
resistance induced by excess of non-esterified FA and circulating TAG can be 
corrected by the administration of PPARα activators by actions to promote removal of 
intracellular lipid through tissue FA oxidation [93].  So far, we found that MLP-
offspring display a lipogenic profile, similar to the one observed in PPARα-/- mice 
(Chpter 5) and that IRF4, required for lipolysis, is under-expressed in MLP-offspring 
as well as in PPAR deficient mice. We also found that IRF4 is regulated by PPARα 
(Fig. 6.2). Given the importance of PPARα-dependent IRF4 activation in preventing 
obesity-related T2DM (through lipolysis) and the fact that MLP-offspring are 
predisposed to develop a diabetic phenotype in later life [279], we suggest that IRF4 
can be a possible target for the prevention of obesity and obesity-related T2DM on 
MLP-offspring. There is significant interest in developing anti-inflammatory drugs as 
therapy for metabolic diseases such as T2DM and insulin resistance. Some 
‘inflammatory’ proteins however, like IRF4 and IRF3, may play key roles in 
metabolic function, independent of their effect on immunity. These achievements will 
need to be fully explored before the potential of this therapeutic avenue can be fully 
realized. 
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Figure 6.2  
 
 
 
 
Figure 6.2: Activation of IRF4 through PPARα. Fasting and adiponectin activate PPARα activity, 
while MLP diet inhibits PPARα. When activated, PPARα regulates IRF4 activation, which inhbitis the 
lipogenic genes, FAS and SREBP-1c, reducing lipogenesis and stimulating lipolysis.  
 
 
In our investigation, using WY14643 (a PPARα agonist) we developed primary 
evidence that PPARα regulates IRF4 but not IRF3 (Chapter 5). In contrast, AMPK 
may regulate IRF3 (but not IRF4). This is based on the fact that IRF3 and IRF4 are 
increased by adiponectin (Chapter 5), an adipokyne known to activate both AMPK 
and PPARα [224, 267]. Interestingly, metformin, known to activate AMPK but not 
PPARα [280], enhances IRF3, but not IRF4 in C57Bl6 mice (Chapter 5). Specific 
AMPK-/- adipose tissue and AMPK-/- adipocytes would be important to expand this 
work. Dr. Paul Caton, in my lab, is currently investigating these issues in AMPK 
deficient adipocytes.  
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6.7  Concluding remarks  
In summary, there is a feedback loop between AMPK and SIRT1. AMPK activates 
SIRT1 through increased β oxidation (increased PGC-1α and increased SIRT3). In 
skeletal muscle AMPK deficiency impairs the beneficial effects of CR on glucose 
tolerance. This is linked to decreased SIRT1 gene expression, which could impair 
insulin signalling pathway, culminating in reduced glucose uptake.  
 
It is likely that the AMPK-SIRT1-PGC-1α-SIRT3 axis during fasting/CR is important 
to prevent metabolic disorders. In liver, AMPK and SIRT1 activate each other to keep 
hepatic lipogenesis. Increased fatty acid delivery (through diet) and decreased fatty 
acid oxidation due to impaired SIRT1/AMPK signalling would led to lipid 
accumulation within hepatocytes, which inhibits tyrosine phosphorylation of IRS-1, 
decreasing insulin signalling. This can be reversed through NMN administration, 
suggesting that NMN is a potential therapeutic mechanism for T2DM.  
 
IRF3 and IRF4 suppression may lead to obesity on MLT-offspring, due to repression 
of fatty oxidation and enhanced lipogenesis. Thus, targeting IRF3 and IRF4 in 
visceral fat through activation of AMPK and PPARα, respectively (perhaps using 
adiponectin) would be a novel approach for the treatment of T2DM 
 
Identification of potential therapeutic targets through elucidation of novel 
mechanisms of metabolic regulation of AMPK and PPARα linked functions, 
complementing, for example, deacetylation catalyzed by the sirtuins, may prove to be 
important for the treatment of T2DM and other metabolic disorders associated with 
aging.  
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Appendix I 
 
Dulbecco’s Modified Eagle’s Medium (DMEM): 
 
Component g/L 
Ionic salts 
CaCl2 
Fe(NO3)3.9H2O 
MgSO4 
KCl 
NaHCO3 
NaCl 
NaH2PO4 
 
0.2 
0.0001 
0.09767 
0.4 
3.7 
6.4 
0.109 
Amino Acids 
L-Alanyl-L-Glutamine 
L-Arginine.HCl 
L-Cysteine.2HCl 
L-Glutamine 
Glycine 
L-Histidine.HCl. H2O 
L-Isoleucine 
L-Leucine 
L-Lysine.HCl 
L-Methionine 
L-Phenylalanine 
L-Serine 
L-Threonine 
L-Tryptophan 
L-Tyrosine.2Na.2H2O 
L-Valine 
 
- 
0.084 
0.0626 
- 
0.03 
0.042 
0.105 
0.105 
0.146 
0.03 
0.066 
0.042 
0.095 
0.016 
0.10379 
0.094 
Vitamins 
Choline Chloride 
Folic Acid 
 
0.004 
0.004 
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myo-Inositol 
Niacinamide 
D-Pantothenic Acid.1/2Ca 
Pyridoxal.HCl 
Pyridoxine.HCl 
Riboflavin 
Thiamine.HCl 
0.0072 
0.004 
0.004 
- 
0.004 
0.0004 
0.004 
Other 
D-Glucose 
HEPES 
Phenol Red.Na 
Pyruvic Acid.Na 
 
4.5 
- 
0.0159 
- 
ADD 
Glucose 
L-Glutamine 
NaHCO3 
 
- 
0.584 
- 
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Appendix II 
 
Foetal Calf Serum (FCS): 
 
pH@RT 
Osmolarity 
Sterility 
Endotoxin 
Haemoglobin 
Total Protein 
7.5 
7.25 mOsm/Kg 
Sterile 
0.2 EU/ml 
12.72 mg % 
3.74 g % 
Biochemical Profile  
Sodium 
Potassium 
Chloride 
Uric Acid 
Calcium 
Phosphorous 
Alkaline Phosphatase 
LDH 
SGOT 
SGPT 
Gamma GT 
Cholesterol 
Bilirubin 
Glucose 
Urea 
Creatinine 
Total Triglycerides 
Albumin 
Alpha Globulins 
Beta Globulins 
Gamma Globulins 
Iron 
136 mM/L 
11 mM/L 
100 mMol/L 
2.2 mg% 
14.1 mg% 
10.8 mg% 
396 IU/L 
518 IU/L 
38 IU/L 
<6 IU/L 
7 IU/L 
34 mg% 
0.16 mg% 
60 mg% 
39 mg% 
3.1 mg% 
55 mg% 
1.69 g% 
1.300 g% 
0.690 g% 
0.070 g% 
173 g% 
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Appendix III 
 
Dulbecco’s Phosphate Buffered Saline (DPBS): 
 
Component g/L 
Inorganic salts 
CaCl2.2H2O 
MgCl2.6H2O 
KCl 
KH2PO4 (anhydrous) 
NaCl 
Na2HPO4 (anhydrous) 
 
- 
- 
0.2 
0.2 
8.0 
1.15 
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Appendix IV 
 
Hanks Balanced Salt Solution (HBSS): 
 
Component g/L 
Inorganic Salts 
CaCl2.2H2O 
MgSO4 (anhydrous) 
KCl 
KH2PO4 (anhydrous) 
NaHCO3 
NaCl 
Na2HPO4 (anhydrous) 
 
0.185 
0.09767 
0.4 
0.06 
0.35 
8.0 
0.04788 
Other 
D-Glucose 
Phenol Red.Na 
 
1.0 
0.011 
ADD 
NaHCO3 
 
- 
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Apendix V 
 
Protocol QIAGEN Total RNA isolation from animal cells (RNeasy mini kit) 
 
It is essential to begin with the correct number of cells in order to obtain optimal RNA 
yield and purity with RNeasy mini columns. The maximum amount of starting 
material is 1.0 x 107 cells and the maximum binding capacity of the RNeasy spin 
column is 100 μg RNA.  For our cell types, QIAGEN recommends starting with no 
more than 3–4 x 106 cells. 
 
All steps of the RNeasy protocol should be performed at room temperature. All 
centrifugation steps are performed at 20-25°C in a standard laboratory 
microcentrifuge. Always wear gloves and use RNAse free equipment! 
 
Procedure: 
 
1. Add 10 μl β-ME per 1 ml Buffer RLT. Dispense in a fume hood and wear 
appropriate protective clothing. Buffer RLT containing β-ME can be stored at 
room temperature for up to 1 month. 
2. Buffer RPE is supplied as a concentrate. Before using for the first time, add 4 
volumes of ethanol (96–100%) as indicated on the bottle to obtain a working 
solution. 
3. Determine the number of cells (no more than 1.0 x 107). Completely aspirate 
the cell-culture medium and wash the cells with PBS. 
Note: Incomplete removal of cell-culture medium will inhibit lysis and dilute 
the lysate, affecting the conditions for binding of RNA to the RNeasy 
membrane. Both effects may reduce RNA yield. 
4. Add 350 μl of RLT buffer (when using 3 x x 106 cells) containing β-
mercaptoethanol (β-ME) (10 μl/ ml). Collect the lysate with a rubber 
policeman. Pipet the lysate into a microcentrifuge tube. Vortex or pipet to mix, 
and ensure that no cell clumps are visible before proceeding to step 5. 
5. Vortex the lysate for 30 seconds to disrupt and homogenize the cell lysate. 
6. Add 1 volume of 70% ethanol to the homogenized lysate, and mix well by 
pipetting. Do not centrifuge. 
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Note: When purifying RNA from certain cell lines, precipitates may be visible 
after addition of ethanol. This does not affect the procedure. 
7. Transfer the sample, including any precipitate that may have formed, to an 
RNeasy spin column placed in a 2 ml collection tube (supplied by QIAGEN). 
Close the lid gently, and centrifuge for 15 s at 8000 x g (10,000 rpm). Discard 
the flow-through. Reuse the collection tube in step 8. 
8. Add 700 μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15 s at 8000 x g (10,000 rpm) to wash the spin column 
membrane. Discard the flow-through. Reuse the collection tube in step 9. 
Note: After centrifugation, carefully remove the RNeasy spin column from the 
collection tube so that the column does not contact the flow-through. Be sure 
to empty the collection tube completely. 
9. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15 s at 8000 x g (10,000 rpm) to wash the spin column 
membrane. Discard the flow-through. Reuse the collection tube in step 10. 
Note: Buffer RPE is supplied as a concentrate. Ensure that ethanol is added to 
Buffer RPE before use. 
10. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge for 2 min at 8000 x g (10,000 rpm) to wash the spin column 
membrane. 
The long centrifugation dries the spin column membrane, ensuring that no 
ethanol is carried over during RNA elution. Residual ethanol may interfere 
with downstream reactions. 
Note: After centrifugation, carefully remove the RNeasy spin column from the 
collection tube so that the column does not contact the flow-through. 
Otherwise, carryover of ethanol will occur. 
11. Optional: Place the RNeasy spin column in a new 2 ml collection tube 
(supplied by QIAGEN), and discard the old collection tube with the flow-
through. Close the lid gently, and centrifuge at full speed for 1 min. Perform 
this step to eliminate any possible carryover of Buffer RPE, or if residual 
flow-through remains on the outside of the RNeasy spin column after step 10. 
12. Place the RNeasy spin column in a new 1.5 ml collection tube (supplied). Add 
30–50 μl RNase-free water directly to the spin column membrane. Close the 
lid gently, and centrifuge for 1 min at 8000 x g (10,000 rpm) to elute the RNA. 
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13. Repeat step 10 using another 30–50 μl RNasefree water, or using the eluate 
from step 10 (if high RNA concentration is required). Reuse the collection 
tube from step 12. 
If using the eluate from step 10, the RNA yield will be 15–30% less than that 
obtained using a second volume of RNase-free water, but the final RNA 
concentration will be higher. 
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Appendix VI 
 
Protocol QIAGEN Total RNA isolation kit for animal tissues (RNeasy midi kit) 
 
It is essential to begin with the correct amount of tissue in order to obtain optimal 
RNA yield and purity with RNeasy columns. A minimum amount of 20 mg and a 
maximum of 250 mg of tissue can generally be processed with RNeasy midi columns. 
1 mg of RNA is the maximum binding capacity of the RNeasy midi column. 
 
To process, do not allow tissue to thaw during handling prior to disruption in Buffer 
RLT. All steps of the RNeasy protocol should be performed at room temperature. All 
centrifugation steps are performed at 20-25°C in a standard laboratory centrifuge. 
Always wear gloves and use RNAse free equipment! 
 
Procedure:  
 
1. Add, before use, 10 μl β-Mercaptoethanol (β-ME) per 1 ml of Buffer RLT 
(dispense in a fume hood and wear appropriate protective clothing). Use a 15 
ml tube. 
2. Buffer RPE is supplied as a concentrate. Before using for the first time, add 4 
volumes of ethanol (96–100%) as indicated on the bottle to obtain a working 
solution. 
3. Add a piece of tissue sample (not more than 250 mg) to 4 ml of Buffer RLT 
and homogenize the sample with tissue homogenizer at full speed, until 
complete homogenization.  Frozen tissues should not be allowed to thaw 
during handling. The relevant procedures should be carried out as quickly as 
possible. 
4. Centrifuge the tissue lysate for 10 min at 3000–5000 x g. Carefully transfer the 
supernatant to a new 15 ml tube (not supplied) by pipetting. Use only this 
supernatant (lysate) in subsequent steps. In most preparations a small pellet 
will form, sometimes accompanied by a fatty upper layer. Transferring the 
pellet or the fatty layer may reduce the amount of RNA that binds to the 
membrane and cause the spin column to clog. 
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Note: To avoid transferring contaminants, hold the pipet tip underneath the 
fatty upper layer, and do not disturb the pellet. 
5. Add 1 volume (4.0 ml) of 70% ethanol to the homogenized lysate, and mix 
immediately by shaking vigorously. Ensure that any precipitates are 
resuspended. Do not centrifuge. Continue without delay with step 6. 
If some lysate is lost during steps 3 and 4, adjust volume of ethanol 
accordingly. 
6. Apply the sample to an RNeasy midi column placed in a 15 ml centrifuge tube 
(supplied by QIAGEN), and close the tube gently. Maximum loading volume 
is 4.0 ml. Centrifuge for 5 min at 3000–5000 x g. Discard the flow-through. 
Reuse the centrifuge tube in step 7. 
If the maximum amount of starting material is used, it may be necessary to 
increase centrifugation time to 10 min in order to allow the lysate to 
completely pass through the column. 
If the volume exceeds 4.0 ml, load aliquots successively onto the RNeasy 
column, and centrifuge as above. Discard the flow-through after each 
centrifugation step. 
7. Add 4.0 ml Buffer RW1 to the RNeasy column. Close the centrifuge tube 
gently, and centrifuge for 5 min at 3000–5000 x g to wash the column. Discard 
the flow-through. Reuse the centrifuge tube in step 8. 
8. Add 2.5 ml Buffer RPE to the RNeasy column. Close the centrifuge tube 
gently, and centrifuge for 2 min at 3000–5000 x g to wash the column. Discard 
the flow-through. Reuse the centrifuge tube in step 9.  
Note: Buffer RPE is supplied as a concentrate. Ensure that ethanol is added to 
Buffer RPE before use. 
9. Add another 2.5 ml Buffer RPE to the RNeasy column. Close the centrifuge 
tube gently, and centrifuge for 5 min at 3000–5000 x g to dry the RNeasy 
silica-gel membrane. It is important to dry the RNeasy membrane since 
residual ethanol may interfere with downstream reactions. This centrifugation 
ensures that no ethanol is carried over during elution. 
Note: Following the centrifugation, remove the RNeasy column from the 
centrifuge tube carefully so the column does not contact the flow-through as 
this will result in carryover of ethanol. 
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10. To elute, transfer the RNeasy column to a new 15 ml collection tube (supplied 
by QIAGEN). Pipet the appropriate volume of RNase-free water (250 μl for 
250 mg of tissue) directly onto the RNeasy silica-gel membrane. Close the 
tube gently. Let it stand for 1 min, and then centrifuge for 3 min at 3000–5000 
x g. 
11. Repeat the elution step (step 10) as described with a second volume of RNase-
free water. 
To obtain a higher total RNA concentration, this second elution step may be 
performed using the first eluate (from step 10). The yield will be 15–30% less 
than the yield obtained using a second volume of RNase-free water, but the 
final concentration will be higher. 
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Appendix VII 
 
Protocol QIAGEN Total RNA isolation kit for animal fibrous tissues (RNeasy mini 
kit) 
 
It is essential to begin with the correct amount of tissue in order to obtain optimal 
RNA yield and purity with RNeasy columns. The maximum amount of starting 
material is 30 mg of tissue sample and the maximum binding capacity of the RNeasy 
spin column is 100 μg RNA. 
 
To process, do not allow tissue to thaw during handling prior to disruption in Buffer 
RLT. All steps of the RNeasy protocol should be performed at room temperature. All 
centrifugation steps are performed in a standard laboratory centrifuge. Always wear 
gloves and use RNAse free equipment! 
 
Procedure: 
 
1. Add 10 μl β-ME per 1 ml Buffer RLT. Dispense in a fume hood and wear 
appropriate protective clothing. Buffer RLT containing β-ME can be stored at 
room temperature for up to 1 month. 
2. Buffer RPE is supplied as a concentrate. Before using for the first time, add 4 
volumes of ethanol (96–100%) as indicated on the bottle to obtain a working 
solution. 
3. Heat a water bath or heating block to 55°C for proteinase K digestion in step 
8. 
4. Remove the tissue sample from storage. Determine the amount of tissue. Do 
not use more than 30 mg. Proceed immediately to step 5. Frozen tissues 
should not be allowed to thaw during handling. The relevant procedures 
should be carried out as quickly as possible. 
5. Add the determined amount of tissue (30 mg) to 300 μl of buffer RLT and 
homogenize the sample at full speed with tissue homogenizer until complete 
homogenization (usually between 20-90 seconds).   
6. Add 590 μl RNase-free water to the lysate. Then add 10 μl proteinase K 
solution, and mix thoroughly by pipetting. 
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7. Incubate at 55°C for 10 min. 
8. Centrifuge at 20–25°C for 3 min at 10,000 x g. A small pellet of tissue debris 
will form, sometimes accompanied by a thin layer or film on top of the 
supernatant. 
9. Pipet the supernatant (approximately 900 μl) into a new 1.5 ml or 2 ml 
microcentrifuge tube (not supplied). Avoid transferring any of the pellet. If 
this is unavoidable, a small amount of pelleted debris may be carried over 
without affecting the RNeasy procedure. Hold the pipet tip under the thin layer 
or film on top of the supernatant, if present. This layer will usually adhere to 
the outside of the pipet tip and should not be transferred. 
10. Add 0.5 volumes (usually 450 μl) of ethanol (96–100%) to the cleared lysate. 
Mix well by pipetting. Do not centrifuge. Precipitates may be visible after 
addition of ethanol. This does not affect the procedure. 
11. Transfer 700 μl of the sample, including any precipitate that may have formed, 
to an RNeasy Mini spin column placed in a 2 ml collection tube. Close the lid 
gently, and centrifuge at 20–25°C for 15 s at 8000 x g (10,000 rpm). Discard 
the flow-through. Reuse the collection tube in step 12. 
12. Repeat step 11 using the remainder of the sample. Discard the flow-through. 
Reuse the collection tube in step 13. 
13. Add 350 μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and 
centrifuge at 20–25°C for 15 s at 8000 x g (10,000 rpm) to wash the 
membrane. Discard the flow-through. Reuse the collection tube in step 16. 
14. Add 10 μl DNase I stock solution to 70 μl Buffer RDD. Mix by gently 
inverting the tube, and centrifuge briefly to collect residual liquid from the 
sides of the tube. 
Note: DNase I is especially sensitive to physical denaturation. Mixing should 
only be carried out by gently inverting the tube. Do not vortex. 
15. Add the DNase I incubation mix (80 μl) directly to the RNeasy spin column 
membrane, and place on the benchtop (20–30°C) for 15 min. 
Note: Be sure to add the DNase I incubation mix directly to the RNeasy spin 
column membrane. DNase digestion will be incomplete if part of the mix 
sticks to the walls or the O-ring of the spin column. 
206 
16. Add 350 μl Buffer RW1 to the RNeasy spin column. Close the lid gently, and 
centrifuge for 15 s at 8000 x g (10,000 rpm) at 20–25°C. Discard the flow-
through. Reuse the collection tube in step 17. 
17. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge at 20–25°C for 15 s at 8000 x g (10,000 rpm) to wash the 
membrane. Discard the flow-through. Reuse the collection tube in step 18. 
Note: Buffer RPE is supplied as a concentrate. Ensure that ethanol is added to 
Buffer RPE before use. 
18. Add 500 μl Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge at 20–25°C for 2 min at 8000 x g (10,000 rpm) to wash the 
membrane. The long centrifugation dries the spin column membrane, ensuring 
that no ethanol is carried over during RNA elution. Residual ethanol may 
interfere with downstream reactions. 
Note: After centrifugation, carefully remove the RNeasy spin column from the 
collection tube so that the column does not contact the flow-through. 
Otherwise, carryover of ethanol will occur. 
19. Optional: Place the RNeasy spin column in a new 2 ml collection tube 
(supplied), and discard the old collection tube with the flow-through. Close the 
lid gently, and centrifuge at full speed for 1 min. 
Perform this step to eliminate any possible carryover of Buffer RPE, or if 
residual flow-through remains on the outside of the RNeasy spin column after 
step 18. 
20. Place the RNeasy spin column in a new 1.5 ml collection tube (supplied by 
QIAGEN). Add 30–50 μl RNase-free water directly to the RNeasy spin 
column membrane. Close the lid gently. To elute the RNA, centrifuge for 1 
min at 8000 x g (10,000 rpm) at 20–25°C. 
21. Repeat step 20 using using another 30-50 μl of RNase-free water or using the 
eluate from step 20. Reuse the collection tube from step 20. If the expected 
RNA yield is >30 μg, there is no need to repeat step 20. Using the eluate from 
step 20, the RNA yield will be 15–30% less than that obtained using a second 
volume of RNase-free water, but the final RNA concentration will be higher. 
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Appendix VIII 
 
Protocol QIAGEN Total RNA isolation kit for adipose tissue (RNeasy midi kit) 
 
It is essential to begin with the correct amount of tissue in order to obtain optimal 
RNA yield and purity with RNeasy columns. A maximum of 500 mg of tissue can 
generally be processed with RNeasy midi columns. 1 mg of RNA is the maximum 
binding capacity of the RNeasy midi column. 
 
To process, do not allow tissue to thaw during handling prior to disruption in Buffer 
RLT. All steps of the RNeasy protocol should be performed at room temperature. All 
centrifugation steps are performed at 20-25°C in a standard laboratory centrifuge. 
Always wear gloves and use RNAse free equipment! 
 
Procedure: 
 
1. Add 10 μl β-ME per 1 ml Buffer RLT. Dispense in a fume hood and wear 
appropriate protective clothing. Buffer RLT containing β-ME can be stored at 
room temperature for up to 1 month. 
2. Buffer RPE is supplied as a concentrate. Before using for the first time, add 4 
volumes of ethanol (96–100%) as indicated on the bottle to obtain a working 
solution. 
3. Remove the tissue sample from storage. Determine the amount of tissue. Do 
not use more than 500 mg. Proceed immediately to step 4. 
4. Place the tissue in a suitably sized vessel containing 5 ml QIAzol Lysis 
Reagent. 
5. Note: Use a suitably sized vessel with sufficient extra headspace to 
accommodate foaming, which may occur during homogenization. Generally, 
round-bottomed tubes allow more efficient disruption and homogenization 
than conical-bottomed tubes. 
6. Place the tip of the tissue homogenizer disposable probe into the vessel and 
operate the tissue homogenizer at full speed until the lysate is uniformly 
homogeneous (usually 30–60 s). 
208 
Note: To avoid damage to the tissue homogenizer and disposable probe during 
operation, make sure the tip of the probe remains submerged in the buffer. 
Note: Incomplete homogenization leads to significantly reduced RNA yields 
and can cause clogging of the RNeasy spin column. 
Foaming may occur during homogenization, especially of brain tissue. If this 
occurs, let the homogenate stand at room temperature for 2–3 min until the 
foam subsides before continuing with the procedure. 
7. Place the tube containing the homogenate on the benchtop at room 
temperature (15–25°C) for 5 min. 
This step promotes dissociation of nucleoprotein complexes. 
8. Add 1 ml chloroform. Securely cap the tube containing the homogenate, and 
shake it vigorously for 15 s. Thorough mixing is important for subsequent 
phase separation. 
9. Place the tube containing the homogenate on the benchtop at room 
temperature for 2–3 min. 
10. Centrifuge at 5000 x g for 15 min at 4°C. After centrifugation, heat the 
centrifuge to room temperature (15–25°C) if the same centrifuge will be used 
in the later steps of this procedure. After centrifugation, the sample separates 
into 3 phases: an upper, colorless aqueous phase containing RNA; a white 
interphase; and a lower, red, organic phase. For tissues with an especially high 
fat content, an additional, clear phase may be visible below the red, organic 
phase. The volume of the aqueous phase should be approximately 3 ml. 
11. Transfer the upper, aqueous phase to a new tube (not supplied). Add 1 volume 
(usually 3 ml) of 70% ethanol, and mix thoroughly by vortexing. Do not 
centrifuge. Proceed immediately to step 12. 
Note: The volume of lysate may be less than 3 ml due to loss during 
homogenization and centrifugation. Precipitates may be visible after addition 
of ethanol. Resuspend precipitates completely by vigorous shaking, and 
proceed immediately to step 12. 
12. Transfer up to 4 ml of the sample to an RNeasy Midi spin column placed in a 
15 ml collection tube (supplied by QIAGEN). Close the lid gently, and 
centrifuge for 5 min at 3000–5000 x g at room temperature (15–25°C). 
Discard the flow-through. Reuse the collection tube in step 13. 
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13. Repeat step 12 using the remainder of the sample (up to 4 ml). Discard the 
flowthrough. Reuse the collection tube in step 14. 
14. Add 4 ml Buffer RW1 to the RNeasy spin column. Close the lid gently, and 
centrifuge for 5 min at 3000–5000 x g to wash the membrane. Discard the 
flowthrough. Reuse the collection tube in step 15. 
15. Add 2.5 ml Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge for 2 min at 3000–5000 x g to wash the membrane. Discard the 
flowthrough. Reuse the collection tube in step 16. 
Note: Buffer RPE is supplied as a concentrate. Ensure that ethanol is added to 
Buffer RPE before use. 
16. Add 2.5 ml Buffer RPE to the RNeasy spin column. Close the lid gently, and 
centrifuge for 5 min at 3000–5000 x g to wash the membrane. 
The long centrifugation dries the spin column membrane, ensuring that no 
ethanol is carried over during RNA elution. Residual ethanol may interfere 
with downstream reactions. 
Note: After centrifugation, carefully remove the RNeasy spin column from the 
collection tube so that the column does not contact the flow-through. 
Otherwise, carryover of ethanol will occur. 
17. Place the RNeasy spin column in a new 15 ml collection tube (supplied by 
QIAGEN). Add the appropriate volume of RNase-free water (150 -250 μl) 
directly to the spin column membrane. Close the lid gently. To elute the RNA, 
wait for 1 min and then centrifuge for 3 min at 3000–5000 x g. 
18. Repeat step 17 using another volume of RNase-free water, or using the eluate 
from step 17 (if high RNA concentration is required). Reuse the collection 
tube from step 17. If using the eluate from step 17, the RNA yield will be 15–
30% less than that obtained using a second volume of RNase-free water, but 
the final RNA concentration will be higher. 
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Appendix IX 
 
Protocol Glucose Assay Kit 
 
1. This assay can be used on serum and plasma samples. 
2. Prepare glucose standards by labeling 9 clean test tubes from 0-8. 
3. Add 250 μl of ultrapure water to tubes 1-8. Add 500 μl of ultrapure water to 
tube 0. 
4. Add 250 μl of glucose standard to tube 1 and mix thoroughly. 
5. Serially dilute the glucose standard* by removing 250 μl from tube 1 and 
adding it to tube 2; mix thoroughly. Next, remove 250 μl from tube 2 and 
place it into tube 3; mix thoroughly. Repeat this process for tubes 4-8. Tube 0 
only has ultrapure water and is used as the blank. 
 
Table 6. 
 
Tube Glucose concentration 
(mg/dl) 
Glucose concentration 
(mM) 
1 720.72 40 
2 360.36 20 
3 180.18 10 
4 90.09 5 
5 45.05 2.5 
6 22.52 1.25 
7 11.26 0.625 
8 5.63 0.3125 
0 0 0 
* Glucose standard is 1.441 g/dL 
 
6. Load 2 μl of sample or standard (in duplicate) to a well. 
7. Add 300 μl of the reagent to each well and mix thoroughly. 
8. Incubate for 20 minutes at room temperature and read the absorbance at 490 
nm. 
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9. Calculate the values of glucose samples using the equation obtained from the 
linear regression of the standard curve by substituting the corrected 
absorbance values for each sample into the equation. 
 
Figure 6 
 
 
 
Figure 6: Illustration of glucose assay standard curve. 
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Appendix X 
 
Protocol Insulin ELISA 
 
 
1. This assay can be used on serum and plasma samples.  
2. All reagents and samples must be brought to room temperature before use. 
3. Prepare the needed volume of Enzyme Conjugate by mixing 5 μl Enzyme 
Conjugate 11x with 50 μl Enzyme Conjugate Buffer (1+10) for each sample. 
4. Prepare the needed volume of Wash Buffer by diluting 100 μl Wash Buffer 
21x in 2000 μl redistilled water (1+20) for each sample. 
5. Prepare a calibration curve for each assay run. 
6. Add 10 μl of calibrator or sample to an anti-insulin well and add 50 μl Enzyme 
Conjugate. Perform each determination in duplicate for calibrators and 
samples. 
7. Incubate on a shaker for 2 hours at room temperature (18-25°C). 
8. Wash 10 times by adding 200 μl Wash Buffer to each well. Aspirate 
completely. After the final wash, invert and tap the plate firmly against 
absorbent paper. 
9. Add 200 μl TMB substrate to each well. 
10. Incubate for 15 minutes at room temperate. 
11. Add 50 μl Stop Solution to each well. Put the plate on a shaker for 
approximately 5 seconds to ensure mixing of substrate and Stop Solution. 
12. Measure the absorbance at 450 nm and evaluate. 
 
Figure 7 
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Figure 7: Illustration of Insulin ELISA standard curve 
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Appendix XI 
 
Protocol RC DC-BioRad protein assay  
 
 
1. Prepare protein standards by labeling 9 clean test tubes from 0 – 8. 
2. Add 500 μl of water to tubes 0 and 2-8. 
3. In tube 1, add 1mg of BSA to 1 ml of ultrapure water and mix by vortexing 
until the solution is homogenized. 
4. Pipette 500 μl from tube 1 to tube 2 and vortex it. Then, pipette 500 μl from 
tube 2 to tube 3 and vortex it.  
5. Repeat the dilution step to the next tubes (4, 5, 6, 7 and 8) to make the 
standard curve. 
6. Tube 0 will has only ultrapure water and is used as blank. 
 
Table 8. 
 
Tube BSA concentration mg/ml 
1 1 
2 0.5 
3 0.25 
4 0.125 
5 0.0625 
6 0.03125 
7 0.015625 
8 0.0078125 
0 0 
 
Table 8: Table showing BSA consecutive dilutions 
 
 
7. Add 5 μl extracted sample to 25 μl reagent A (20 μl surfactant solution to 1 
mL alkaline copper tartrate solution). 
8. Add 200 μl Folin reagent. 
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9. Incubate at room temperature for 30 min. 
10. Measure absorbance (650 nm) on an optical plate reader. 
11. Use the dilutions of bovine serum albumin (BSA; 3.9·10-3 – 2 mg/mL) 
previously made and calculate the concentration of the sample, using the 
equation obtained from the linear regression of the standard curve by 
substituting the corrected absorbance values for each sample into the equation. 
 
Figure 8 
 
 
 
Figure 8: Illustrates a standard curve for protein assay 
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Appendix XII 
 
Antibodies’ dilutions: 
 
Antibody Dilution factor 
mouse anti-p53 1: 1000 
rabbit anti-acetylated 
lysine 
1: 1000 
rabbit anti-ACC 1:10 000 
rabbit anti-phospho-ACC-
ser218 
1: 1000 
polyclonal rabbit anti- 
AMPK 
1: 1000 
polyclonal rabbit anti-
phospho-AMPK-thr172 
1: 1000 
polyclonal rabbit anti-Akt 1: 10 000 
polyclonal rabbit anti-
phospho-Akt-ser473 
1: 1000 
rabbit anti-β-actin 1: 5000 
mouse anti-SIRT1 1: 1000 
rabbit anti-SIRT6 1: 1000 
goat anti-PGC-1α 1: 1000 
mouse anti-IRS-1 1: 1000 
mouse anti-phospho-
tyrosine 
1: 1000 
mouse anti-GAPDH 1: 10 000 
goat anti rabbit 
(secondary) 
1: 10 000 
rabbit anti-mouse 
(secondary) 
1: 10 000 
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Appendix XIII 
 
Primer sequences: 
 
Gene Forward Primer Reverse Primer 
ACC mouse TCCTGCGTGTGTGTTCGG 
AGTCTGCTTCAGCAATAAA
TTCAG 
FAS mouse 
CACTGCATTGACGGCCGGG
T 
GGACAAGCCCAGGCTGCGA
G 
G6Pase 
mouse 
AGGGTAAAAGAAAAGAGC 
GTT G 
GTAGACATGGCTTGCATAT
GGT 
GCN-5 mouse 
AATGAGCAGGTCAAGGGCT
ATG 
TACTCCTTTAGGTGGTTCAT
CAGGT 
NAMPT 
mouse 
GCGAGCGAGCGGTGACT 
CTGCGAGCAAGGAGAAAAA
TG 
PCK1 mouse TGCTGCAGAACACAAGGGC GGTCGCATGGCAAAGGG 
PDHK4 
mouse 
AGGCAAGACATCGGGTGG 
CCTGGGTGAAGGGTTGACA
CT 
PGC-1α 
mouse 
CATTTGATGCACTGACAGAT
GGA 
CCGTCAGGCATGGAGGAA 
PGC-1β 
mouse 
GGCCTTGTGTCAAGGTGGA
T 
GGTGCTTATGCAGTTCCGTA
C 
PPARα 
mouse 
AGCCATGTACGTAGCCATC
CA 
TCTCCGGAGTCCATCACAAT 
SCD-1 mouse 
CGCCCAAGCTGGAGTACGT
C 
GGGCCCATTCGTACACGTC
A 
SIRT1 mouse 
CAGGTTGCAGGAATCCAAA
CAAATCAGGCAAGATGCTG
T 
CAGTGTCATGGTTCCTTTGC
CACCGAGGAACTACCTGAT 
 
SIRT3 mouse TGCTACTCATCTTGGGACCT CACCAGCCTTTCCACACC 
SIRT6 mouse 
CCGTCACGGGACAGAGCAG
TCG 
GGTCTCCAGAGGGTCAGAG
GGGT 
218 
SREBP-1α 
mouse 
GGAGCCATGGATTGCACAT
T 
GCTTCCAGAGAGGAGGCCA
G 
SREBP-1c 
mouse 
GCAGACCCTGGTGAGTGG 
GTCGGTGGATGGGCAGTTT 
 
TNFα mouse CGGAGTCCGGGCAGGT 
GCTGGGTAGAGAATGGATG
AACA 
XBP-1 mouse 
AAGAACACGCTTGGGAATG
G 
CTGCACCTGCTGCGGAC 
AdipoR1 rat CTTCTACTGCTCCCCACAGC 
TCCCAGGAACACTCCTGCTC 
 
AdipoR2 rat 
CCACACAACACAAGAATCC
G      
CCCTTCTTCTTGGGAGAATG
G    
Adipo R1 
mouse 
ACGTTGGAGAGTCATCCCG
TAT 
CTCTGTGTGGATGCGGAAG
AT 
AdipoR2 
mouse 
TCCCAGGAAGATGAAGGGT
TTAT 
TTCCATTCGTTCGATAGCAT
GA 
AdipoQ 
AATCCTGCCCAGTCATGAA
G 
CATCTCCTGGGTCACCCTTA 
IRF3 
mouse/rat 
GGCTTGTGATGGTCAAGGT CATGTCCTCCACCAAGTCCT 
IRF4 mouse GGAGGCCAGAGCATCAAGC AATCCCCGGAGAGTTTGCA 
IRF4 rat 
TTGACTTTTCCTTCTCTTCCC
TCA 
CTTGCCTTTAAATAGTGCCC
AAG 
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Aims: SIRT1 and AMP-activated protein kinase (AMPK) share common activators, actions and target molecules.
Previous studies have suggested that a putative SIRT1-AMPK regulatory network could act as the prime initial
sensor for calorie restriction-induced adaptations in skeletalmuscle—themajor site of insulin-stimulated glucose
disposal. Our study aimed to investigate whether a feedback loop exists between AMPK and SIRT1 in skeletal
muscle and how this may be involved glucose tolerance.
Main methods: To investigate this, we used skeletal muscle-speciﬁc AMPKα1/2 knockout mice (AMPKα1/2−/−)
fed ad libitum (AL) or a 30% calorie restricted (CR) diet and L6 rat myoblasts incubated with SIRT1 inhibitor
(EX527).
Key ﬁndings: CR-AMPKα1/2−/− displayed impaired glucose tolerance (*p b 0.05), in association with down-
regulated SIRT1 andPGC-1α expression (b300% vs. CR-WT, ±±p b 0.01).Moreover, AMPK activitywas decreased
following SIRT1 inhibition in L6 cells (~0.5-fold vs. control, *p b 0.05).
Signiﬁcance: This study demonstrates that skeletalmuscle-speciﬁc AMPK deﬁciency impairs the beneﬁcial effects
of CR on glucose tolerance and that these effects may be dependent on reduced SIRT1 levels.© 2014 Elsevier Inc. All rights reserved.Introduction
The downregulation of AMPK activity in response to high glucose,
with a parallel decrease in SIRT1 activity, was observed in cultured
HepG2 cells (Suchankova et al., 2009; Zang et al., 2004). This was asso-
ciated with increased lactate release, suggesting a decrease in the
NAD+/NADH ratio, which likely contributed to the decrease in SIRT1
activity. These ﬁndings together with the demonstration that SIRT1
and AMPK share common activators, actions and target molecules
(Ruderman et al., 2010) led us to an examination of a possible link
between the SIRT1 and the AMPK in skeletal muscle. The precise inter-
actions between SIRT1 and AMPK in skeletalmuscle remain unclear, but
given the function of skeletal muscle as themajor site of glucose uptake
and the knownmetabolic regulatory roles of SIRT1-AMPK, this signaling
network is potentially of great importance. For example, AMPK has
important acute metabolic actions in skeletal muscle, such as theInstitute, Bart's and the London
of London, 4 Newark Street E1
auckland.ac.nzpromotion of long chain fatty acids (LCFA), oxidation (lipid-lowering ef-
fect), glucose uptake and glucose and glycogen breakdown (glucose-
lowering effect) (Holness et al., 2012; O'Neill, 2013a; O'Neill, 2013b).
SIRT1 has been shown to play an important role in controlling glucose
metabolism, insulin action, fat storage and nutrient sensing (Guarente,
2006; Barzilai et al., 2012).
However, in marked contrast to the effects of AMPK, insulin sup-
presses fat oxidation and stimulates glycogen, lipid and protein synthe-
sis andmay often oppose the actions of AMPK (Pessin and Saltiel, 2000;
Rennie, 2007). Interestingly, common actions of AMPK and insulin are
also observed, in particular, the stimulation of glucose uptake into skel-
etal muscle (Shulman, 2000). It has been recently established that
AMPK acts as the prime initial sensor for fasting-induced adaptations
in skeletal muscle and that SIRT1 downstream signaling is blunted in
the absence of AMPK (Cantó et al., 2010).
Caloric restriction (CR) has been shown to protect against onset age-
related diseases (Colman et al., 2009; Smith et al., 2010) and to reduce
mortality linked to T2DM and cardiovascular diseases (Hammer et al.,
2008;Marchal et al., 2012). The effects of CR have been linked to chang-
es in activity of AMPK and SIRT1.
The research here described aims to understand themechanisms by
which AMPK and SIRT1 may interact to regulate glucose tolerance in
56 M.F.P. Silvestre et al. / Life Sciences 100 (2014) 55–60skeletalmuscle during CR. To understand these signalling pathways, we
utilized skeletalmuscle-speciﬁc AMPKα1/2 double knockoutmice sub-
jected to CR as manipulations to modify glucose tolerance. In addition,
L6 skeletal muscle myoblasts were used to determine regulatory inter-
actions between AMPK and SIRT1.Materials and methods
Experimental animals
Female skeletal muscle-speciﬁc AMPKα1/2-knockout (AMPK−/−) or
wild-type control (WT) mice were maintained on CR (CR-AMPK−/−;
WT-AMPK−/−) or ad libitum (AL-AMPK−/−; AL-AMPK−/−) feeding re-
gimes at Institut Cochin, INSERM, Paris, France. CR was conducted be-
tween 2.5 and 4 months of age and lasted for 10 weeks. Food was
adjusted on a daily basis to ensure that CRmice consumed 70% of the cal-
ories consumed by AL-fedmice (calculated on the average of food intake
during the lastweekbefore starting the caloric restriction protocol).Mice
were sacriﬁced in the immediate post-absorptive state or after 5 h of
fasting (all groups).
All mice were maintained on a 12:12-h light–dark cycle (light from
7 am to 7 pm), with controlled temperature (22 °C± 2 °C) and air con-
ditioned environment, and received standard high-carbohydrate rodent
chow.
Mouse studies were reviewed and approved (agreement no. 75-
886) by the Directeur Départemental des Services Vétérinaires of the
Préfecture of Police of Paris and were performed in accordance with
the principles and guidelines established by the European Convention
for the Protection of Laboratory Animals.Oral glucose tolerance test (OGTT)
To examinewhole-body glucose homeostasis,mice (17/group)were
fasted overnight, followed by oral gavage of glucose (3 g/kg of body
weight). Blood samples for glucose analysis were collected from the
tail vein at 0, 20, 40, 60, 80 and 120min after glucose gavage. Blood glu-
cose concentration was measured in whole blood with an automatic
glucose monitor (Glucotrend II; Roche Diagnostics). Serum insulin
levels were measured in the blood samples collected during OGTT at
time 0 and at time 20min, using a speciﬁc ELISA (Linco, St Charles, MO).Cell culture
Cellswere cultured at 37 °C and 5% CO2, in DMEMcontaining 25mM
of glucose, non-essential amino acids and supplementedwith 10% (v/v)
foetal calf serum (FCS), 2 mM glutamate, 500 IU/ml penicillin and
100 μM streptomycin. For treatments, myoblasts were either main-
tained in DMEM (with FCS), as described above (termed ‘fed cells’) or
in serum-free DMEM (without FCS; termed ‘starved cells’). Fed and
starved cells were incubated with SIRT1 inhibitor Ex527 (10 M; 3.5 h;
Tocris Bioscoence). Negative controls consisted of 1 ml of media con-
taining an equal concentration of DMSO.Immunoblotting
Immunoblotting was conducted as previously described (Laemmli,
1970), using the primary antibodies (anti ACC, anti-phospho-ACC-
ser218, anti-AMPK, anti-AMPK-thr172, anti-PGC-1α and anti-acetyl ly-
sine) and secondary antibodies anti-rabbit and anti-mouse (Cell Signal-
ing Technologies, MA, USA). Reference protein measurements were
made with mouse monoclonal anti-β-actin (clone AC-15; Sigma,
Poole, UK) primary antibody.Quantitative RT-PCR
All gene expression was measured by qRT-PCR, as previously de-
scribed (Higuchi et al., 1992) using Taqman or Sybr greenmethodology.
The following primers were used: NAMPT, 5′-GCGAGCGAGCGGTGACT-
3′ and 5′-CTGCGAGCAAGGAGAAAAATG-3′; PGC-1α, 5′-CATTTGATGC
ACTGACAGATGGA-3′ and 5′-CCGTCAGGCATGGAGGAA-3′; SIRT1, 5′-
CAGGTTGCAGGAATCCAAACAAATCAGGCAAGATGCTGT-3′ and 5′-CAGT
GTCATGGTTCCTTTGCCACCGAGGAACTACCTGAT-3′; SIRT3, 5′-TGCTAC
TCATCTTGGGACCT-3′ and 5′-CACCAGCCTTTCCACACC-3′; SIRT6, 5′-
CCGTCACGGGACAGAGCAGTCG-3′ and 5′-GGTCTCCAGAGGGTCAGAGG
GGT-3′. Gene expression was determined by ΔΔCT normalized against
18S control ribosomal RNA.
Immunohistochemistry
Soleus and gastrocnemius muscles were embedded in cryomatrix
and quickly frozen in isopentane cooled with liquid nitrogen. Cryostat
sections (10 μm) were washed in PBS, permeabilized with 0.1% Triton
X-100 and left for 1 h in blocking solution (1× PBS, 1.5% goat serum,
0.1% Triton X-100). Rabbit poly-clonal antibodies directed against Lam-
inin (Z0097, Dako) (1/100 dilution) and monoclonal antibodies against
MyHCI (NOQ7.5.4D, Sigma) and MyHCIIA (SC-71, Santa Cruz biotech-
nology) were applied overnight at 4 °C to the treated sections. The
next day, after three washes with 1× PBS containing 0.05% Tween-20,
cryosections were incubated for 1 h with appropriate ﬂuorescent sec-
ondary antibodies (Alexa Fluor 488 goat anti-rabbit IgG 1/1000 dilution,
Alexa Fluor 594 goat anti-mouse IgG 1/1000 dilution; Invitrogen). After
three washes with 1× PBS containing 0.05% Tween 20, samples were
mounted in Vectashield mounting medium.
Statistical analysis
Results are expressed as mean ± SEM. Statistical comparisons were
obtained using GraphPad (GraphPad Software, CA, USA). Statistical dif-
ferences were calculated using a paired t-test or a two-way ANOVA
followed by Bonferroni's post-test, where appropriate.
Results
Loss of AMPKα1 and AMPKα2 subunits decreases AMPK protein expression
in the skeletal muscle of AL- and CR-fed mice
Skeletal muscle AMPK protein levels were undetectable in AL- and
CR-AMPK−/−mice (Fig. 1). Moreover, levels of AMPK activity, denoted
by phosphorylation on Thr172, were abolished in the skeletal muscle of
AL- and CR-AMPK−/−mice compared to AL-WT and CR-WT, respective-
ly (Fig. 1A).
Acetyl CoA carboxylase (ACC) is a down stream target of AMPK,
whereby AMPK inhibits ACC activity through phosphorylation on
Ser218 (Hutchinson and Bengtsson, 2006). Enhanced ACC phosphoryla-
tion at Ser218 in the skeletal muscle of CR-WT is clearly lost in AMPK−/−
mice (Fig. 1). ACC phosphorylation at Ser218 was increased in the skele-
tal muscle of CR-WT mice but was clearly lost in CR-AMPK−/− mice
(Fig. 1A).
AL-AMPK−/−mice gained similarweight over 10 weeks compared to
AL-WT mice, and body weight reduction in CR-WT and CR-AMPK−/−
was also comparable (Fig. 1B).
Taken together, these data demonstrate that these mice are suitable
for study of the effects of reduced skeletal muscle AMPK signalling.
AMPKα1/2 knockout impairs CR-mediated improvements in whole-body
glucose tolerance
To assess the effects of the experimental diets and AMPK−/− on
whole body glucose tolerance and insulin secretion, we utilized an
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Fig. 1. (A) Representative western blot of total AMPK and phospho-AMPK-thr172 protein (MW: 63 kDa) and of total ACC and phospho-ACC-ser218 protein (MW: 215 kDa). AL=mice fed
ad libitum; CR= calorie restrictedmice (30% caloric restriction);−/−=AMPKα1/2 knockoutmice;+/+=WTmice. (B)Weight gained after 10 weeks of AL vs. CR treatment. Data are
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in basal fasting plasma glucose and insulin levels between the four
groups (Figs. 2A and C). However, CR-WT mice displayed improved
glucose tolerance, where blood glucose levels were signiﬁcantly lower
20–40 min post-glucose injection compared to AL-WT (*p b 0.05)
(Figs. 2A andB). Notably, this effectwas lost in CR-AMPK−/−mice, dem-
onstrating that skeletalmuscle AMPK is required formediating the ben-
eﬁcial effects of CR on glucose tolerance. Interestingly, glucose levels
peaked at 40 min post-glucose injections in CR-AMPK−/−, but at 20
min post-glucose in AL-AMPK−/−mice, perhaps indicating subtly dif-
ferent mechanisms of action. The early raised blood glucose levels
were lost between 60 and 120 min, and blood glucose returned to
basal levels after 120 min in all four groups (Fig. 2A). CR-WT mice did
not display increased plasma insulin levels after 20 min compared to
AL-WT and AL-AMPK−/−, indicating that the improvements in glucose
tolerance relative to these groups were likely mediated by increased
peripheral insulin sensitivity rather than elevated pancreatic insulin
secretion (Fig. 2C). However, plasma insulin was slightly reduced in
CR-AMPK−/−mice compared with the other three groups, suggesting
that AMPK deﬁciency in CRmay lead to lower insulin secretion (Fig. 2C).
In order to demonstrate that improved glucose tolerance follow-
ing CR is not a result of a shift in ﬁber type, we have counted the
number of myosin heavy chain I and myosin heavy chain IIA ﬁbers
in WT and KO soleus and gastrocnemius muscle, under CR condi-
tions. No changes were observed in the number of ﬁbers in gastroc-
nemius and soleus muscle from CR-WT and CR-KO mice (Figs. 2D
and E).SIRT1, SIRT6 and SIRT3 gene expressions are suppressed by AMPK deletion
in the skeletal muscle of AL-fed mice
NAD+ biosynthetic activity of NAMPT results in activation of NAD+-
dependent sirtuin enzymes, particularly SIRT1 (Yang et al., 2007). AMPK
has been reported to induce NAMPT with consequent raised NAD+
levels and increased SIRT1 activity (Fulco et al., 2008). We studied
NAMPT gene expression in order to better understand the possible
link AMPK-NAMPT-SIRT1 in CR. Loss of AMPKα1/2 subunits led to a
marked decrease in skeletal muscle NAMPT mRNA expression in
AL mice (b75% vs. AL-AMPK +/+, **p b 0.01) (Fig. 3A). CR also sup-
pressed skeletal muscle NAMPT gene expression in WT mice (b75% vs.
AL-AMPK +/+, **p b 0.01). Skeletal muscle NAMPT gene expression
levels were comparable in AL-AMPK−/− mice, CR WT mice and CR-
AMPK−/− mice (b75% vs. AL-AMPK +/+, **p b 0.01). This data shows
that deﬁciency in AMPK and CR separately lower skeletal muscle
NAMPT expression, but AMPK deﬁciency does not lead to further
NAMPT mRNA decrease in CR mice (Fig. 3.1A).
We next undertook to determine the relevance of the observed
NAMPT/AMPK changes to sirtuin levels and function. SIRT1 has been re-
ported to improve glucose uptake in skeletal muscle (Guarente, 2006).
Loss of AMPK decreased SIRT1 mRNA expression in the skeletal muscle
of AL-fed animals (Fig. 3.1B). However, in contrast, SIRT1 gene expres-
sion was unchanged in both CR-WT and CR-AMPK−/−mice (Fig. 3.1B).
SIRT6, another nuclear sirtuin, reportedly enhances skeletal muscle
insulin signaling and activation of Akt in mice, leading to hypoglycemia
and associated increases inmembrane association of GLUT1 and GLUT4,
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SIRT6 gene expressionwasmoderately suppressed by AMPK deﬁciency,
both in AL-fed mice and CR mice (cf. SIRT1 gene expression, where the
effect of CR is blocked by AMPK deﬁciency) (Fig. 3.1C).
The mitochondrial sirtuin, SIRT3, has been reported to mediate CR-
associated reduction of oxidative damage (Li and Kazgan, 2011)
aswell as to promote fatty acid oxidation and insulin sensitivity in skel-
etal muscle. SIRT3 mRNA showed decreased gene expression in CR-
AMPK−/− mice when compared to CR-WT (b80%, ±±±p b 0.001). In
contrast, there were no observed differences in SIRT3 mRNA levels be-
tween AL-WT and AL-AMPK−/−mice (Fig. 3.1D).
In summary, CR did not increase gene expression of SIRT1, SIRT3 or
SIRT6. In AL-fed mice, AMPK deﬁciency caused a modest decrease in
SIRT1 and SIRT6 but did not affect SIRT3. Under CR, all sirtuins have de-
creased gene expression when AMPK is deﬁcient. SIRT6, and to a lesser
extent, SIRT1, are modestly decreased, while SIRT3 shows a signiﬁcant
marked decreased mRNA expression.
PGC-1α gene and protein expression and acetylation status
In skeletal muscle, PGC-1α target genes for FA oxidation are induced
by the deacetylase SIRT1 (Dominy et al., 2010). PGC-1α controls the
transcription of SIRT3 to activate thermogenesis in brown adipose tissue
(Giralt et al., 2011) and to suppress the production of reactive oxygen
species (ROS) in the mitochondria (Kong et al., 2010). SIRT6 has not
been reported to interact with PGC-1α. Accordingly, and because
SIRT6 changes were minimal in response to AMPK deﬁciency and CR,
we speculated that PGC-1α gene and protein expression would be al-
tered in parallel with changes in SIRT1 and/or SIRT3 expression.Acetylation status was also assessed to verify whether SIRT1 activity
altered in association with changes in SIRT1 gene expression. Skeletal
muscle PGC-1α gene expression was similar in AL-WT mice and AL-
AMPK−/−mice. It has been reported that gene and protein expression
of PGC-1α in mouse skeletal muscle is enhanced by fasting (Caton et al.,
2011), and in the present experiments, PGC-1α gene expression was
substantially increased in CR-WT mice compared with AL-AMPK−/−
mice (N3-fold vs. AL-WT, **p b 0.01). The absence of AMPK led to
ablation of CR-mediated increases in PGC-1α gene expression (b300%
vs. CR-WT, ±±p b 0.01) (Fig. 3.2A). The marked increase in PGC-1α
gene expression elicited by CR-WTmice was not, however, accompanied
by any marked change in PGC-1α protein.
PGC-1α protein is deacetylated by SIRT1, and thus suppression
of SIRT1 activity would be predicted to increase PGC-1α protein acety-
lation.When deacetylated, PGC-1α is activated and acts as amaster reg-
ulator of mitochondrial biogenesis (Cantó et al., 2009). PGC-1α protein
was therefore immunoprecipitated and probed with anti-acetyl-lysine
antibody to assess the acetylation level of PGC-1α. Skeletal muscle
PGC-1α acetylationwasmodestly (30%) but signiﬁcantly (*p b 0.05) in-
creased in AL-AMPK−/−mice comparedwith AL-WTmice and substan-
tially (0.5-fold, *p b 0.05) increased in CR-WT animals compared with
AL-WT mice (N0.5-fold vs. AL-AMPK+/+, *p b 0.05). The absence of
AMPK completely abrogated the CR-dependent increase in PGC-1α pro-
tein acetylation (b30% vs. CR –WT, ± p b 0.05).
SIRT1 inhibition downregulates AMPK in starved L6 myoblasts
Ex527 is known to inhibit SIRT1 gene expression in different cell
types (Cantó et al., 2009; Wu et al., 2012). In agreement, we show
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59M.F.P. Silvestre et al. / Life Sciences 100 (2014) 55–60here that SIRT1 mRNA levels were suppressed in starved L6 myoblasts,
incubated with Ex527 (~100% vs. control, **p b 0.01; Fig. 4A). The im-
pact of SIRT1 inhibition on AMPK expression and activity was analyzed
in fed and starved cells. Although total AMPK protein was unaffected by
SIRT1 inhibition, a signiﬁcant down regulation of phosphoAMPK-Thr172B
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We report here that CR-mediated improvement in whole body glu-
cose tolerance is partly dependent on skeletal muscle AMPK activity.
WT mice fed a CR diet displayed improved glucose tolerance, while
this effectwas ablated in the absence of skeletalmuscle AMPK. These ef-
fects did not reﬂect differential effects in weight gain since CR induced a
signiﬁcant body weight loss in WT and AMPK−/−mice.
AMPK phosphorylates and activates the insulin receptor, providing a
direct link between AMPK and the insulin signaling pathway; this path-
way promotes energy conservation and survival of muscle exposed to
severe glucose deprivation (Chopra et al., 2012). AMPK-induced in-
crease in skeletal muscle and liver insulin signaling pathway results in
increased blood glucose uptake (Lin et al., 2004; Burcelin et al., 2003).
In addition, AMPK activity also improves skeletal muscle and liver gly-
cogen synthesis capacity by increased glycogen synthase activity
(O'Neill, 2013a, 2013b; Moore et al., 2012), enhancing blood glucose
disposal, allowing faster glycemia reduction.
In addition to decreased skeletal muscle glucose tolerance, we also
observed reduced serum insulin levels 20 min post-OGTT glucose infu-
sion in CR-AMPK−/− mice. This suggests that ﬁrst-phase glucose-
stimulated insulin secretion (GSIS) from pancreatic β-cells is partially
suppressed when AMPK is absent from skeletal muscle. Therefore,
these data highlight the intriguing possibility for a mechanism by
which a crosstalk between insulin-sensitive tissues and pancreatic islets
might occur. In particular, myokines produced by an AMPK-dependent
process may be important for the regulation of β-cell insulin secretion
in response to CR. This opens very interesting therapeutic perspectives.
Further studies on β-cells of muscle-speciﬁc AMPK−/− mice must be
done to better understand this pathway.
The importance of NAMPT in protecting the body against age-
induced T2D has been reported (Yoshino et al., 2011). This occurs in
part through improved insulin secretion and glucose homeostasis
(Revollo et al., 2007), via increases in NAD+ levels and consequent
SIRT1 activation. In this study, we demonstrated that the AMPK inacti-
vation in skeletal muscle is associated with changes in NAMPT expres-
sion and SIRT1 activity. Previous studies have shown that (Caton et al.,
2011; Fulco et al., 2008) SIRT1 activity seems to be decreased when
AMPK is lacking, as a result of decreased AMPK-mediated NAMPT ex-
pression, which suggest that SIRT1 and AMPK may be linked (Fulco
et al., 2008). However, the decrease of SIRT1 mRNA expression in the
skeletal muscle of AL-fed AMPK−/− mice was no longer observed
when mice were subjected to CR, suggesting that caloric restriction
plays an important role in protecting skeletal muscle from the effects
of decreased SIRT1 expression when AMPK is absent. The compromised
SIRT1 activity in AMPK−/− mice abolished the SIRT1 dependent
deacetylation of PGC-1α in AL-fed mice. This down regulation of PGC-
1α activity compromises its function on glucose and lipid metabolism
(Benton et al., 2010). The decreased PGC-1α gene expression is a possi-
ble mechanism by which AMPK deﬁciency decreases insulin secretion
and glucose uptake. While some studies have reported increased
SIRT1 mRNA and protein in response to CR (Schenk et al., 2011), our
study is consistent with previous reports that have shown SIRT1 gene
and protein expression to beunaffected byCR in skeletalmuscle and ad-
ipose tissue (Tauriainen et al., 2011). Interestingly, SIRT1 inhibition
down regulates AMPK activity in L6 myoblasts, which suggests a possi-
ble feedback loop that might exist between these two proteins, where
AMPK regulates SIRT1 activity through NAMPT concentrations and, on
the other hand, SIRT1 regulates AMPK possibly through LKB1
deacetylation (Lan et al., 2008). Xiao et al. found that 60% of
SIRT6(−/−) animals had very low levels of blood glucose and died short-
ly after weaning (Xiao et al., 2010). Feeding the mice with glucose-
containing water increased blood glucose and rescued 83% of mutant
mice, suggesting that the hypoglycemia is a major cause for the lethali-
ty. They showed that SIRT6 deﬁciency results in more abundantmembrane association of GLUT1 and GLUT4, which enhances glucose
uptake. The authors further demonstrated that SIRT6 negatively regu-
lates Akt phosphorylation at Ser473 and Thr308 through the inhibition
of multiple upstream molecules, including insulin receptor, IRS1 and
IRS2. The absence of SIRT6, consequently, enhances insulin signaling
and activation of Akt, leading to hypoglycemia. These data uncover an
essential role of SIRT6 inmodulating glucosemetabolism throughmedi-
ating insulin sensitivity (Xiao et al., 2010). Controversially, in our exper-
iments, we found that reduced SIRT6 possibly due to reduced AMPK-
mediated SIRT1 expression was associated with non-signiﬁcant en-
hanced glucose plasma levels upon CR.
In summary, AMPK deﬁciency impairs the beneﬁcial effects of CR on
glucose tolerance, possibly because it is linked to decreased SIRT1 gene
expression, which could impair insulin signaling pathway, culminating
in reduced glucose uptake.Conﬂict of interest statement
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 A Key Role for Interferon Regulatory Factors in 
Mediating Early-Life Metabolic Defects in Male 
Oﬀ spring of Maternal Protein Restricted Rats
restricted conditions during development exhibit 
increased adiposity in childhood and later life 
 [ 6 ] , whilst the oﬀ spring of rats fed a low-protein 
diet display a greater predisposition to develop 
obesity and related metabolic disorders in 
response to high-fat feeding compared to con-
trols  [ 1 ,  5 ] . This phenomenon, termed the ‘thrifty 
phenotype’, suggests that foetal malnutrition 
may lead to physiological changes that pro-
gramme the foetus for survival in what it pre-
dicts to be a poor nutritional environment. This 
evolutionary programming is less advantageous 
when food is abundant, potentially predisposing 
to obesity  [ 5 ] . However, the underlying mecha-
nisms responsible for this programming of obes-
ity have yet to be described.
 Recent studies have identifi ed the immunoregu-
latory proteins, interferon regulatory factors 3 
and 4 (IRF3 and IRF4) as key regulators of adi-
pocyte function  [ 7 ,  8 ] . IRF4 increases during adi-
 Introduction
 ▼
 An adverse intra-uterine environment has also 
been implicated as a potential trigger for devel-
opment of obesity in later life  [ 1 – 3 ] . Examples of 
poor maternal nutrition include maternal con-
sumption of diets high in saturated fat or a diet 
low in protein diet  [ 1 ,  4 ] . Maternal consumption 
of a low protein (Maternal Low Protein; MLP) diet 
results in oﬀ spring with a low birth weight in 
humans and animal models  [ 4 ] . Moreover, there 
exists a strong positive correlation between low 
birth-weight and the development in later life of 
obesity, insulin resistance, and type 2 diabetes 
 [ 5 ] . Epidemiological and experimental evidence 
suggests that an imbalance between prenatal 
(e. g., maternal protein restriction) and post-natal 
(e. g., excess dietary carbohydrate) nutrition can 
predispose to development of obesity  [ 1 ] . In 
agreement, children exposed to growth-
 Authors  M.  F. P.  Silvestre 1 ,  J.  Kieswich 2 ,  M.  M.  Yaqoob 2 ,  M.  J.  Holness 1 ,  M.  C.  Sugden 1 ,  P.  W.  Caton 1 
 Aﬃ  liations   1   Centre for Diabetes, Bart’s and the London School of Medicine and Dentistry, Queen Mary University of London, 
London, UK 
   2   Department of Translational Medicine and Therapeutic, William Harvey Research Institute, Charterhouse Square, 
London, UK 
 Abstract
 ▼
 An adverse intra-uterine environment, induced 
by maternal consumption of diets high in satu-
rated fat or low in protein have been implicated 
as a potential trigger for development of meta-
bolic disease in later life. However, the underly-
ing mechanisms responsible for this programming 
of obesity have yet to be described. Recent stud-
ies have demonstrated that interferon regulatory 
factors 3 (IRF3) and 4 (IRF4) function to repress 
adipogenesis. We investigated whether impaired 
IRF3 and IRF4 function may predispose to devel-
opment of metabolic disease in a model of pro-
grammed obesity. Changes in IRF3 and IRF4 
levels, adipogenic gene expression, and adi-
ponectin signalling were measured in white adi-
pose tissue from programmed male oﬀ spring of 
rat dams fed a low-protein diet (MLP), which are 
predisposed to obesity. 3T3L1 adipocytes were 
used to determine novel regulatory mechanisms 
governing IRF expression. IRF3 and IRF4 levels 
were suppressed in MLP rats, together with 
raised lipogenic and adipogenic gene expression. 
Adiponectin and adiponectin receptor 1 and 2 
mRNA levels were reduced in MLP rats, along 
with levels of PPARα and activity of AMP-acti-
vated protein kinase (AMPK), 2 downstream tar-
gets of adiponectin. Further studies determined 
that both IRF3 and IRF4 are induced by adiponec-
tin, with adiponectin-AMPK and adiponectin-
PPARα signalling regulating IRF3 and IRF4, 
respectively. We have demonstrated that impaired 
ability to repress adipogenesis and lipogenesis, 
through dysregulated adiponectin-PPARα-AMPK-
IRF signalling, may play a causal role in predis-
posing MLP oﬀ spring to development of obesity 
and metabolic disease in later life.
 Supporting Information for this article is avail-
able online at http://www.thieme-connect.de/
ejournals/toc/hmr
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pocyte diﬀ erentiation and functions to repress adipogenesis and 
lipogenesis and induce lipolysis in white adipose tissue. IRF4 
expression is repressed by insulin, and consequently IRF4 levels 
are reduced in insulin resistant mouse models, as well as being 
elevated during fasting and reduced during re-feeding. Adi-
pocytes lacking IRF4 display increased expression of lipogenic 
genes including fatty acid synthase (FAS; gene code:  Fasn ) and 
sterol regulatory-element binding-protein 1 (SREBP1). Moreo-
ver, IRF4 knockout mice have larger adipocytes, are obese, and 
develop T2DM. Less is known about the regulation of IRF3  [ 7 ,  8 ] .
 To further examine the early life mechanistic changes following 
exposure to an adverse intra-uterine environment responsible 
for onset of obesity and metabolic syndrome in later-life, we 
examined the role of IRF3 and IRF4 in the MLP model of foetal 
programming. Further to this, we investigated novel mecha-
nisms involved in regulation of IRF3 and IRF4 in adipocytes and 
white adipose tissue.
 Materials and Methods
 ▼
 Experimental animals
 Studies were conducted in adherence to the regulations of the 
UK Animal Scientifi c Procedures Act (1986), under project 
license PPL 70/7276. All animals were maintained on a 12-h 
light/dark cycle (light from 07:00 AM). All experiments were 
conducted in the fed state, unless stated otherwise. Animals 
were sacrifi ced under CO 2 asphyxiation.
 Maternal low protein model
 Pregnant female Wistar rats (250–300 g; Charles River, Kent, UK) 
were randomly assigned to either control (CON; 20 % protein) or 
an isocaloric maternal low protein (MLP; 8 %) diets (Hope Farms 
BV, Woerden, Netherlands) and maintained on the respective 
diet throughout pregnancy and lactation (12 rats/group). Preg-
nant dams fed the low-protein diet did not exhibit any diﬀ er-
ences in caloric intake compared to controls. Despite this, MLP 
oﬀ spring weighed signifi cantly less at 3 days of age than CON 
oﬀ spring (28 %; p < 0.05). Male oﬀ spring were weaned at 24 days 
and maintained on standard rodent diet thereafter. CON and 
MLP oﬀ spring were killed at 8 weeks and visceral WAT depots 
were snap-frozen for analysis, whilst blood was collected for 
measurement of glucose and insulin.
 PPARα–/– mice
 Male PPARα–/– mice, bred onto a SV/129 genetic background, 
were provided by Drs. J. Peters and F. J. Gonzalez (National Insti-
tutes of Health, Bethesda, MD). Wild-type SV/129 mice (from 
Charles River, UK) were used as controls.
 Metformin treatment
 Eight-week-old male C57Bl/6 mice (Charles River, Kent, UK) 
maintained on standard rodent diet were administered met-
formin (250 mg/kg/day) or an equal volume of water daily for 7 
days by oral gavage.
 3T3L1 Culture and diﬀ erentiation
 3T3-L1 preadipocytes were cultured (37 °C; 5 % CO 2 ) in Dulbec-
co’s Modifi ed Eagle Media (DMEM; 25 mM glucose) supple-
mented with 10 % bovine calf serum (BCS), (both Sigma Aldrich, 
Poole, UK) until confl uent. Two days post-confl uence (diﬀ eren-
tiation day 0), to induce diﬀ erentiation media was changed and 
replaced with DMEM/10 % foetal calf serum (FCS) supplemented 
with insulin (1 μg/ml), dexamethasone (0.25 mM), and isobutyl-
1-methylxanthine IBMX (0.5 mM). After 2 days (diﬀ erentiation 
day 2), media was replaced with DMEM/10 % FCS supplemented 
with insulin (1 μg/ml). After 4 days (diﬀ erentiation day 4) media 
was replaced with DMEM/10 % FCS. All media contained 100 U/
ml penicillin and 100 μg/ml streptomycin (both Sigma Aldrich, 
Poole, UK). Diﬀ erentiation of pre-adipocytes to adipocytes was 
confi rmed by measurement of PPARγ gene expression. Treat-
ments, carried out on diﬀ erentiation day 8, were as follows; adi-
ponectin (30 μg/ml), WY-14643 (10 μM) for 24 h. All treatments 
were carried out in DMEM containing 10 % FCS.
 Immunoblotting
 Solubilised protein samples [10 μg; measured and equalised in 
each fraction using an RC-DC BioRad system (BioRad, UK)] were 
separated by SDS-PAGE and transferred onto PDVF membrane 
(GE Healthcare, Amersham, UK). Blots were blocked with 5 % 
(w/v) bovine serum albumin (BSA) or 5 % milk in Tris-buﬀ ered 
saline/0.1 % Tween-20 (TBS/T) solution and then incubated over-
night in primary antibody. Antibodies used in this study are 
anti-phospho(Thr 172 )-AMP-activated protein kinase (AMPK), 
anti-AMPK, anti-phospho(Ser 171 )-acetyl CoA carboxylase (ACC) 
and anti-ACC (Cell Signalling Technologies, MA, USA). Detection 
of bands was achieved by using the chemiluminescence sub-
strate SuperSignal West Pico (Pierce, Rockford, IL, USA). Refer-
ence protein measurements were made with mouse monoclonal 
anti-β-actin (clone AC-15; Sigma, Poole, UK) primary antibody 
in a 3 % (w/v) milk-TBS/T solution, at 4 °C.
 Quantitative RT-PCR
 Gene expression was measured by qRT-PCR, using Taqman ® or 
Sybr green ® methodology. Gene expression was determined by 
ΔΔCt methodology, normalised against 18S ribosomal RNA 
(Applied Biosystems, UK). Changes in gene expression are repre-
sented as fold change relative to one, where control equals one. 
All primer and probes are from Eurogentec, UK. A list of primers 
can be found in supplemental  Table 1S (Supporting Informa-
tion).
 Serum insulin and glucose
 Insulin was analysed by ELISA (Mercodia, Uppsala, Sweden) 
using rat insulin as standard. Plasma glucose was measured by a 
glucose oxidase/peroxidase method (Roche Diagnostics, Lewes, 
UK).
 Statistical analysis
 Results are expressed as mean ± SEM. Statistical comparisons 
were obtained using GraphPad (GraphPad Software, CA, USA). 
Statistical diﬀ erences were calculated using an unpaired  t -test.
 Results
 ▼
 Metabolic data for MLP oﬀ spring
 Pregnant dams fed a low-protein diet did not exhibit any diﬀ er-
ences in food intake compared to controls (data not shown). 
Despite this MLP oﬀ spring weighed signifi cantly less at 3 days of 
age than control litter mates (28 %; p < 0.05). After 8-weeks con-
sumption of standard rodent diet, MLP oﬀ spring displayed no 
changes in fasting insulin (16.0 ± 3.2 μU/ml) compared to con-
trols (14.4 ± 1.3 μU/ml) (p = 0.65). Additionally, no changes in 
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fasting plasma glucose levels were found in MLP oﬀ spring 
(4.36 ± 0.13 mmol/l) compared to control (4.11 ± 0.21 mmol/l) 
(p = 0.33), whilst glucose area under the curve (AUC) analysis for 
glucose tolerance tests resulted in a nonsignifi cant increased 
AUC values for MLP (9.76 ± 1.29 mmol/l/min) compared to con-
trol (7.45 ± 0.79 mmol/l/min) (p = 0.16) (  ●  ▶   Table 1 ).
 MLP oﬀ spring display altered adipogenic and lipogenic 
gene expression
 Whilst no signifi cant changes in metabolic data were observed 
at this early stage in the MLP rats, it is possible that mechanistic 
changes may occur during this early-life period, which would 
predispose to later development of metabolic disease. Therefore, 
by focussing on altered lipogenesis and adipogenesis in white 
adipose tissue, we next attempted to identify early-life meta-
bolic changes, which would likely lead to onset of the estab-
lished later-life metabolic defects induced by MLP. IRF3 and IRF4 
are recently identifi ed as repressors of adipogenesis and lipo-
genesis  [ 7 ,  8 ] . Gene expression of IRF3 and IRF4 was markedly 
reduced in white adipose tissue of MLP rats as compared to con-
trols (  ●  ▶   Fig. 1a, b ). These changes occurred in parallel with 
increased mRNA expression of SREBP1c, elevated mRNA and 
protein levels of FASN as well as increased ACC protein (  ●  ▶   Fig. 
1c–e ), consistent with a role for IRF4 in repressing transcription 
of these genes. This data implies that early life changes in IRF3 
and IRF4 occur in MLP rats and may contribute to increased risk 
of development of obesity and metabolic syndrome in later life.
 IRF3 and IRF4 suppression is associated with impaired 
adiponectin signalling
 Previous studies have demonstrated that insulin exerts regula-
tory control of IRF4, whilst less is known about IRF3 regulation 
in the context of obesity and metabolic syndrome. Insulin was 
reported to repress IRF4 expression in vitro in adipocytes and in 
vivo under fed conditions, and in obese, hyperinsulinaemic 
rodent models  [ 7 ] . However, despite marked reductions in IRF3 
and IRF4 expression, we did not observe signifi cant changes in 
serum insulin levels in our models (  ●  ▶   Table 1 ). This suggested 
the existence of an alternative regulatory mechanism control-
ling IRF4, and potentially IRF3, in white adipose tissue. Adipok-
ines, such as adiponectin, are bioactive peptides secreted from 
adipose tissue, which exert metabolic control over a number of 
insulin sensitive tissue, including, in an autocrine manner, adi-
pose tissue. We next investigated potential alterations in adi-
ponectin signalling in MLP rats, with the aim of determining 
alternative mechanisms of IRF3 and IRF4 regulation. Remarka-
bly, we found that mRNA levels of adiponectin (AdipoQ; 
 Table 1  Serum insulin and glucose changes between control and MLP rats. 
  CON  MLP  p-Value 
 Fasting glucose (mM)  4.11 ± 0.13  4.36 ± 0.21  0.33 
 Fasting insulin (μU/ml)  14.4 ± 1.3  16 ± 3.21  0.65 
 Glucose – AUC (mmol/l/min)  7.54 ± 0.79  9.76 ± 1.29  0.16 
 Fig. 1  Reduced IRF levels in white adipose tissue of MLP oﬀ spring. Visceral WAT was isolated from 8-week-old oﬀ spring of MLP and control Wistar rats 
(n = 6); Gene expression of  a  Irf3 ,  b  Irf4 ,  c  Srebp1c , and  d  Fasn .  e Protein levels of FASN and ACC. Western blots are representative. Data are expressed as 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control. 
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  ●  ▶   Fig. 2a ) and adiponectin receptor 1 (AdipoR1) and receptor 2 
(AdipoR2) were dramatically suppressed in MLP rats by  ≈ 90 % 
relative to control (  ●  ▶   Fig. 2b, c ), suggesting that impaired adi-
ponectin signalling may lead to decreased IRF3 and IRF4 expres-
sion. To investigate this further, we used the 3T3L1 adipocyte 
cell line. Consistent with impaired adiponectin signalling and 
reduced IRF expression in the white adipose tissue of MLP rats, 
incubation of 3T3L1 adipocytes with adiponectin led to increased 
mRNA levels of IRF3 and IRF4 (  ●  ▶   Fig. 2d, e ). This suggests that, in 
addition to insulin, adiponectin provides an additional level of 
regulatory control over IRF3 and IRF4 in white adipose tissue.
 Adiponectin regulates IRF3 and IRF4 through AMPK 
and PPARα
 Adiponectin, via signalling through AdipoR1 and AdipoR2 has 
been reported to exert metabolic eﬀ ects through activation of 
the energy sensing enzyme AMP-activated protein kinase 
(AMPK) and the nuclear receptor peroxisome-proliferator acti-
vated receptor α (PPARα)  [ 9 ] . Both AMPK and PPARα play impor-
tant roles in regulating lipogenesis and fatty acid oxidation 
 [ 9 – 11 ] . Consistent with observed reductions in adiponectin and 
AdipoR1 expression, MLP rats also displayed decreased protein 
levels of phospho(Thr 172 )-AMPK (  ●  ▶   Fig. 3a ). Since phosphoryla-
tion at Thr 172 leads to AMPK activation, this observation sug-
gests reduced AMPK activity in MLP rats. In addition, protein 
levels of phospho(Ser 79 )-ACC, a downstream target of AMPK, 
were also reduced in MLP oﬀ spring compared to control (  ●  ▶   Fig. 
3a ). Total protein levels of AMPK were unchanged, demonstrat-
ing that decreased AMPK activation did not occur because of 
MLP-induced reductions in total protein. In contrast, total-ACC 
protein levels were elevated in MLP mice, refl ecting increased 
lipogenesis, changes that are consistent with increased lipogenic 
gene expression (  ●  ▶   Fig. 1e ). Furthermore, refl ecting decreased 
AdipoR2 expression, we also observed decreased mRNA levels of 
PPARα in MLP rats, compared to control (  ●  ▶   Fig. 3b ). Transcrip-
tional modulation by PPARα requires the presence of the co-
activator PPARγ co-activator 1α (PGC1α). Consistent with this, 
PGC1α mRNA levels were also suppressed in MLP rat adipose 
tissue (  ●  ▶   Fig. 3c ).
 To further analyse the potential role of adiponectin-AMPK-
PPARα signalling in regulating IRF3 and IRF4 expression, we ini-
tially used 3T3L1 adipocytes. Use of 3T3L1 adipocytes allowed 
for specifi c examination of IRF4 regulation in a model lacking 
macrophages, which may infl uence results given the role of IRF4 
in immune regulation  [ 12 ] . Adipocyte diﬀ erentiation was con-
fi rmed by measurement of mRNA levels of PPARγ (data not 
shown). Treatment of diﬀ erentiated adipocytes with WY14643, 
a potent PPARα agonist, had no eﬀ ect on IRF3 mRNA (  ●  ▶   Fig. 4a ) 
but did induce expression of IRF4 (  ●  ▶   Fig. 4b ). We further ana-
lysed these putative signalling mechanism using PPARα knock-
out mice, which displayed  ≈ 90 % reduction in PPARα mRNA 
levels in white adipose tissue, together with a marked reduction 
in PGC1α mRNA levels (  ●  ▶   Fig. 4c, d ). Signifi cantly, in PPARα 
knockout mice the normal IRF4 responses to fasting and feeding 
were disrupted (  ●  ▶   Fig. 4e ). Consistent with previous reports  [ 7 ] 
IRF4 levels were induced by fasting in wild-type mice. However, 
this eﬀ ect was blunted in PPARα knockout mice, where IRF4 lev-
els were reduced in fasted compared to fed mice. Similar to MLP 
rats, PPARα knockout mice also displayed reduced IRF4 levels 
(  ●  ▶   Fig. 4f ), together with raised levels of ACC and SREBP1c 
(  ●  ▶   Fig. 4g, h ), indicative of elevate lipogenesis and adipogenesis 
in white adipose tissue. Taken together, these results indicate 
that an adiponectin-PPARα signalling pathway induces IRF4 
mRNA expression in white adipose tissue. Moreover, this path-
 Fig. 2  Impaired adiponectin signalling in white 
adipose tissue of MLP oﬀ spring leads to reduced 
IRF levels. Visceral WAT and serum were isolated 
from 8-week-old oﬀ spring of MLP and control Wis-
tar rats (n = 6);  a serum insulin levels; mRNA levels 
of  b  AdipoQ ,  c  AdipoR1 , and  d  AdipoR2 in white adi-
pose tissue. 3T3-L1 adipocytes were treated with 
adiponectin (30 μg/ml; 24 h) and mRNA levels of 
 e  Irf3 and  f  Irf4 were measured by qPCR. Data are 
expressed as mean ± SEM. *p < 0.05, ***p < 0.001 
vs. control. 
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way is dysregulated in response MLP, and this may in part medi-
ate the metabolic defects associated with this MLP.
 Adiponectin-AMPK signalling may regulate IRF3
 In contrast to IRF4, IRF3 was unaﬀ ected by PPARα agonist in 
vitro, indicating an alternative regulatory mechanism for IRF3 
(  ●  ▶   Fig. 4a ). Since adiponectin induced both IRF3 and IRF4, but 
PPARα regulated IRF4 only, we reasoned that AMPK, another tar-
get of adiponectin, may exert regulatory control over IRF3. To 
test this, we used metformin, as a known activator of AMPK  [ 13 ] , 
rather than for its actions as an anti-diabetic treatment. Admin-
istration of metformin to control mice led to signifi cant induc-
tion of IRF3 (  ●  ▶   Fig. 5a ) but had no eﬀ ect on IRF4 mRNA levels 
(  ●  ▶   Fig. 5b ), implying that adiponectin-AMPK signalling selec-
tively induces IRF3 in white adipose tissue.
 Discussion
 ▼
 We report here that expression of IRF3 and IRF4, 2 key repres-
sors of adipogenesis, are reduced in oﬀ spring of rats fed a pro-
tein-restricted diet during pregnancy and lactation, in parallel 
with no changes in fasting insulin and glucose. Human epide-
miological studies have consistently reported that exposure to 
an adverse intrauterine environment, such as protein-restric-
tion, leads to an increased risk of development of obesity, T2DM, 
and cardiovascular disease in later life  [ 3 ,  5 ,  6 ] . Experimental 
model studies have reported that MLP oﬀ spring gain more 
weight, have increased susceptibility to development on meta-
bolic syndrome and display impaired adipocyte function when 
placed a high fat diet  [ 1 ,  14 ,  15 ] . However, the underlying regula-
tory mechanisms driving these processes are yet to be fully elu-
cidated. Our data provides evidence that a loss of ability to 
eﬃ  ciently repress adipogenesis and lipogenesis, as a result of 
marked early-life reductions in IRF3 and IRF4, may contribute to 
impaired adipocyte function and increased risk of obesity in 
later life. Whilst metabolic changes observed in this model are 
mild, the early life mechanistic changes reported here would 
likely make a key contribution to the expected, and previously 
reported, metabolic deterioration likely observed in these ani-
mals in later life.
 Previous studies have described that IRF4 expression and func-
tion is suppressed by insulin, and that as a result, IRF4 expres-
sion is lower in white adipose tissue depots obtained from 
rodent models characterised by insulin resistance; HFD,  ob / ob 
and  db / db mice  [ 7 ] . Despite this well characterised role of insu-
lin, our MLP model displayed a marked reduction in IRF3 and 
IRF4, without signifi cant changes in serum insulin. Instead, our 
data point the involvement of the adiponectin-PPARα and adi-
ponectin-AMPK signalling pathways in the regulation of IRF4 
and IRF3 respectively. Adiponectin is a bioactive adipokine 
expressed at high levels and secreted from adipose tissue  [ 16 ] . 
Adiponectin exerts metabolic regulatory eﬀ ects via autocrine, 
paracrine, and endocrine function, through the receptors adi-
poR1 and adipoR2, which in turn activate AMPK and PPARα 
 [ 9 ,  16 ] . Conversely, PPARα agonists have been reported to upreg-
ulate adiponectin and AdipoR1 and AdipoR2, whilst adiponectin 
is suppressed in PPARα knockout mice  [ 17 ] . PPARα is a transcrip-
tion factor for genes involved in lipolysis and fatty acid oxidation 
and PPARα null mice maintained on a high-fat diet become more 
obese than wild type  [ 18 ] . Despite suppression of insulin levels 
and increases in FA supply, PPARα-defi cient mice exhibit an 
impaired ability to adequately upregulate hepatic FA oxidation 
in response to fasting  [ 19 ] . Insulin resistance induced by excess 
of nonesterifi ed FA and circulating TAG can be corrected by the 
administration of PPARα activators by actions to promote 
removal of intracellular lipid through tissue FA oxidation  [ 20 ] . 
PPARα is activated under calorie restriction, increasing the 
expression of genes encoding mitochondrial FA oxidation 
enzymes, thereby increasing the capacity for FA oxidation and 
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 Fig. 3  Reduced AMPK and PPARα signalling in 
white adipose tissue of MLP oﬀ spring. Visceral 
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intracellular lipid clearance  [ 21 ] . AMPK activation occurs in 
response to a rise in AMP associated with metabolic stresses that 
interfere with ATP production (e. g., hypoxia or calorie restric-
tion/glucose deprivation) or accelerated ATP consumption (e. g., 
muscle contraction), so as to preserve or maintain tissue func-
tion  [ 22 ] . Therefore, AMPK also plays an important role in regu-
lating lipid homeostasis in adipose tissue, having been shown to 
inhibit lipogenesis and during the longer-term increase lipolysis 
 [ 10 ] . The fact that PPARα levels and other oxidation genes 
(PGC-1α) and proteins (AMPK) are suppressed in MLP rats, while 
lipogenic genes are enhanced (SREBP-1c and FAS), suggest that 
these mice may develop a similar phenotype to PPARα –/– mice, 
and that the MLP phenotype may be a direct result of reduced 
PPARα levels, leading to increased IRF4 levels. Under both condi-
tions, fatty acid oxidation is decreased and lipogenesis is 
enhanced, again potential involving an IRF-mediated mecha-
nism. Several mechanisms for these actions of AMPK and PPARα 
have been described. Our data suggests a further mechanism of 
action, namely via induction of IRF3 and IRF4, and consequent 
repression of lipogenesis and induction of lipolysis in white adi-
pose tissue. These changes were in turn regulated by adiponec-
tin, and these signalling pathways were all impaired in MLP rats.
 In addition to specifi c eﬀ ects on lipolysis and lipogenesis, low 
levels of IRF4 may also refl ect poorly diﬀ erentiated adipocytes, 
since IRF4 is expressed only in fully diﬀ erentiated adipocytes. 
Poorly diﬀ erentiated adipocytes are often present in obesity and 
can lead to hypoxia, infl ammation, and an altered adipokine 
profi le, including lower adiponectin levels  [ 23 ] . Dysregulation of 
these processes are linked to onset of T2DM. Moreover, reduced 
adiponectin levels occurring as a result of poor diﬀ erentiation, 
may represent an initial cause of the impaired adiponectin sig-
nalling observed in MLP mice. Alternatively, this mechanism of 
impaired adiponectin signalling may induce a feed-forward 
loop, with further reductions in adiponectin signalling and con-
sequent worsening of the MLP phenotype. In addition, whilst 
 Fig. 5  Adiponectin-AMPK signalling may regulate IRF3 expression in 
white adipose tissue. Visceral WAT was isolated from 8-week-old C57Bl/6 
mice administered metformin (250 mg/kg/day; 7 days) or saline equiva-
lent (n = 6); mRNA levels of  a  Irf3 and  b  Irf4 were measured by qPCR. Data 
are expressed as mean ± SEM. *p < 0.05 vs. control. 
 Fig. 4  Adiponectin-PPARα signalling induces IRF4 expression in white adipose tissue. 3T3-L1 adipocytes were treated with WY14643 (10 μM; 24 h) and 
mRNA levels of  a  Irf3 and  b  Irf4 were measured by qPCR. Visceral WAT and serum were isolated from 8-week-old PPARα knockout and control mice (n = 6); 
mRNA levels of  c  Ppar α  d  Pgc1 α,  e ,  f  Irf4 ,  g  Srebp1c were assessed by qPCR.  h Protein levels of ACC. Western blots are representative. Data are expressed as 
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control (FED);  ### p < 0.001 vs. control (FAST). 
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adiponectin has been reported to induce PPARα, the reverse has 
also been documented, with adiponectin upregulated by PPARα 
agonists and suppressed in white adipose tissue of PPARα knock-
out mice  [ 17 ] . Thus, suppressed PPARα levels in MLP mice may 
contribute to further impairment of adiponectin signalling and 
consequent exacerbation of the MLP phenotype. Further studies 
are required to determine the exact mechanistic interactions by 
which PPARα regulates IRF4.
 In addition to an established role in adipocytes, IRFs are present 
in macrophages and infi ltrating lymphocytes. IRF4 is essential 
for the function and homeostasis of both mature B and mature T 
lymphocytes. IRF4-defi cient mice exhibited a profound reduc-
tion in serum immunoglobulin concentrations and impaired T 
lymphocyte function  [ 24 ] . The altered IRF levels could poten-
tially represent reduced immune infi ltrate into the white adi-
pose tissue. Further research is needed to clarify this. However, 
given the increased infl ammation and macrophage recruitment 
observed in response to reduced adiponectin levels in other 
studies  [ 16 ] , a reduced immune infi ltrate seems unlikely, instead 
suggesting a specifi c role for adipocyte-IRF3 and IRF4 in this 
model.
 In summary, we propose that in early life in response to protein 
restriction adiponectin signalling is impaired leading to reduced 
activity of PPARα and AMPK, which in turn lead to decreased 
levels of IRF3 and IRF4. This would lead to an inability to repress 
adipogenesis and lipogenesis, and confer increased susceptibil-
ity to development of an obese phenotype in later-life.
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